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Abstract 
Natural products have been used as a valuable source of new lead drugs. The 
Plectranthus L’Her (Lamiaceae) genus possess a wide diversity of ethnomedicinal uses 
which indicate the presence of bioactive molecules. Also, innovative methods for natural 
drug delivery, as phytosome, have showed to be a promising strategy for the 
improvement of delivery and stability. 
In this work, three plants from the Plectranthus genus were studied: P. 
madagascariensis, P. neochilus and P. porcatus. Several extracts were prepared by the 
combination of extraction methods (infusion, decoction, microwave, ultrasound, 
maceration and supercritical fluid extraction) with different polarity solvents (water, 
acetone, methanol and scCO2). Those extracts were profiled by HPLC-DAD and the main 
components were identified, including polyphenols (caffeic acid, chlorogenic acid and 
rosmarinic acid), diterpenes (7α-acetoxy,6β-hydroxyroyleanone and coleon U) and 
flavones (rutina y naringenina). 
The prepared extracts were screened for their antimicrobial (Gram positive and 
negative bacteria and yeasts), antioxidant (DPPH radical scavenging activity) and 
cytotoxic activities (MDA-MB-231 cell line). Extracts from P. madagascariensis (acetone 
maceration and acetone ultrasound) and P. neochilus (acetone ultrasound) showed 
antibacterial effects against Gram positive bacteria strains, namely, Bacillus subtilis, 
Staphylococcus aureus and S. epidermidis and a Gram negative bacteria strain, Klebsiella 
pneumonia (MIC values 1.95-250 μg/mL). The ultrasound extract of P. madagascariensis 
prepared with acetone showed potent antibacterial effect against Staphylococcus spp., 
including a methicillin-resistant strain (MRSA), with MIC values ranging from 1.95 to 7.81 
µg/mL. These results validate the traditional uses of such plants as anti-infectious 
agents. All methanolic extracts showed potent antioxidant effects at 100 ng/mL (60.8-
89.0%). The maceration acetone extract from P. madagascariensis showed moderate 
cytotoxic effects in the MDA-MB-231 breast cancer cell line with IC50 of 64.52 µg/mL.  
The organic solvent extracts from P. madagascariensis were the most bioactive and 
thus characterized (identification and quantification) using HPLC-DAD. Furthermore, the 
compounds were identified by authentic standard overlay: rosmarinic acid, 7α,6β-
dihydroxyroyleanone, 7α-acetoxy-6β-hydroxyroyleanone and coleon U. A diterpenic 
compound was isolated from the ultrasound acetonic extract of P. madagascariensis 
and spectroscopically characterized (1H- and 13C-NMR) as 7α-formyloxy-6β-
hydroxyroyleanone. This was the first time this compound was isolated from this plant. 
The cytotoxic effect of the identified compounds was evaluated in a battery of cancer 
cell lines (MDA-MB-231, MCF-7, HCT116, NCI-H460 and MCR-5). The diterpenic 
compounds showed moderate to potent cytotoxicity in the majority of tested cell lines. 
A high selectivity for cancer cell lines was observed for 7α,6β-dihydroxyroyleanone and 
7α-acetoxy-6β-hydroxyroyleanone with selectivity index of 4.3 and 3.2, respectively. 
The combination of the observed results and literature data afforded the 
establishment of new structure-activity relationships of roylenanone abietanic 
  
xi 
 
compounds. The relevance of lipophilicity and of the presence of an electron donating 
group at 6 and/or 7 positions was observed.  
The antibacterial acetonic ultrasound extract from P. madagascariensis identified in 
the initial screening was selected for incorporation into a phytosomal formulation and 
subsequently coated by chitosan. Phytosomes were amorphous, uniform in shape as 
shown by AFM and SEM, and with an average size of 1082 ± 363 nm and zeta potential 
of +20.59 ± 12.02 mV. The encapsulation of the antibacterial extract was determined by 
HPLC (57.7±0.06%) and the chemical interactions between the formulation components 
was cofirmed by DSC and DRIFTS. Such phytosomes showed a sustained release of the 
extract 4 and lower skin-like permeation fluxes. An improvement up to a 4-fold factor in 
the anti-Staphylococci activity (MIC values 0.98-31.25 µg/mL) was observed. The safety 
of such formulation was verified by in vitro human keratinocytes cytotoxicity assays and 
by in vivo acute and sub-chronic dermal irritation tests in mice. 
This study showed the potential of the Plectranthus genus as source of lead 
antibacterial and antiproliferative agents and validate the ethnomedicinal uses of the 
studied plants. The isolated abietane diterpenes obtained from P. madagascariensis 
possess promising selective cytotoxic effects, namely, aginst the lung cancer lines 
tested. Also, the developed formulation of extract of P. madagascariensis corresponds 
to a potent topical antibacterial candidate with a broad spectrum of activity.  
Keywords: Plectranthus; Diterpenes; Cytotoxicity; Antibacterial; Phytosome.   
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Resumen 
Los productos naturales han sido una valiosa fuente de potenciales fármacos. Las 
plantas del género Plectranthus L'Her (Lamiaceae) poseen una amplia diversidad de usos 
etnomedicinales, que son una indicación de la presencia de potenciales fármacos en su 
composición. Los innovadores nanocarregadores de productos naturales, como el 
fitosoma, han demostrado ser una estrategia prometedora para la mejora de su 
veiculación y estabilidad. 
En este trabajo, tres plantas del género Plectranthus fueron estudiadas: P. 
madagascariensis, P. neochilus y P. porcatus. Varios extractos fueron preparados por la 
combinación de métodos de extracción (infusión, decocción, maceración, microondas, 
ultrasonido o extracción con fluido supercrítico) utilizando disolventes de diferente 
polaridad (agua, acetona, metanol o dióxido de carbono supercrítico). Los extractos 
preparados fueron perfilados por HPLC-DAD y se identificaron los majores componentes 
principales, incluyendo polifenoles (ácido cafeico, ácido clorogénico y ácido 
rosmarínico), diterpenos (7α-acetoxi-6β-hidroxiroileanona y coleona U) y flavonas. 
Los extractos preparados han sido evaluados por su actividad antimicrobiana 
(bacterias Gram positivas, Gram negativas, levaduras), antioxidante (captación de 
radicales por DPPH) y citotóxica (células MDA-MB-231). Los extractos de P. 
madagascariensis (maceracion y ultrasonido con acetona) y P. neochilus (ultrasonido 
com acetona) mostraron efectos antibacterianos contra Bacillus subtilis, Staphylococcus 
aureus, S. epidermidis (bacterias Gram positivas) y Klebsiella pneumoniae (bacterias 
Gram negativas). Lo extracto de ultrasonido de P. madagascariensis obtenido con 
acetona reveló efectos antibacterianos potentes en Staphylococcus spp., incluyendo una 
cepa resistente a la meticilina, con valores de concentración mínima inhibitoria en el 
rango de 1,95 a 7,81 µg/mL. Esto está de acuerdo con los usos tradicionales de tales 
plantas como agentes anti-infecciosos. Cada extracto metanólico mostró potentes 
efectos antioxidantes en una concentración de extracto de 100 ng/mL (60,8-89,0%). El 
extracto de maceración de P. madagascariensis mostró algunos efectos citotóxicos en 
la línea celular de cáncer de mama MDA-MB-231 con IC50 de 64,52 mg/mL.  
Dado que los extractos más bioactivos se obtuvieron de P. madagascariensis, 
aquellos se caracterizaron con más detalle con la identificación y cuantificación de los 
principales compuestos en los extractos. Cuatro compuestos fueron identificados por 
comparación con estándares: ácido rosmarínico, 7α,6β-dihidroxiroyleanona, 7α-
acetoxi-6β-hidroxiroileanona y coleona U. Se aisló un compuesto diterpénico del 
extracto ultrasonido de acetona de P. madagascariensis que se caracterizó por RMN 1H 
y 13C como 7α-formiloxi-6β-hidroxiroileanona. Esto supone el aislamiento por primera 
vez, de este compuesto en esta planta. Los efectos citotóxicos de los compuestos 
determinados en una batería de líneas celulares de cáncer y en conjugación con los 
datos disponibles de la literatura proporcionaron el establecimiento de algunas 
relaciones estructura-actividad de la estructura abietanica de la roilenanona. Se observó 
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cierta selectividad para líneas celulares de cáncer de 7α,6β-dihidroxiroileanona y 7α-
acetoxi-6β-hidroxiroileanona con el índice de selectividad de 4,3 y 3,2 respectivamente. 
El extracto más antibacteriano resultante del cribado inicial fue seleccionado para su 
incorporación en una formulación fitosomal y posteriormente recubierto por el 
quitosano. Los fitosomas obtenidos eran amorfos, uniformes en forma (SEM y AFM), con 
un tamaño medio de 1082 ± 363 nm y lo potencial zeta de 20,59 ± 12,02 mV. La eficiencia 
de encapsulación se determinó por HPLC (57,7 ± 0,06%). La interacción entre los 
componentes de la formulación se demostró mediante DSC y DRIFTS. Los fitosomas 
mostraron una liberación sostenida y el flujo de membrana de baja con una cierta 
mejora de la actividad anti-estafilococos (concentración mínima inhibitoria de 0,49 a 
31,25 mg/ml). La seguridad de dicha formulación se demuestra in vitro por la baja 
citotoxicidad en queratinocitos humanos y in vivo con ensayos de irritación cutánea 
aguda y sub-crónica en ratones. 
Este estudio demostró el potencial del género Plectranthus como fuente de nuevos 
agentes antibacterianos y de tratamiento del cáncer, justificándose algunos de los usos 
etnomedicinales de esas plantas. Los diterpenos del tipo abietano aislados a partir de P. 
madagascariensis poseen prometedores efectos citotóxicos selectivos contra algunas 
líneas de cáncer. Además, la formulación desarrollada de extracto de P. 
madagascariensis corresponde a un candidato antibacteriano tópico potente con un 
amplio espectro de actividad. 
Palabras-chave: Plectranthus; diterpenos; citotoxicidad; antibacterianos; fitosoma.   
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Resumo 
Os produtos naturais têm sido uma valiosa fonte de novos produtos farmacêuticos. 
As plantas de género Plectranthus L'Her (Lamiaceae) possuem uma ampla diversidade 
de usos etnomedicinais, que correspondem a uma indicação da presença de potenciais 
fármacos na sua composição. Métodos inovadores para a veiculação dos produtos 
naturais, como os fitossomas, demostraram ser uma estratégia promissora para a 
melhora da veiculação e estabilidade destes produtos. 
Três plantas do género Plectranthus foram estudadas: P. madagascariensis, P. 
neochilus e P. porcatus. Extratos foram preparados pela conjugação de técnicas de 
extração como infusão, decocção, maceração, micro-ondas, ultrassons ou de extração 
por fluidos supercríticos, utilizando como solventes água, acetona, metanol ou dióxido 
de carbono supercrítico. Os extratos preparados foram perfilados por HPLC-DAD e 
identificados alguns dos principais componentes, por comparação com padrões, 
verificando-se na sua constituição polifenois, diterpenos e flavonoides. 
Os mesmos extratos foram avaliados em termos das suas atividades antimicrobiana 
(bactérias de Gram positivo, Gram negativo e leveduras), antioxidante (captura de 
radicais) e citotóxica (células MDA-MB-231). Extratos de P. madagascariensis 
(maceração e ultrassons em acetona) e P. neochilus (ultrassons em acetona) 
apresentaram efeitos antibacterianos contra Bacillus subtilis, Staphylococcus aureus, S. 
epidermidis e Klebsiella pneumoniae. O extrato de ultrassons de P. madagascariensis 
obtido com acetona apresentou potentes efeitos antibacterianos em espécies de 
Staphylococcus, incluindo uma estirpe resistente à meticilina, verificando-se uma 
concentração mínima inibitória no intervalo de 1,95 a 7,81 µg/mL. Esta atividade 
encontra-se de acordo com os usos tradicionais destas plantas como agente anti-
infecioso. Os extratos metanolicos apresentaram potentes efeitos antioxidantes a uma 
concentração de extrato de 100 ng/mL (60,8-89,0%). O extrato de maceração em 
acetona de P. madagascariensis apresentou alguns efeitos citotóxicos na linha celular 
de cancro de mama MDA-MB-231 com um IC50 de 64,52 mg/mL. Uma vez que os 
extratos mais bioativos foram obtidos a partir de P. madagascariensis, estes foram 
caracterizados em maior detalhe com identificação e quantificação dos principais 
compostos nesses extratos. Quatro compostos foram identificados por comparação 
com padrões: ácido rosmarinico, 7α,6β-dihidroxiroyleanona, 7α-acetoxi-6β-
hidroxiroileanona e coleona U. Um composto diterpenico foi isolado a partir do extrato 
de ultrassons com acetona de P. madagascariensis e caracterizado por RMN de 1H e 13C 
como 7α-formiloxi-6β-hidroxiroileanona. Este composto foi isolado pela primeira vez a 
partir desta planta. Os efeitos citotóxicos dos compostos purificados foram 
determinados numa bateria de linhas celulares de cancro e em conjugação com dados 
da literatura, foram estabelecidas algumas relações de estrutura-atividade na estrutura 
abietanica do tipo roileanona. Foi observada alguma seletividade para linhas celulares 
de cancro por parte da 7α,6β-dihidroxiroileanona e 7α-acetoxi-6β-hidroxiroileanona 
com com índice de seletividade de 4,3 e 3,2 respetivamente. 
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O extrato com maior potência antibacteriana identificado na triagem inicial foi 
selecionado para sua incorporação numa formulação fitossomal com posterior 
encapsulação por quitosano. Os fitossomas obtidos apresentavam-se amorfos, 
uniformes na forma (SEM e AFM), com um tamanho médio de 1082 ± 363 nm e potencial 
zeta de 20,59 ± 12,02 mV. A eficiência de encapsulação determinada por HPLC (57,7 ± 
0,06%). A existência de interações entre os componentes da formulação foi analisada 
por A ocorrência de encapsulação foi demonstrada por DSC e DRIFTS. Os fitossomas 
demonstraram uma libertação sustentada com redução da permeação trans-cutanea. 
Uma melhoria em até 4 vezes na atividade anti-estafilococo (concentração mínima 
inibitória de 0,49 a 31,25 mg/ml). A segurança desta formulação foi demonstrada por 
baixa citotoxicidade em queratinocitos humanos in vitro e por irritação negligenciável in 
vivo nos ensaios de irritação cutânea aguda e sub-crónica em ratinhos. 
Este estudo demonstrou o potencial do género Plectranthus como fonte de novos 
agentes antibacterianos justificando-se alguns dos usos etnomedicinais destas plantas. 
Os diterpenos do tipo abietano isolados a partir de P. madagascariensis possuem efeitos 
citotóxicos com alguma seletividade face a algumas linhas celulares de cancro. A 
formulação desenvolvida a partir do extrato de P. madagascariensis corresponde a um 
promissor candidato a antibacteriano tópico com amplo espectro de atividade e elevada 
potência. 
Palavras-chave: Plectranthus; diterpenos; citotoxicidade; antibacterianos; fitossoma. 
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1. State of the art, hypothesis and objectives 
1.1. Natural products as new drugs source 
1.1.1. Historic perspective 
The medicinal use of plants has been directly related to human evolution. Primitive 
hominids, as the Neanderthals, should have been aware of the therapeutic utility of 
various plants. Pollen vestiges of medicinal plants have been found in their graves, dated 
more than 60,000 years old1. The first archeologic evidences of plant extract production 
consisted in several extraction pots, similar to modern Soxlet extractors, dated about 
3,500 BC, back to ancient Mesopotamian. Ancient Sumerian texts, from about 2,100 BC, 
described elaborated methods of bulk extract production using water and oils as 
solvents. The Egyptian Ebers Papyrys, from around 1,550 BC, contains the description of 
more than 700 sources of natural medicinal products and their indications2. Later, the 
roman physician Pedanius Dioscorides compiled De Materia Medica which included the 
description of about 600 plant based medicines1. At the end of Roman empire, Galen, a 
Greek physician and pharmacist left a registry of 540 medicines based in plants and 
introduced the notion that herbal components could be not only beneficial but also 
harmful depending on dose and extracted components2. Even though the ancient 
knowledge of the therapeutic properties of plants, only in XVIII and XIX centuries the 
first purified compounds were isolated from plants. Morphine was isolated by Sertürner 
in 1804 from the opium powder extracted from Papaver somniferum and it became the 
first purified natural product commercialized (by Merck, 1826)2,3. In subsequent years 
diverse natural products were isolated from plants and some of them are still currently 
used as the cases of atropine from Atropa belladonna, caffeine from Coffea arabica, 
colchicine from Colchicum autumale or salicin from Salix alba2. The increasing 
knowledge about drug chemical structures and the evolution of chemical synthesis led 
to a growing interest of the pharmaceutic industries in the drug total chemical synthesis, 
over the isolation from natural sources. The 1990s advent of combinatory chemistry and 
the implementation of high throughput screening (HTS) programs led to an abrupt 
reduction of the pharmaceutic industry in phytochemistry research programs3,4. Those 
new techniques were expected to create a surge of new active substances discovered, 
which did not occur. Also, the total number of approved new chemical entities had some 
of the lowest values in the past two decades5, besides of an increasing spending in 
research and development. In this period, only one de novo new chemical entity was 
reported to the public domain resulting from the use of combinatory chemistry and HTS 
(the antitumor sorafenib)5. Those disappointing results from HTS have been related to 
the chemical characteristic of the compounds constituting the databases subject of HTS. 
Feher and Schmidt6 have disclosed the main differences between drug molecules, 
natural products and combinatorial chemistry compounds. They noted that molecules 
obtained from combinatory synthesis had a lower number of chiral centres, a less 
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prevalent presence of complex ring systems and a substantial difference in the degree 
of saturation and number and distribution of the heteroatoms in comparison to natural 
products and drug molecules6. Those authors suggest that if the constitution of HTS 
databases would be based on nature-like molecules, the new chemical entity discovery 
process would have an improved hit-ratio6. Such approach have been recently adopted 
in some groups5,7 and even some natural product databases have been disclosed to the 
public8. Newman and Cragg have comprehensively reviewed the natural products, semi-
synthetic and natural inspired molecules that have been approved by the Food and Drug 
Administration (FDA)4,5,9,10. On their most recent review, they verified that from all 1,135 
new drugs approved in the 1981 to 2010 period, about 50% have natural origin (fully 
natural, derivatives or mimics)5.  Those reviews along with other compilations of the 
natural product impact on clinical used drugs, firm the statement that the natural 
products are the most reliable source of new drug molecules3,11,12. The value of natural 
products in drug discovery has been highlighted in the recent Nobel prize attribution to 
Dr. William C. Campbell and Professor Satoshi Ōmura13,14 for their discovery of 
avermectins, fermentation products of Streptomyces avermitilis, as active drugs against 
a number of parasitic diseases including river blindness and lymphatic filariasis, and to 
Professor Youyou Tu for his discovery of artemisinin as the active component of the 
Artemesia annua, and that resulted in a key reduction of malaria morality15,16.  
Considering that up to 95% of the Earth’s biodiversity was still not studied for any 
biologic activity, a virtually infinite natural chemical diversity is yet available for use in 
further drug discovery17. 
1.1.2. The pharmacologic relevance of natural products 
The metabolism of plants resulted in the production of numerous compounds that 
can be classified according its functions as primary or secondary metabolites18. Primary 
metabolites are directly involved in normal growth, development and reproduction 
processes while secondary metabolites are not absolutely necessary for the survival of 
the plant but play an important role in interspecies defences, intra/interspecies 
interaction and environmental adaptation18,19 . Some of the most relevant plant 
secondary metabolites are terpenoids, alkaloids and phenolic compounds18. The plant 
secondary metabolites have contributed to the development of new drugs in three 
ways: being new drug entities with good pharmacologic activity and adequate 
pharmacokinetics and toxicological characteristics in the unmodified state; as source of 
lead compounds which present some biologic activity but could be modified by hemi-
synthesis to obtain more potent drug candidates; and by revealing new targets and 
action mechanisms which could further be used to the development of synthetic 
analogues20.  
Modern pharmaceutical research comprehends a multi-disciplinary approach 
involving chemists’, biologists’ and pharmacists’ contribution to obtain leading drug 
candidates. To find such bioactive compounds in higher plants, a targeted approach, 
with a careful plant to study selection, based in ethnobotanical references or 
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chemotaxonomic studies would assure the highest hit rate21. The existence of 
bibliographic and/or local references to the traditional medicinal use of some plants are 
powerful indicators to the presence of bioactive compounds in those plants (i.e. the 
discovery of artemisinin from the traditionally used Chinese plant Artemesia annua for 
Malaria treatment15). The alternative approach could be focused on a specific class of 
molecules, with a known biologic activity and that could be taxonomically characteristic 
of some plant genus (e.g. some taxanes produced by Taxus brevifolia are also produced 
in other Taxus species22). 
A large number of methods could be used for the extraction of natural products from 
vegetal matrixes and were discussed in detail in some reference books and articles21,23–
25. In this work, solid-liquid extractions using organic and/or aqueous solvents were the 
most frequently employed methods but also non-conventional techniques employing 
supercritical fluids were also applied. The choice of a method of extraction is dependent 
on the plant material characteristics and on the quality and quantity of compounds to 
be extracted23,24. The extraction process could be exhaustive/total, extracting as much 
compounds as possible, or selective, extracting preferentially one type of desired 
metabolites. In total extractions is recommended the use of a polar solvent, namely, an 
alcoholic solvent which increase the permeability of the cellular wall facilitating the 
extraction of secondary metabolites. In selective extractions, the selection of solvent 
should follow the “like-dissolves-like” principle: polar solvents extract preferentially 
polar compounds (flavonoids, polyphenols, tannins and some alkaloids) while nonpolar 
solvents solubilize lipophilic compounds (fatty acids, waxes, sterols, along with some 
alkaloids, some terpenoids and some coumarins)23,24.  
A solid-liquid extraction is a dynamic process involving a series of simple steps (Figure 
1). Initially, the contact of the plant material with the solvent conduct to its penetration 
into the solid matrix. This step was generally very fast due to capillary forces acting on a 
porous solid. When the solvent reaches the cellular structures some of the plant  
 
 
Figure 1. Representation of the extraction process and its basic terminology. 
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components were dissolved and migrate by diffusion to the solid-liquid interface at an 
approximately constant velocity. At this step, interactions with the solid matrix limit the 
mass transfer but the solute was gradually incorporated into the bulk solution by 
convection (natural or forced). The extraction rate is low at this period and the limiting 
step of the process. 
1.2. Plectranthus genus (Lamiaceae): chemistry and bioactivities 
Lamiaceae family comprises 236 genera and about 7000 species of flowering plants, 
most of them with aromatic characteristics26. Many are known for their ethnobotanical 
uses and essential oil production as the cases of sage (Salvia genus), basil (Ocimum 
genus) and mint (Mentha genus). Other important genus in this family is Plectranthus 
L’Her (tribe Ocimeae, subfamily Nepetoideae). This genus comprises more than 300 
species and is mainly distributed through tropical and sub-tropical regions of Africa, Asia 
and Australia27. The morphologic identification of Plectranthus plants could be puzzling 
due to the lack of clear-cut morphological criteria to distinguish among species within 
the genus28. Also species classified originally in the closely related genus Isodon, 
Solenostemon, Englerastrum and the former genus Coleus are now part of the 
Plectranthus genus due to phylogeny studies with resource to genetic tolls29. This genus 
is actually considerer paraphyletic, as currently circumscribed, and three clades have 
been phylogenetically established: a sigmoid ‘Coleus’ clade, including the species of the 
former Coleus genus; a sigmoid ‘Plectranthus’ clade; and a straight ‘Plectranthus’ 
clade30. Plectranthus is an economically important genus due to their horticultural, 
floricultural and ethnomedicinal uses27,28. Most Plectranthus species are robust, prolific 
and many possesses attractive leaves or flowers which justifies their gardening uses for 
over more than 100 years31,32. However more than 85% of the Plectranthus citations in 
literature are due to their uses in traditional medicine (as reviewed by Lukhoba et al. 
200627) and for the biologic activities of their extracts or isolated compounds that 
includes anti-infectious33–35, antioxidant36,37, anti-inflammatory38 and cytotoxic39–41 
effects. 
1.2.1. Ethnopharmacological uses 
Plectranthus species have been used for their medicinal properties namely in 
digestive42,43, skin44, infective45,46 and respiratory47 conditions, among others. The 
species more frequently cited for their ethcnomedicinal uses were P. barbatus Andr. 
(formerly known as Coleus forskohlii) used in gastric problems, wounds, skin allergy, 
colds, cough, abdominal pain, rheumatic, bacterial, fungal and viral infections27,45,46,48,49 
and P. amboinicus (Lour.) Spreng (syn of C. aromaticus), used in dyspepsia, indigestion, 
diarrhoea, skin ulcerations, burn, skin allergies, chronic cough, asthma, bronchitis, 
fevers, headaches, muscular-skeletal pain, and infections27,42,43. The biologic activities 
and phytochemistry of P. barbatus have been extensively studied and reviewed48,49, and 
many pharmacologic activities could be justified by the presence of the bioactive 
labdane diterpene forskolin (1). This compound is a specific activator of the adenylyl 
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cyclase which result in cardiotonic, bronchodilator, antihypertensive, anti-inflammatory 
and platelet aggregation inhibitory effects50. In P. amboinicus, several studies support 
the medicinal uses with the activity of their extracts but the link between its 
pharmacologic properties with the traditional uses have not yet been clearly 
established51–53. This example emphasises the importance of the phytochemical study 
of medicinal plants for the validation of their traditional uses by the identification of the 
bioactive secondary metabolites. 
1.2.2. Phytochemical insights of the Plectranthus genus 
The Plectranthus genus, as a member of the Nepetoideae subfamily, is 
chemotaxonomically characterized by the presence of the caffeic acid esters, rosmarinic 
acid (2) and the nepetoidins A (3) and B (4) (Figure 2) with absence or scarce presence 
of iridoids and caffeoyl phenylethanoid glycosides54. This genus is rich in essential oils 
(more than 0.5% of the dry weight as volatile oil) with a major yield of 
monoterpenoids54,55. But the more frequently studied compounds from the genus 
Plectranthus are diterpenoids, mainly found in the coloured leaf-glands56. This chemical 
profile is similar to some genus of the Nepetoideae subfamily, as Salvia spp.54. The 
abundance of essential oils57 along with other antibacterial58, antifungal54 and 
antioxidant54,58 secondary metabolites was suggested to offer an improved 
environmental protection54.  
 
1 
 
2 
 
 
3 R1 = H, R2 = OH 
4 R1 = OH, R2 = H 
Figure 2. Structures of the bioactive diterpene forskolin (1) from P. barbatus and of the chemotaxonomic relevant 
caffeic acid esters rosmarinic acid (2) and the nepetoidins A (3) and B (4). 
 
The phytochemical study of the Plectranthus genus have been focused in two main 
objectives: a chemotaxonomic approach as represented by the studies of the Eugster 
group in the 1970s and 1980s56,59–63; and a bioactivity guided approach as verified in the 
studies from the Simões group in the 2000s and 2010s39,40,64–66. 
Presently, the only review of the Plectranthus genus phytochemistry, compiled by 
Abdel-Mogib and its collaborators55, have focused on the identified compounds up to 
1999. The major constituents obtained in this genus were essential oils, phenolics and a 
high variety of diterpenes. The more frequently found diterpenic structures were 
abietenoids as royleanones, spirocoleons, vinylogous quinones, quinone methides, 
acylhydroquinones, 1,4-phenanthraquinones (Figure 3) along with some miscellaneous 
phenolic abietanoids, dimeric abietanoids and secoabietanoids55. 
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Royleanone Spirocoleon Vinylogus quinones Quinone methides 
    
    
   
Acylhydroquinones 1,4-Phenanthraquinones 
 
Figure 3. Representative structures and more frequent patterns of substitution of the major abietenoid classes 
obtained from the Plectranthus genus as described by Abdel-Mogib, Albar and Batterjee in 200255. 
. 
Over the 2000-2015 period, phytochemical studies in the Plectranthus genus have led 
to the identification of 166 secondary metabolites. Those discoveries highlighted some 
chemotaxonomic trends, namely, the presence of the hydroxycinnamic acids, rosmarinic 
acid and the nepetoidins A and B (table 1) as chemical markers of the Plectranthus genus 
plants29,54.  
The presence of flavonoids was thought to be rare in the genus, however in the last 
15 years, 17 flavonoids were found in the genus, especially in P. amboinicus (11 
flavonoids from whole plant extracts) (Table 2).   
The abundance of diterpenic structures was confirmed in the genus, especially from 
abietane and labdane type, but also some kaurane, pimarane, halimane an beyranes 
were found (Tables 3 to 14). Abdel-Mogib suggested that the absence of clerodane 
diterpenoids could be a distinguish character between Plectranthus and Salvia genus67, 
however, four clerodanes were recently found for the first time in Plectranthus plants 
(Table  11).  
Triterpenic fractions in the Plectranthus genus remain poor studied, however, 9 
triterpenes were found in recent years (Table 15). Also, some acetophenones, 
sesquiterpenes and other miscellaneous compounds were found in the genus (Table 16). 
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Hydroxycinnamic acids 
 
  
H1 H4 
H5 R = H 
H6 R = CH3 
 
  
H2 R = H 
H3 R = OH  
H7 H8  
 
 
H9 R1 = H, R2 = OH 
H10 R1 = OH, R2 = H 
H11 n = 26 
H12 n = 28 
 
Table 1. Hydroxycinnamic acids found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
H1 Gallic acid P. amboinicus (St, MeOH) 53,68 
H2 Caffeic acid 
P. amboinicus (WP, MeOH); P. forsteri 
’marginatus’ (Lf, MeOH) 
53,68–70 
H3 p-Coumaric acid P. amboinicus (WP, MeOH, H2O/EtAc) 53,68 
H4 Chlorogenic acid P. amboinicus (Lf, H2O/EtAc) 70 
H5 Rosmarinic acid 
P. amboinicus (WP, MeOH, EtAc); P. barbatus 
(AP, H2O); P. forsteri ’marginatus’ (Lf, MeOH); 
P. madagascariensis (AP, MeOH) 
36,53,68–
72 
H6 Methyl rosmarinate P. barbatus (in vitro culture, MeOH) 73 
H7 Salvianolic acid A P. amboinicus (AP, H2O) 53,71 
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Table 1 (cont.). Hydroxycinnamic acids found in the Plectranthus plants over the period 2000-2015.   
H8 Shimobashiric acid P. amboinicus (AP, H2O) 53,71 
H9 Nepetoidin A  
P. ambiguous; P. argentatus; P. argentifolius; 
P. asirensis; P. barbatus; P. buchananii; P. 
ciliates; P. coeruleus; P. comosus; P. crassus; P. 
aff. cyaneus; P. cylindraceus; P. ecklonii; P. 
elegans; P. ernstii; P. forsteri ’marginatus’; P. 
frederici; P. gracilis; P. grandis; P. hadiensis; P. 
hilliardiae; P. hyemalis; P. igniarius; P. 
kivuensis; P. lanuginosus; P. madagascariensis; 
P. mutabilis; P. neochilus; P. njassae; P. 
oertendahlii; P. ovatus; P. parviflorus; P. 
petiolaris; P. pseudomarrubioides; P. 
purpuratus; P. saccatus; P. sanguineus; P. aff. 
spicatus; P. strigosus; P. tenuiflorus; P. 
xerophilus; P. zuluensis (not specified) 
54,69 
H10 Nepetoidin B 
P. ambiguous; P. argentatus; P. argentifolius; 
P. asirensis; P. barbatus; P. buchananii; P. 
ciliates; P. coeruleus; P. comosus; P. crassus; P. 
aff. cyaneus; P. cylindraceus; P. ecklonii; P. 
elegans; P. ernstii; P. forsteri ’marginatus’; P. 
frederici; P. gracilis; P. grandis; P. hadiensis; P. 
hilliardiae; P. hyemalis; P. igniarius; P. 
kivuensis; P. lanuginosus; P. madagascariensis; 
P. mutabilis; P. neochilus; P. njassae; P. 
oertendahlii; P. ovatus; P. parviflorus; P. 
petiolaris; P. pseudomarrubioides; P. 
purpuratus; P. saccatus; P. sanguineus; P. aff. 
spicatus; P. strigosus; P. tenuiflorus; P. 
xerophilus; P. zuluensis (not specified) 
54,69 
H11 
hexacosan-1,26-diol 
diester 
P. strigosus (WP, Acet) 64 
H12 
octacosan-1,28-diol 
ferulate diester 
P. strigosus (WP, Acet) 64 
Lf – leaf; AP – aerial parts; St – steam; WP – whole plant. Acet – acetone; EtAc – ethyl acetate; MeOH – 
methanol H2O – water.  
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Flavonoids 
  
 
F1, R = H 
F2, R = OH 
F3 F4 
   
   
F5 
F6, R = H 
F7, R = OH 
F8, R = OCH3 
F9 
   
 
  
F10 F11 F12 
   
 
 
F13 F14 
 
 
  
F15 F16 F17 
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Table 2. Flavonoids found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
F1 Apigenin P. amboinicus (WP, EtAc) 53 
F2 Luteolin P. amboinicus (WP, EtAc) 53 
F3 5-O-Methyl-luteolin P. amboinicus (WP, EtAc) 53 
F4 Chrysoeriol P. amboinicus (WP, TCM or H2O/EtAc) 53 
F5 Quercetin P. amboinicus (WP, H2O/EtAc) 53,68 
F6 Salvigenin 
P. amboinicus (Lf, TCM); P. cyaneus (Lf, 
EtOH); P. strigosus (WP, Acet) 
53,64,74 
F7 Eupatorin P. mollis (Lf, Acet) 75 
F8 3’-O-Methyleupatorin P. mollis (Lf, Acet) 75 
F9 Cirsimaritin P. amboinicus (Lf, TCM) 53 
F10 
3,5,7,3’,4’-Pentahydroxy 
flavanone 
P. amboinicus (WP, EtAc) 53 
F11 
5,4’-Dihydroxy-3,7-dimethoxy 
flavone 
P. amboinicus (WP, EtAc) 53 
F12 Eriodictyol P. amboinicus (WP, EtAc) 53 
F13 
Scutellarein 4’-O-methyl ether 7-
O-glucuronide 
P. barbatus (AP, H2O) 36 
F14 Rutin P. amboinicus (St, MeOH) 53,68 
F15 Pachypodol   P. cylindraceus (AP, EtOH) 76 
F16 Casticin  P. cylindraceus (AP, EtOH) 76 
F17 Chrysosplenol D  P. cylindraceus (AP, EtOH) 76 
Lf – leaf; AP – aerial parts; St – steam; WP – whole plant. Acet – acetone; EtAc – ethyl acetate; EtOH – 
ethanol; MeOH – methanol; TCM – chloroform. 
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Diterpenoids: Abietane Royleanones 
 
   
D1 
D2 6,7 
D3 R1 = H, R2 = OH 
D4 R1 = OH, R2 = OH 
D5 R1 = OH, R2 = OCH3 
D6 R1 = OH, R2 = OCHO 
D7 R1 = OH, R2 = OAc 
D8 R1 = OH, R2 = fatty acid 
carboxylate 
D9 R1 = H, R2 = OH 
D10 R1 = OH, R2 = OH 
D11 R1 = OH, R2 = OAc 
 
   
  
D12 R = CH2COCH3 
D13 8α, 9α-epoxide 
D14 R1 = OH, R2 = H 
D15 R1 = OAc, R2 = OAc 
 
Table 3. Abietane Royleanones found in the Plectranthus plants over the period 2000-2015.    
 Compound Plectranthus species (section, solvent) Ref 
D1 Royleanone P. grandidentatus (AP, Acet) 77,78 
D2 6,7-dehydroroyleanone  
P. bishopianus (Lf, MeOH);  
P. grandidentatus (AP, Acet) 
77–79 
D3 Horminone P. grandidentatus (AP, Acet) 77,78 
D4 6β,7α-dihydroxyroyleanone  P. bishopianus (Lf, MeOH) 79 
D5 
7α-methoxy-6β-
hydroxyroyleanone 
P. bishopianus (Lf, MeOH) 79 
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Table 3 (cont.). Abietane Royleanones found in the Plectranthus plants over the period 2000-2015.    
D6 
7α-formyloxy-6β-
hydroxyroyleanone  
P. hadiensis (Lf, DCM) 80 
D7 
7α-acetoxy-6β-
hydroxyroyleanone 
P. hadiensis (Lf, DCM); P. 
grandidentatus (AP, Acet) 
77,78,80 
D8 
7-Fatty acid esters of 6,7-
dihydroxyroyleanone 
P. grandidentatus (AP, Acet) 77,78 
D9 6β-hydroxyroyleanone P. grandidentatus (AP, Acet) 77,78 
D10 7β,6β-dihydroxyroyleanone 
P. forsteri ’marginatus’ (Lf, MeOH); P. 
madagascariensis (AP, MeOH) 
69,72 
D11 
7β-acetoxy-6β-
hydroxyroyleanone 
P. forsteri ’marginatus’ (Lf, MeOH); P. 
madagascariensis (AP, MeOH) 
69,72 
D12 
9α-(2-oxopropyl)abietane 
derivative 
P. grandidentatus (AP, Acet) 81 
D13 
8α,9α-epoxycoleon U-
quinone 
P. xanthanthus (AP, Acet 70%) 82 
D14 Coleon U-quinone 
P. forsteri (Lf, Acet); P. 
madagascariensis (AP, MeOH); P. 
xanthanthus (AP, Acet 70%) 
72,82,83 
D15 Xanthanthusin G P. xanthanthus (AP, Acet 70%) 82 
Lf – leaf; AP – aerial parts; Acet – acetone; DCM – dichloromethane; MeOH – methanol. 
 
Diterpenes: Abietane spirocoleons 
 
  
D16 R1 = CH2OH, R2 = OH 
D17 R1 = H, R2 = OAc 
D18 D19 
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Table 4. Spirocoleons found in the Plectranthus plants over the period 2000-2015.    
 Compound Plectranthus species (section, solvent) Ref 
D16 
(13S,15S)-6β,7α,12α,19-
tetrahydroxy-13β,16-cyclo-8-
abietene-11,14-dione 
P. porcatus (AP, Acet) 35 
D17 Coleone P P. zeylanicus (WP, Hex) 84 
D18 3β-hydroxy-3-deoxibarbatusin P. barbatus var. grandis (Lf, TCM) 85 
D19 Barbatusin P. barbatus var. grandis (Lf, Hex) 85 
 
Diterpenes: Abietane Acylhydroquinones 
   
D20 R1 = OH, R2 = OH 
D21 R1 = OCOCH3, R2 = OH 
D22 R1 = OH, R2 = OAc 
D23 R = OH 
D24 R = OAc 
D23 R = OH 
D24 R = OCH(CH3)2 
 
Table 5. Abietane Acylhydroquinones found in the Plectranthus plants over the period 2000-2015.    
 Compound Plectranthus species (section, solvent) Ref 
D20 Coleon U 
P. grandidentatus (AP, Acet); P. forsteri 
(Lf, Acet); P. xanthanthus (AP, Acet 70%) 
77,82,83 
D21 Coleon U 11-acetate P. xanthanthus (AP, Acet 70%) 82 
D22 14-O-Acetylcoleon U P. grandidentatus (AP, Acet) 86 
D23 16-O-Acetylcoleon C P. xanthanthus (AP, Acet 70%) 82 
D24 
16-Acetoxycoleon U 11-
acetate  
P. xanthanthus (AP, Acet 70%) 82 
D25 Xanthanthusin F P. xanthanthus (AP, Acet 70%) 82 
D26 Xanthanthusin G P. xanthanthus (AP, Acet 70%) 82 
Lf – leaf; AP – aerial parts. Acet – acetone. 
  
 
15 
 
Diterpenes: Abietane Quinone Methides 
  
 
D27 D28 D29 
   
 
 
D30 R = H 
D31 R = OH 
D32 R = H 
D33 R = OH 
  
Table 6. Abietane Quinone Methides found in the Plectranthus plants over the period 2000-2015.    
 Compound Plectranthus species (section, solvent) Ref 
D27 Taxodione P. barbatus (AP, EtOH 70%) 87 
D28 
5,6-didehydro-7-
hydroxytaxodone 
P. barbatus (AP, EtOH 70%) 87 
D29 
11-hydroxy-19-(methyl-
buten-2-oyloxy)-abieta-5,7,9 
(11),13-tetraene-12-one 
P. lucidus (Lf, DCM); P. purpuratus (Lf, 
DCM) 
80 
D30 Parviflorone D 
P. ecklonii (Lf, DCM), (WP, Acet); P. 
lucidus (Lf, DCM); P. strigosus (WP, 
Acet) 
41,64,80 
D31 Parviflorone F  
P. ecklonii (Lf, DCM); P. nummularius 
(Lf, Acet); P. strigosus (WP, Acet) 
64,80,88 
D32 Parviflorone C 
P. purpuratus subsp. tongaensis (Lf, 
DCM) 
80 
D33 Parviflorone E 
P. nummularius (Lf, Acet); P. purpuratus 
subsp. tongaensis (Lf, DCM)  
80,88 
Lf – leaf; AP – aerial parts; WP – whole plant. Acet – acetone; DCM – dichloromethane; EtOH – ethanol. 
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Diterpenes: Phenolic abietenoids 
   
D34 R = H 
D35 R = OH 
D36 
D37 R = H 
D38 R = OH 
   
 
 
 
D39 D40 D41 
 
Table 7. Phenolic abietenoids found in the Plectranthus plants over the period 2000-2015.    
 Compound Plectranthus species (section, solvent) Ref 
D34 11-Hydroxysugiol P. cyaneus (Lf, EtOH) 74 
D35 11,20-dihydroxysugiol P. cyaneus (Lf, EtOH) 74 
D36 Carnosolon P. cyaneus (Lf, EtOH) 74 
D37 20-deoxocarnosol P. barbatus (AP, EtOH 70%) 87 
D38 
6α,11,12,-trihydroxy-7b,20-
epoxy-8,11,13-abietatriene 
P. barbatus (AP, EtOH 70%) 87 
D39 Hinokiol P. strigosus (WP, Acet) 64 
D40 Plectranthol A P. nummularius (Lf, Acet) 88 
D41 Plectranthol B P. nummularius (Lf, Acet) 88 
Lf – leaf; AP – aerial parts; WP – whole plant. Acet – acetone; EtOH – ethanol. 
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Diterpenes: Kaurenes 
 
  
D42 R = CH2OH 
D43 R = COOH 
D44 D45 
   
 
  
D46 R1 = H, R2 = OH 
D47 R1 = OH, R2 = H 
D48 R1 = COOH, R2 = OAc 
D49 R1 = COOH, R2 = H 
D50 R1 = CH2OH, R2 = H 
D51 R1 = OH, R2 = H, R3 = CH3 
D52 R1 = OH, R2 = OAc, R3 = CH3 
D53 R1 = H, R2 = OAc, R3 = CHO 
D54 R1 = H, R2 = H, R3 = CHO 
 
Table 8. Kaurenes found in the Plectranthus plants over the period 2000-2015.    
 Compound Plectranthus species (section, solvent) Ref 
D42 ent-16-Kauren-19-ol P. strigosus (WP, Acet) 64 
D43 ent-16-Kauren-19-oic P. strigosus (WP, Acet) 64 
D44 Xylopic acid P. strigosus (WP, Acet) 64 
D45 Xylopinic acid  P. strigosus (WP, Acet) 64 
D46 ent-12-Acetoxy-15-
hydroxykaur-16-en-19-oic 
acid 
P. fruticosus (AP, Acet) 
89 
D47 ent-12-Acetoxy-7-
hydroxykaur-16-en-19-oic 
acid 
P. fruticosus (AP, Acet) 
89 
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Table 8 (cont.). Kaurenes found in the Plectranthus plants over the period 2000-2015.    
D48 ent-12-acetoxy-15,16-
epoxykauran-19-oate 
P. fruticosus (AP, Acet) 89 
D49 ent-15β,16β-epoxykauran-
19-oic acid 
P. fruticosus (AP, Acet) 90 
D50 ent-15β,16β-epoxykauran-
19-ol 
P. fruticosus (AP, Acet) 90 
D51 ent-7-Hydroxykaur-15,16-en-
19-oic acid 
P. coesta (Lf, MeOH); P. fruticosus (AP, 
Acet) 
89,91 
D52 ent-12-Acetoxy-17-oxokaur-
15-en-19-oic acid 
P. fruticosus (AP, Acet) 89 
D53 ent-17-oxokaur-15,16-en-19-
oic acid 
P. coesta (Lf, MeOH) 91 
D54 ent-7-Hydroxy-15,16-
epoxykauran-19-oic acid 
P. coesta (Lf, MeOH); P. fruticosus (AP, 
Acet) 
89,91 
Lf – leaf; AP – aerial parts; WP – whole plant. Acet – acetone; MeOH – methanol. 
 
Diterpenes: Labdanes 
 
  
 
D55 D56 D57 
   
  
 
D58 R1 = R2 = H 
D59 R1 = COCH3, R2 = OH 
D60 R1 = H, R2 = OAc 
D61 D62 
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D63 R1 = R2 = R3 = H 
D64 R1 = R2 = H, R3 = OH 
D65 R1 = R2 = H, R3 = OAc 
D66 R1 = H, R2 = R3 = OH 
D67 R1 = H, R2 = OH, R3 = OAc 
D68 R1 = R2 = R3 = OH 
D69 R1 = OH, R2 = H, R3 = OAc 
D70 R1 = R2 = OH, R3 = OAc 
D71 R1 = OAc, R2 = OH, R3 = OH 
D72 R1 = OAc, R2 = OH, R3 = H 
D73 R1 = OAc, R2 = OH, R3 = OAc 
D74 R1 = OAc, R2 = H, R3 = OAc 
D75 R1 = H, R2 = OH, R3 = OH 
D76 R1 = H, R2 = OH, R3 = OAc 
D77 R1 = R2 = H, R3 = OH 
D78 R1 = R2 = H, R3 = OAc 
D79 R1 = OH, R2 = R3 = H 
D80 R1 = R2 = R3 = OH 
D81 R1 = OH, R2 = H, R3 = OH 
D82 R1 = OH, R2 = H, R3 = OAc 
D83 R1 = R2 = OH, R3 = OAc 
D84 R1 = R2 = OH, R3 = αOAc 
D85 R1 = OAc, R2 = R3 = H 
D86 R1 = OAc, R2 = R3 = OH 
D87 R1 = OAc, R2 = OH, R3 = OAc 
D88 R1 = OAc, R2 = H, R3 = OAc 
D89 R1 = R2 = H 
D90 R1 = H, R2 = OH 
D91 R1 = H, R2 = OAc 
D92 R1 = R2 = OH 
D93 R1 = OH, R2 = OAc 
   
  
 
D94 D95 D96 
 
Table 9. Labdanes found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
D55 Rhinocerotinoic acid P. ornatus (AP, Acet) 86 
D56 
12-hydroxy-8,13E-labdadien-
15-oic acid 
P. barbatus (WP, EtOH) 92 
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Table 9 (cont.). Labdanes found in the Plectranthus plants over the period 2000-2015.   
D57 
3β-acetoxylabda-
8(17),12E,14-trien-2r-ol 
P. fruticosus (AP, Acet) 90 
D58 
ent-Labda-8(17),12Z,14-
trien-2r-ol 
P. fruticosus (AP, Acet) 90 
D59 
ent-2r-acetoxylabda-
8(17),12Z,14-trien-3β-ol  
P. fruticosus (AP, Acet) 90 
D60 
ent-3-Acetoxylabda-
8(17),12Z,14-trien-2r-ol (2)  
P. fruticosus (AP, Acet) 89 
D61 Forskoditerpene A P. barbatus (WP, EtOH) 93 
D62 
1R,11S-Dihydroxy-8R,13R-
epoxylabd-14-ene 
P. ernstii (WP, Hex) 94 
D63 
6b-hydroxy-8,13-epoxy-labd-
14-ene-11-one 
P. barbatus (in vitro culture, MeOH) 73 
D64 
1,9-dideoxy-
deacetylforskolin 
(deacetylforskolin) 
P. barbatus (in vitro culture, MeOH) 73 
D65 1,9-dideoxyforskolin P. barbatus (in vitro culture, MeOH) 73 
D66 1-deoxy-deacetylforskolin P. barbatus (in vitro culture, MeOH) 73 
D67 1-deoxyforskolin P. barbatus (in vitro culture, MeOH) 73 
D68 Forskolin D P. barbatus (WP, EtAc) 95 
D69 
Deoxycoleonol (9-deoxy-
deacetylforskolin) 
P. barbatus (WP, EtAc), (in vitro culture, 
MeOH) 
73,95 
D70 Forskolin 
P. barbatus (WP, EtAc), (in vitro culture, 
MeOH) 
73,95 
D71 1-Acetyl-7-deacetylforskolin P. barbatus (WP, EtAc) 95 
D72 1-Acetoxycoleosol P. barbatus (WP, EtAc) 95 
D73 Forskolin B P. barbatus (WP, EtAc) 95 
D74 Forskolin E P. barbatus (WP, EtAc) 95 
D75 1-Deoxycoleonol B P. barbatus (in vitro culture, MeOH) 73 
D76 6-Acetyl-1-deoxyforskolin P. barbatus (WP, EtOH/EtAc) 92,95 
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Table 9 (cont.). Labdanes found in the Plectranthus plants over the period 2000-2015.   
D77 1,9-Dideoxycoleonol B P. barbatus (in vitro culture, MeOH) 73 
D78 6-acetyl-1,9-dideoxyforskolin P. barbatus (WP, EtOH) 92 
D79 Plectrornatin B P. ornatus (AP, Acet) 96 
D80 Isoforskolin (Coleonol B) 
P. barbatus (WP, EtOH) (in vitro culture, 
MeOH) 
73,95,97 
D81 9-deoxyc-oleonol B P. barbatus (in vitro culture, MeOH) 73 
D82 Forskolin G P. barbatus (WP, EtOH/EtAc) 95,97 
D83 6-Acetylforskolin 
P. barbatus (Rt, EtOH), (WP, EtAc); P. 
ornatus (AP, Acet) 
95,98,99 
D84 Forskolin I P. barbatus (Rt/WP, EtOH) 97,98 
D84 Plectrornatin C (Coleolin) 
P. barbatus (in vitro culture, MeOH); P. 
ornatus (AP, Acet) 
73,86,96 
D85 
1,6-Diacetyl-7-
deacetylforskolin 
P. barbatus (WP, EtAc) 95 
D87 
Forskolin A (1,6-di-O-
acetylforskolin) 
P. barbatus (WP, EtAc), P. ornatus (AP, 
Acet), (AP, Hex) 
95,99,100 
D88 
1,6-di-O-acetyl-9-
deoxyforskolin 
P. neochilus (AP, toluene), P. ornatus 
(AP, Acet), (AP, Hex) 
99–101 
D89 Forskoditerpenoside E P. barbatus (WP, EtOH) 93 
D90 Forskoditerpenoside C P. barbatus (WP, EtOH) 93 
D91 Forskoditerpenoside D P. barbatus (WP, EtOH) 93 
D92 Forskoditerpenoside A P. barbatus (WP, EtOH) 102 
D93 Forskoditerpenoside B P. barbatus (WP, EtOH) 102 
D94 Spirocoleonol B P. barbatus (in vitro culture, MeOH) 73 
D95 Colroforskolin P. barbatus (in vitro culture, MeOH) 73 
D96 Coleorol P. barbatus (in vitro culture, MeOH) 73 
Lf – leaf; Rt – root; AP – aerial parts; WP – whole plant. Acet – acetone; DCM – dichloromethane; EtAc – 
ethyl acetate; EtOH – ethanol; Hex – n-hexane; MeOH – methanol. 
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Diterpenes: Halimane 
 
D97 
 
Table 10. Halimanes found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
D97 
11-acetoxyhalima-5,13E-dien-
15-oic acid 
P. ornatus (AP, Acet) 86 
AP – aerial parts; Acet – acetone. 
Diterpenes: Clerodanes 
   
D98 R = H       D99 R = CH3 D100 D101 
Table 11. Clerodanes found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
D98 
11-acetoxy-2-oxo-
neocleroda-3,13E-dien-15-oic 
acid 
P. ornatus (AP, Hex) 100 
D99 Plectrornatin A  P. ornatus (AP, Acet) 96 
D100 
11-acetoxyneocleroda-3,13E-
dien-15-oic acid 
P. ornatus (AP, Hex) 100 
D101 
11-acetoxy-3β-
hydroxyneocleroda-
4(18),13E-dien-15-oic acid 
P. ornatus (AP, Hex) 100 
Lf – leaf; AP – aerial parts; Acet – acetone; Hex – n-hexane. 
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Diterpenes: Pimaranes 
  
D102 D103 
 
Table 12. Pimaranes found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
D102 
rel-15(ζ),16-Epoxy-7α-
hydroxypimar-8,14-ene  
P. ernstii (WP, Hex) 94 
D103 
rel-15(ζ),16-Epoxy-7-
oxopimar-8,14-ene 
P. ernstii (WP, Hex) 94 
WP – whole plant. Hex – n-hexane. 
 
Diterpenes: Beyranes 
   
D104 D105 D106 
Table 13. Beyranes found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
D104 
ent-7α-acetoxy-15-beyeren-
18-oic acid  
P. saccatus (AP, Acet) 35 
D105 
ent-3β-(3-methyl-2-bute- 
noyl)oxy-15-beyeren-19-oic 
acid 
P. saccatus (Lf, Acet) 83 
D106 
ent-3β-(3-methylbutanoyl)  
oxy-15-beyeren-19-oic acid 
P. saccatus (Lf, Acet) 83 
Lf – leaf; AP – aerial parts; Acet – acetone. 
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 Miscellaneous diterpenoids 
 
 
 
 
D106 D107 R1 = OH, R2 = H 
D108 R1 = H, R2 = OH 
D109 R1 = R2 = O 
D110 
   
 
 
 
D111 D112 D113 
   
 
 
 
 D114  
 
Table 14. Miscellaneous diterpenoids found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
D107 Dehydroabietane  P. barbatus (AP, EtOH 70%) 87 
D108 (4R,19R) Coleon A P. aff. puberulentus (Lf, Acet) 83 
D109 (4R,19S) Coleon A P. aff. puberulentus (Lf, Acet) 83 
D110 Coleon A-lactone 
P. barbatus (Lf, TCM), P. puberulentus (Lf, 
Acet) 
83,103 
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Table 14 (cont.). Miscellaneous diterpenoids found in the Plectranthus plants over the period 2000-2015.   
D111 
1,11-epoxy-20-
norabietanoid 
P. cyaneus (Lf, EtOH) 74 
D112 xanthanthusin E P. xanthanthus (AP, Acet 70%) 82 
D113 13-epi-sclareol P. barbatus (Rt, EtOH) 104 
D114 (16S)-coleon E P. barbatus (AP, H2O) 36 
D115  Coelusin factor P. barbatus (Rt, Acet) 105,106 
Lf – leaf; Rt – root; AP – aerial parts; Acet – acetone; EtOH – ethanol; H2O – water; TCM – Chloroform. 
 
Triterpenoids 
   
T1 T2 T3 
   
  
 
T4 T5 T6 
   
   
   
T7 T8 T9 
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Table 15. Triterpenoids found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
T1 Ursolic acid 
 
P. mollis (Lf, Acet); P. ornatus (AP, Acet); P. 
rotundifolius (tubers peel and flesh, EtOH); 
P. strigosus (WP, Acet) 
64,75,99,107 
T2 Oleanolic acid P. bishopianus (Lf, MeOH); P. ornatus (AP, 
Acet); P. rotundifolius (tubers peel and 
flesh, EtOH) 
79,99,107 
T3 Maslinic acid P. rotundifolius (tubers  peel and flesh, 
EtOH) 
108 
T4 Corosolic acid  P. mollis (Lf, Acet) 75 
T5 Betulinic acid P. barbatus (in vitro culture, MeOH) 73 
T6 3-epi-Maslinic acid P. barbatus (in vitro culture, MeOH) 73 
T7 β-Sitosterol  P. bishopianus (Lf, MeOH) 79 
T8 Stigmasterol  P. bishopianus (Lf, MeOH); P. mollis (Lf, 
Acet); P. zeylanicus (WP, Hex) 
75,79,84 
T9 Stigmaste-5,22,25-
trien-3-β-ol 
P. zeylanicus (WP, Hex) 84 
Lf – leaf; Rt – root; AP – aerial parts; WP – whole plant. Acet – acetone; DCM – dichloromethane; EtOH 
– ethanol; Hex – n-hexane; MeOH – methanol.  
 
 
Miscellaneous compounds 
 
   
M1 M2 M3 
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M4 M5 R = OCH3 
M6 R = H 
M7 R1 = COCH3, R2 = COCH3 
M8 R1 = COCH3, R2 = H 
M9 R1 = H, R2 = COCH3 
   
   
   
   
M10 M11 M12 
   
   
   
 
M13 
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Table 16. Miscellaneous diterpenoids found in the Plectranthus plants over the period 2000-2015.   
 Compound Plectranthus species (section, solvent) Ref 
M1 Cinncassiol A  
 
P. zeylanicus (WP, Hex) 
84 
M2 Cinncassiol C P. zeylanicus (WP, Hex) 84 
M3 (+)-Sesamin P. mollis (Lf, Acet) 75 
M4 4α,7α,11-enantioeudesmantriol P. barbatus (WP, EtOH) 102 
M5 2-hydroxy-3,4,5,6-tetramethoxy-
acetophenone 
P. venteri (Lf, DCM) 109 
M6 2-hydroxy-4,5,6-trimethoxy-
acetophe-none 
P. venteri (Lf, DCM) 109 
M7 Plectranthone P. cylindraceus (AP, EtOH) 76 
M8 Desacetylplectranthone  P. cylindraceus (AP, EtOH) 76 
M9 Isodesacetylplectranthone  P. cylindraceus (AP, EtOH) 76 
M10 4,6-dihydroxy-1,5(H)-guai-9-ene  P. strigosus (WP, Acet) 64 
M11 4,6-dihydroxy-1,5(H)-guai-10(14)-
ene 
P. strigosus (WP, Acet) 64 
M12 10(14)-Aromadendrene-4β,15-diol  P. fruticosus (AP, Acet) 89 
M13 1,2,3,4,6-penta-O-galloyl-b-D-
glucose 
P. barbatus (Lf, MeOH) 110 
Lf – leaf; Rt – root; AP – aerial parts; WP – whole plant; Acet – acetone; DCM – dichloromethane; EtOH 
– ethanol; Hex – n-hexane. 
 
From the abundant diterpenic structures, royleanones are some of the most 
widespread, not only in the Plectranthus genus, but in all Lamiaceae family and 
associated to diverse pharmacologic activities including antimicrobial33,34, 
antimycobacterial65 and antitumoral39,40 activities. Chemically those diterpenes are 
hydroquinonic abietanes with a 12-hydroxy-11,14-di-oxo-quinone moiety in ring C. The 
presence of a conjugated quinone system in such compounds exists in redox equilibrium 
between a diphenol (hydroquinone) and diketone (quinone) forms (Figure 4). Those 
systems possess several physiologic examples as the case of coenzyme Q in electron 
transport systems, vitamin K in blood antihemorrhagic system along with several 
“quinoenzymes” whose action is dependent on hydroxylated amino acids111. Such 
compounds are also a source of stable free radicals and were able to bind irreversible to 
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some amino acids and proteins, acting as Michael acceptors, often leading damage 
and/or protein loss of function. Those properties could be in the source of antimicrobial 
or cytotoxic activities of such natural compounds112,113. 
 
 
 
Figure 4. Simplified representation of the reduction and oxidation reactions between diketone and diphenol forms 
(illustration adapted from de Melo, 2016 114). 
1.3. Microbial resistance and antimicrobials from Plectranthus genus 
Since the discovery of penicillin by Alexander Fleming in 1928 there was a revolution 
in antibiotherapy with the development of the main classes of clinical used antibiotics 
in the following 30 years115. Although from the 1970s there has been a dearth of new 
compounds. After the initial success of the golden age of antibiotics, drug resistance 
began to emerge, and some molecules initially active against many bacterial strains 
were no longer effective116. Bacterial resistance is often driven by decreased 
susceptibility to antibacterial agents originated by halted division, genetic alteration, 
and over-expression of efflux pumps117 (Figure 5). Such targets could be modulated by 
natural products with appropriate molecule shape, aromatic ring count and the 
presence of some polar atoms118.   
 
Figure 5. Antibiotic targets and identified mechanisms of antibiotic resistance117. 
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The World Health Organization (WHO) considered the spreading of multidrug 
resistant (MDR) organisms a public health problem and emphasised the surge for new 
antibacterial agents, with new modes of action119. While combinatory chemistry 
approaches have not been particularly effective in the development of new 
antimicrobial agents120, the neglected natural products have been once again in focus 
of antimicrobial screenings.  Natural antimicrobial products generally possess complex 
architectural scaffolds and densely deployed functional groups, affording the maximal 
number of interactions with molecular targets, often leading to exquisite selectivity for 
pathogens versus the host112,121.  
1.3.1. Antimicrobial compounds from Plectranthus spp. 
From the Plectranthus genus, relevant antimicrobial metabolites have been obtained 
(Figure 6). Rijo et al. reviewed in 2013 the antimicrobial properties of many diterpenic 
compounds obtained from Plectranthus plants33. Among the antimicrobial diterpenes 
widespread in Plectranthus genus, interesting antibacterial acitivites have been found in 
pimarane (15,16-epoxy-7α-hydroxypimar-8,14-ene and 15,16-epoxy-7-oxopimar-8,14-
ene94) (5, 6), neoclerodane (plectrornatin A96) (7), labdane (1,11-dihydroxy-8,13- 
 
    
5 6 7 8 
    
  
 
 
9 10 11 R = H            12 R = OH 
    
    
13 14 15 16 
 
Figure 6. Antimicrobial compounds obtained from Plectranthus species. 
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epoxylabd-14-ene94 and plectrornatin C96) (8, 9) and halimane (11-acetoxyhalima-5,13-
dien-15-oic acid66,86) (10) diterpenes. Abietane diterpenes as Parvifloron D (11) and F 
(12) were obtained from the ethyl acetate extract of P. ecklonii and were both active 
against Listeria monocytogenes122, but only 11 showed relevant antimicrobial activity 
against Staphylococcus, Enterococcus123 and Mycobacterium strains122. Royleanone type 
abietane diterpenes are antimicrobial secondary metabolites, frequently obtained from 
Lamiaceae plants, and widespread in the Plectranthus genus. Horminone34  (13) along 
with its 16-O-acetoxy derivative34  (14) and their related 7α,6β-dihydroxyroyleanone 
(15) and 7α-acetoxy-6β-hydroxyroyleanone (16) were some of the most frequently 
found royleanone-type antimicrobial diterpenes. 
The 7α-acetoxy-6β-hydroxyroyleanone (16) have been obtained in fair amounts from 
P. grandidentatus78, P. hereroensis34 and P. sanguineus124. Considering its broad range 
of activities (Gram positive, Gram negative and Mycobacterium strains) and low MIC 
values (3.12-15.6 μg/mL), this compound was selected as antimicrobial lead compound. 
From the royleanone 16, a library of 12-O-ester (17-19), 6β,12-O-diester (26-23) and 6β-
O-ester (24-27) derivatives was synthetized, delivering new insights on the structure 
activity relationships (SAR) of the antimicrobial diterpenoids65,125 (Figure 7). The 
lipophilic framework composed by the three 6-membered rings (A, B and C) was  
 
 
 R R’ 
 
16   
17   
18   
19 
  
20   
21   
22   
23   
24   
25   
26   
27   
 
Figure 7. 12-O-ester (17-19), 6β,12-O-diester (20-23) and 6β-O-ester (24-27) derivatives of the prototype antimicrobial 
7α-acetoxy-6β-hydroxyroyleanone (16). 
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required for the insertion into the bacterial cell membrane while the oxygenated 
substituents (hydroxyl, carbonyl and esters) act as hydrogen-bond-donor/acceptor 
group and interact with other hydrogen-bond-acceptor/donor groups in the prokaryotic 
membrane as peptidoglycans and lipoteichoic acid33,126.  The esterification of the 
compound 16 in the position 6 and 12 increased the lipophilicity which in most 
derivatives originated an increase of its antimicrobial activity. 
Enthusiastic results of this derivatization were verified for the 12-chlorobenzoyl (18), 
12-methoxybenzoyl (19) and 12-nitrobenzoyl (20) esters along with the 6,12-dibenzoyl 
ester (21) with activity improvement against a multidrug resistant (MDR) 
Mycobacterium tuberculosis (TB) strain. The obtained anti-MDR-TB activity was even 
superior to the first line antituberculostatic agents isoniazid and rifampicin65. The 
royleanone derivative 18 presented potent activity with acceptable cytotoxicity in a 
Vero cell model and could be considered an improved antimycobacterial prototype in 
comparison to the royleanone 1665.  
Royleanone derivatives 17, 18 and 27 showed improved antibacterial activity in Gram 
positive human pathogens over the prototype royleanone 16125. A trend for a 
diminished antimicrobial activity for the 6β,12-O-diester derivatives was also verified. 
Those correspond to the more lipophilic derivatives which could display an unfavourable 
shape and/or steric hindrance, and an incorrect spatial distribution of the hydrophobic 
moieties wall and the loss of some important hydrogen donor/receptor interactions that 
were maintained in the monoester derivatives. Those observations were in concordance 
with other works in which the excess increase in lipophilicity led to a decrease in the 
antimicrobial activity112,127,128.  
The antimicrobial mechanism of action of diterpenoid compounds remain unclear. 
The only diterpenic compound in which a tentative of antibacterial action mechanism 
establishment was performed is horminone (13). This compound possesses a negative 
site, between the C7 hydroxyl and the C14 carbonyl, which was showed to be favourable 
for the binding of a positive ion like Mg2+ (and eventually Ca2+). The horminone-Mg2+ 
complex was suggested to play an important role in the antimicrobial activity, being able 
to cross its membrane and at the cytosol level interacting with ribosomal ribonucleic 
acid and thus inhibiting the protein synthesis in bacteria129,130. This mechanism was 
proposed to be also responsible for the cytotoxicity verified for compound 13 in some 
mammalian cell lines129,130. Also the presence of carbonyl and hydroxyl groups at the 7 
position of B ring and at the 11, 12 and 14 positions of the ring C was discussed to play 
a significant role in the biologic activities of the abietane diterpenoids129,130. The 
proposed mechanism of cell toxicity for horminone could not be extrapolated to many 
abietane diterpenes as some potent antimicrobials (i.e. 16-27) present a decreased basic 
character of the oxygen atom of the acetyl group at position 7 when compared with the 
Lewis basic character of the hydroxyl at position 7 of compound 13. Such chemical 
features were not the optimal for the coordination of the Mg2+ cation and such 
mechanism should only take place if hydrolysis of the acetyl group occurs37,125. Although 
some indications of membrane interaction and disruption effects were in study by our 
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group131. Interestingly many diterpenes showed an effective antimicrobial effect against 
drug resistant pathogens34. Also, some diterpenes as abietic acid, isopimarinic acid and 
totarol were known to inhibit the action of efflux pumps and thus reverting the resistant 
of some drug resistant strains132,133. Considering those effects played by some 
diterpenes, it is possible that other abietane diterpenes, as the case of royleanones, 
possess such action mechanism, but further studies are needed to explore this 
hypothesis.  
The Plectranthus genus constitutes an important source of antimicrobial secondary 
metabolites that due to its interesting potency could correspond to infectious diseases 
drug candidates. The improvement of compound efficacy and the elucidation of the 
action mechanism of such compounds would correspond to future lines of the work with 
antimicrobial Plectranthus derived compounds. 
1.3. Cancer biology and antiproliferative potential of Plectranthus spp. 
Cancer is a group of diseases occurring in higher multicellular organisms. It is 
associated with alterations in gene expression leading to dysregulated balance of the 
cell proliferation and programmed death and originating a tumoural cell population 
ultimately able to invade tissues and metastasize in distant sites134. When a malignant 
cancer is present, the host suffer significant morbidity, and it could be lethal if the 
condition remains untreated. Cancer constitutes the fourth world cause of death and its 
prevalence is estimated to increase in following years135. However, the reason why 
cancer accounts for a major proportion of deaths nowadays is because of a much higher 
life expectancy which nearly duplicated in the last 100 years136. This assume special 
relevance due to the slow carcinogenesis process, in which 10 to 20 years may pass from 
the initial growth of a neoplasm to the formation of a clinical detectable tumor135. The 
causes of cancer are still unclearly defined, but both internal (genetic predisposition, 
gene expression alterations, immune system failure, etc.) and external (virus, chemicals, 
radiation, etc.) are involved. Those factors may also act together to initiate or promote 
cancer development134. 
The developments in genetics and molecular biology contributed substantially for the 
better understanding of the cancer cell biology and its interactions with the surrounding 
medium. Such techniques led to the reinterpretation of the tumour, from a group of 
rapidly dividing cancerous cells, to complex mixtures of several cell types that 
collaborate to create malignant growth: the tumour microenvironment134,137,138. By 
2000 it was proposed that virtually all cancers possess six hallmark capabilities that 
favour its growth and metastatic dissemination: sustaining proliferative signalling, 
insensitivity to growth suppressors, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis and activating tissue invasion and 
metastasis137 (Figure 8). The 2010 update on the cancer hallmarks added additional 
capabilities: reprogramming of energy metabolism and evading immune destruction138 
(Figure 8). Those capabilities were potentiated in the presence of enabling 
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characteristics as genome instability, which contributes to tumour cell variability, and 
inflammation, which contribute to the establishment of multiple hallmark functions. The 
knowledge of such mechanisms of tumorigenesis was related to the uprising of many 
new cancer therapeutics.   
 
 
 
 
 
 
Figure 8. Cancer hallmarks evolution from 2000 to 2010137,138. 
 
The cancer treatment can be archived by three main strategies: chirurgic, 
radiotherapy or chemotherapy. In most cancers, it is not possible (or advisable) to use a 
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single treatment option for the total resolution of the disease134. Classic cancer 
chemotherapy uses small molecules or biologics to destroy rapidly dividing cells. This 
treatment modality can treat the entire body, including cells that may have escaped 
from the primary tumours. However, normal cells that divide quickly (i.e. bone marrow, 
reproductive system or hair follicles) are also affected by the chemotherapeutic agents. 
Also, the low specificity of many chemotherapeutic agents for cancer cells could result 
in low efficacy (the drug don’t reach the tumour site) and severe toxicity (systemic side 
effects). Thus, there is a current need for the development of alternative anticancer 
drugs with improved specificity and minimal side-effects134. Natural products have been 
a reliable source of new drug scaffolds, namely anti-cancer drugs5. Almost half of all the 
approved anti-cancer drugs in Europe, North America and Japan are natural products 
(14%), their semi-synthetic derivatives (28%) or inspired by natural products (5%)139.  
1.3.1. Cytotoxic and antiproliferative activities in the Plectranthus genus 
Plants from the Plectranthus genus have showed in many studies the potential for 
anticancer applications based on its ethnopharmacologic indications (as reviewed by 
Lukhoba et al., 200627) and cytotoxicity screenings of both extract and isolated 
compounds.  
Several studies have focused on cytotoxicity screenings of medicinal plants including 
members of the genus Plectranthus. The screening of 67 Lamiaceae species from 
Australian flora included 25 Plectranthus species140. In this study, the most potent 
cytotoxic effects were verified for P. fasciculatus (IC50 of 5.50 μg/mL in D.mel-II 
Drosophila cell model), although 6 other Plectranthus species showed relevant 
cytotoxicity140. Saeed et al.141 screened 26 South-African medicinal plants traditionally 
used in the treatment or prevention of cancer. From those, the extracts of P. barbatus 
and P. ciliates inhibited the growth of two leukaemia cell lines (the drug sensitive CCRF-
CEM and the drug resistant CEM/ADR5000)141. The screening of 7 Plectranthus species 
(P. ornatus, P. amboinicus, P. argentatus, P. cilatus, P. hadiensis, P. zuluenesis and P. 
fructicosus) indicated that the most potent cytotoxic effect was present in acetone 
extracts of P. cilatus142.  
Different studies revealed considerable cytotoxicity in P. amboinicus extracts143–145. 
The extract obtained with ethyl acetate inhibited considerably the growth of the breast 
cancer cell line MCF-7143. The ethanolic extract from the same plant presented relevant 
cytotoxicity towards a human lung cancer cell line (A549) with fifth percent growth 
inhibition of 31.2 μg/ml (MTT, 48h) while a lower growth inhibition effect was verified 
in Vero cells, which could represent some selectivity144. The hydroethanolic extract from 
P. amboinicus, showed interesting in vivo antitumor effects in mice inoculated with 
Sarcoma-180 and Ehrlich carcinoma with the higher doses reducing the tumour growth 
up to 66%145.  
The extracts from P. hadiensis were screened by two different groups, being verified 
moderate cytotoxicity in FL (IC50 of 150 μg/mL) and HeLa (IC50 = 141.3 μg/mL) cervical 
cancer lines.  
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The ethanolic extract from aerial parts of P. neochilus of was showed some 
cytotoxicity in Artemia salina model with LC50 of 210.31 μg/mL146, and more recently, an 
hexane extract showed growth inhibitory effects in head and neck squamous cell 
carcinoma cell lines147. 
The promising results of plant extract screening could be followed by the bioguided 
isolation of the active compounds. In the Plectranthus genus this strategy conducted to 
the elucidation of some promising anticancer lead compounds, mainly labdane and 
abietane diterpenes, as described therefore.  
The labdane diterpene forskolin (1) (Figure 3), isolated from the roots of P. barbatus, 
was one of the first Plectranthus isolated compounds with promising anticancer 
activities. In the late 1980s was considered a promising antimetastatic agent due to its 
ability to limit metastasis formation in mice model148. This compound is a adenylyl 
cyclase activator, leading to an increase of cAMP and protein kinase A (PKA) intracellular 
level50. Some oncogenic pathways are influenced by the modulation of cAMP and 
therefore it was expected a favourable outcome for the treatment of such cancer forms 
with forskolin149. In concordance, this compound showed to be a potent inhibitor of the 
growth of the “low cAMP addicted” KM12C colon cancer cell line with induction of cycle 
arrest at G1 phase and further apoptosis150. 
Coleusin factor (28) (Figure 9) is a forskolin related labdane also obtained from the P. 
barbatus root that showed antiproliferative effects in hepatoma151, gastric cancer106 and 
rat osteoscarcoma cell lines152. This compound induce G0/G1 cycle arrest and apoptosis, 
both in vivo and in vitro106 models. The occurrence of cycle arrest was related to the 
increase of p27Kip1 and decrease of cyclin D1 in a p53-dependent p21 pathway153 while 
the apoptosis was related to caspase activation and dissipation of mitochondria 
membrane potential with cytochrome C release into cytosol106. More recently coleusin 
factor was showed to restore differentiation in osteoscarcoma cells by BMP-2 induction 
and the expression of transcription factor RUNX2 in absence of apoptosis105. 
Other compounds, also obtained from P. barbatus, also have could have potential 
anticancer applications. Coleon A lactone (29), also obtained from P. puberulentus62,83, 
present potent anti-angiogenic effects in zebrafish embryo model along with inhibition 
of mouse and bovine aortic endothelial cell lines with potency similar to those of a 
known vascular endothelial growth factor (VEGF) receptor inhibitor and two 
phosphoinositide 3-kinase (PI3K) inhibitors103. 13-epi-sclareol (30) showed a cell 
proliferation inhibition similar to the verified for tamoxifen in MCF-7 breast cancer 
model but significantly superior to tamoxifen in Ishikawa uterine cancer model with low 
cytotoxicity in Vero model, which could represent some selectivity to cancer cells154. 
Coleon C (31) appears to exerts a direct inhibitory effect on tumour proliferation in vitro 
and also in vivo (Lewis lung carcinoma in mouse) with some selectivity to human 
melanoma (A375) and human acute myeloid leukaemia (HL60) cancer cells over non-
cancer cells. The mechanism of its effects seems to be related to the induction of 
apoptosis in the sub-G0/G1 cycle phase155. 
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Figure 9. Antiproliferative compounds obtained from Plectranthus species. 
 
 
Abietane diterpenes possessing conjugated quinone systems, such as parvifloron D 
(11) obtained from Plectranthus ecklonii41 or coleon U-quinone (32) and coleon U 11-
acetate (33), obtained from P. xanthanthus82, were described as potent cytotoxic against 
human leukaemia cancer cells. The related compounds coleon U (34) and 7α-acetoxy-
6β-hydroxyroyleanone (17), obtained from P. grandidentatus39, and their hemisynthetic 
derivatives also showed transversal cytotoxic activity to several cancer cell lines39,40. 
Moreover, coleon U (34) was described as a potent and selective activator of the pro-
apoptotic protein kinase C delta (PKCδ) which could explain its reported anti-tumour 
action156 (discussed in more detail in 1.3.2. sub-section).   
At last, some compounds rarely found in the Plectranthus genus were also found to 
have cytotoxic effects. Taxodione (35) was originally obtained from Taxodium distichum 
Rich (Cupressaceae)157 but also present in P. barbatus87. This compound was found to 
be one of the main cytotoxic compounds present in some Lamiaceae species including 
Rosmarinus officinalis158, Salvia chorassanica159 and Salvia staminea160 and tested into 
a comprehensive panel of mammal cancer cell lines (IC50 0.3-60.32 µg/mL). Other 
cytotoxic compound frequently found in other Lamiaceae was 20-deoxocarnosol (36), 
which was also found in P. barbatus, and possessing growth inhibition of several cancer 
cell lines (IC50 4.6 to 32 µM)87,161. Maslinic acid (36) is a pentacyclic triterpenic compound 
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found in olive skin (Olea europaea) but also obtained from tubercles of P. rotundifolius 
(formerly Coleus tuberosus) which showed potent antiproliferative activity against HT29 
and Caco2 colon cancer cell lines107,108,162. Cycle arrest at G0 phase and apoptosis 
thought caspase-3 activation in a p53 dependent pathway were observed for maslinic 
acid108,162,163.  
The overall studies on Plectranthus derived antiproliferative and cytotoxic extracts 
and compounds indicate that this genus is a source of potential anticancer lead 
compounds. Further studies, including bioassay guided isolation of pure compounds 
from active extracts, derivatization of known compounds with establishment of 
structure-activity relationships (SAR) and the detailed characterization of the underlying 
action mechanisms in both in vitro and in vitro models were needed for the 
establishment of potential new anticancer therapies.   
1.3.2. PKC as anticancer natural product target 
The protein kinase C (PKC) family consists of ten serine/threonine protein kinases 
classified based on their regulatory domain structure and cofactor requirements for 
activation. Three isoforms subfamilies could be considered: classical (or conventional) 
PKC including α, βI, βII, and γ; novel PKCs including δ, ε, η and θ; and atypical PKCs 
including ζ and λ\ι164. All PKC family members share a common structure composed by 
a cell membrane targeting NH2-terminal regulatory domain and a COOH-terminal 
catalytic domain, with four conserved (C1-C4) and five variable (V1-V5) regions (Figure 
11). These two major domains are linked by a flexible hinge region (V3), which is the site 
of caspase proteolytic cleavage, protein-protein interactions and tyrosine 
phosphorylations165.  
The classical and novel isoforms contain a C1 domain with two cysteine-rich motifs 
(C1a and C1b), which is the binding site of diacylglycerol (DAG) and also the competitive 
binding site to tumour-promoting phorbol esters (i.e. TPA, 41)166. The C2 domain differs 
from classic PKC to novel PKC. Whereas the classical C2 domain binds to PS of 
membranes in a Ca2+-dependent manner, novel PKC contain a variant (C2-like) that binds 
to phospholipids in a Ca2+-independent manner165. Atypical PKC isoforms contain a 
modified C1 domain, termed ‘atypical’ C1 domain that retains the ability to bind anionic 
phospholipids, although with lower affinity. Additionally, these isoforms present a 
Phox/Bem1 (PB1) domain responsible for their interaction with other PB1-containing 
proteins164,165. The regulatory domain of PKCs contains an auto-inhibitory 
pseudosubstrate sequence that retains the kinase in an inactive state by occupation of 
the substrate binding pocket in the catalytic domain (Figure 10). The catalytic domain of 
PKCs is a highly conserved region among the distinct PKC isoforms and contains the ATP 
binding site (C3) and the substrate binding site (C4)164,165.  
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Figure 10. PKC families regulatory and catalytic domains. 
 
This multifamily of structurally related kinases has a crucial role in cellular signalling 
transduction, being their members involved in the regulation of several biological 
processes, including proliferation, apoptosis, differentiation, survival, and migration. In 
fact, dysregulation of PKCs, in terms of both expression levels and activity, is frequently 
associated with distinct human diseases, including cancer164. Among the several PKC 
isoforms, PKCα, δ, ε and ζ have deserved particular attention in cancer research. PKCα 
has been predominantly linked to increased proliferation and/or survival, being 
commonly recognized as a tumour promoter. For instance, in U87 glioblastoma cell line, 
PKCα increased the resistance to apoptosis in response to radiation and 
chemotherapy167,168. Nevertheless, depending on the cellular background, PKCα can also 
behave as a tumour suppressor. For example, in LNCaP cells, the activation of PKCα by 
phorbol esters induced apoptosis, an effect abrogated by the expression of a PKCα 
kinase-dead mutant upon PMA treatment and radiation169. In contrast, PKCδ is 
frequently associated with pro-apoptotic functions. In fact, PKCδ has been broadly 
implicated as a death mediator of chemotherapeutic agents and radiotherapy. Ectopic 
overexpression of PKCδ induced growth inhibition in NIH 3T3 cells170, an effect also 
observed for other cell lines. However, pro-survival properties of PKCδ in a number of 
tumour models, including breast, lung, pancreatic and liver cancer were also 
described171. PKCε has been described as an oncogenic isoform. It is frequently 
overexpressed in a large number of cancers, namely in breast172, prostate173, and in 
primary NSCLC cancers174. PKCε has a prominent anti-apoptotic function, promoting 
survival in several tumour cells, what has been intimately related with the modulation 
of caspases and Bcl-2 family proteins. Actually, it was reported that PKCε has the 
potential to enhance the progression and to confer resistance to apoptosis of prostate 
cancer175,176. Regarding PKCζ, both up- and down-regulation of this isoform have been 
reported in human cancers. Also for this isoform much controversy exists around its role 
in cancer development177. Many studies have reported a tumour suppression function 
for PKCζ, which mainly occurs through down-regulation of Ras-induced interleukin-6 
production by PKCζ178. It was also revealed a link with c-Myc, which contributes to the 
more aggressive phenotype associated with PKCζ loss179. However, there are several 
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reports highlighting a pro-survival role for PKCζ180,181. The proliferation and anti-
apoptotic activities of PKCζ seem to involve ERK and NF-kB/IkB pathways182,183. 
Some compound classes obtained from Lamiaceae family plants were able to 
modulate the PKC activity. Carnosol (38) (Figure 11) is an abietane diterpene with an o-
diphenolic C-ring and a lactone moiety between C7 and C20 atoms and was first isolated 
from Salvia carnosa184. This compound is present in high yields in Rosmarinus officinalis 
leafs185 and showed promising antiproliferative activity in prostate, breast, skin, 
leukaemia, and colon cancer cell models186. The cytotoxicity of carnosol seems to be 
linked to the modulation of multiple deregulated pathways including nuclear factor 
kappa B (NF-kB), PI3K and PKC187. In addition, the concomitant administration of 
carnosol with other cytotoxic agents promoted a synergistic effect in reducing cancer 
cell viability188. Coleon U (34), has been isolated from several Plectranthus species such 
as P. forsteri83, P. grandidentatus39, P. madagascariensis189 and P. myrianthus56. This 
diterpene is a quinone methide abietane exhibiting  potent cytotoxic effects transversal 
to several cancer cell lines including breast39,40, leukemia40,190 and melanoma40,190. The 
mechanism by which coleon U induces its cytotoxic effect may be related with in vitro 
selective activation of novel PKCs namely PKCδ and ε. This effect, originates a nucleus 
translocation of activated PKC isoforms and the subsequent apoptosis mediated by 
metacaspases in the yeast model156. However, coleon U is easily degraded to its oxidized 
form coleon U-quinone that owns also cytotoxic effects82,83. Whether this derivative is 
also a PKC activator is still unknown. These abietane diterpenoids coleon U and carnosol 
may be lead compounds for anticancer treatment particularly as PKC modulators. 
However, the degradation profiles of carnosol191 and coleon U83 highlight the need of 
more stable derivatives for further potential clinical use. 
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Figure 11. Chemical structure of some natural products that act as PKC isoforms modulators. 
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Other natural products have also found to target PKC isoforms. The most clinically 
relevant were the marine origin polioxygenated macrocyclic lactones known as 
bryostatins192,193. This class of compounds showed antiproliferative activity against a 
wide range of cancer cell lines such as P388 leukemia194, ovarian sarcoma195, B16 
melanoma195,196 or M5076 reticulum cell sarcoma195. Subsequently, the bryostatin 1 (39) 
was submitted to more than thirty-five human clinical trials (phase I/II). Nevertheless, 
the efficacy of bryostatin 1 used as a single drug, for example against melanoma, 
colorectal cancer and gastric carcinoma, has been variable and with some disappointing 
results. However, when combined with conventional chemotherapeutic agents, such as 
paclitaxel197 and gemcitabine198, significant synergistic effects were observed. These 
results indicated that bryostatin 1 could be a useful enhancer of the cytotoxic activity of 
some therapeutic regimens, rather than an anticancer agent. Consequently, bryostatin 
1 has been under different clinical studies in combination with diverse therapeutics. 
Food and Drug Administration (FDA) has approved the bryostatin 1 as an Orphan Drug 
in combination with paclitaxel against the oesophageal carcinoma199. Synthetic 
analogues have been developed by different strategies mainly by Wender200,201 and 
Keck202 groups but more recently a function oriented strategy was able to produce 
simplified analogues with a nanomolar binding affinity to PKC203.  
Another group of clinical importance were the ingenanes obtained from the milky 
latex of Euphorbia species such as E. antiquorum, E. drummondii, E. helioscopia, E. hirta 
and E. paralias204,205. Extracts from Euphorbiaceae plants have been used in traditional 
medicine for centuries in the treatment of some skin conditions as warts, keratosis and 
cancers206. The E. peplus phytochemical study of these extracts yielded several 
macrocyclic diterpenes, being the ingenol mebutate (40) the most active 
component207,204,208,209, including antitumour activity in several cancer cell lines 
including  breast, colon, lung and melanoma210,211,212. The mechanism of action of 
ingenol mebutate is, at least, partially related to the activation of PKC to which has a 
potent binding affinity. In vitro, low isozyme selectivity was verified with a Ki ranging 
from 0.105 - 0.376 nM213. These results supported the preclinical and clinical trials for 
the topical treatment of actinic keratosis (AK) carried out by both FDA and EMA 
(European Medicines Agency)214. Recent studies indicated that both a dual proapoptotic 
and an immunostimulatory effects occurred  in the leukaemia disease215.  
The role of PKCs in carcinogenesis is known since the late 1980s. Nevertheless, the 
development of PKC targeting drugs has not been an easy task. The PKCs isoforms are 
the target of many natural products, although very few are selective to solely one 
isoform, which is not suitable to clinical use. The natural products arise as useful 
compounds for the study of bio-molecular complex interactions involved in the 
carcinogenesis process. Furthermore, some natural products or their closely related 
analogues are under clinical trials. Two approved compounds for specific cancer types 
are bryostatin 1 (39) in combination with paclitaxel and ingenol mebutate (40). The 
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search for more selective PKC modulators remains a promising strategy for future 
anticancer treatment. 
1.4. Natural product delivery systems 
Besides the importance of natural products in the development of new drugs, 
intrinsic physical and chemical characteristics of the natural drugs stand for a poor 
pharmacokinetic profile. For adequate bioavailability, drugs should present a good 
balance between hydrophilicity (ability to dissolve in water mediums as gastrointestinal 
fluids and blood) and lipophilicity (ability to cross lipidic mediums as the case of biologic 
membranes). However, many plant secondary metabolites, from the most prevalent 
classes, are either low fat soluble (i.e. flavonoids, polyphenols, etc.), low water soluble 
(i.e. terpenes) or present high molecular weight (i.e. saponins, tannins) which also limits 
their oral bioavailability. Also, the stability of natural products was frequently impaired 
in the gastro-intestinal environment or can be either metabolized by gut bacteria or 
suffer rapid liver metabolism. 
Many strategies have been applied to overcome those limitations. The most used 
were the chemical derivatization or the novel drug delivery systems (NDDS). The first 
implies a chemical modification of the compound structure with possible implications 
on its original activity. Also, this strategy could only be applied to a pure compound and 
not to a standardized extract. It is somewhat frequent that the isolation of the most 
active compound in an extract not always led to an improvement of the activity, which 
could be explained by the existence of a synergic potential between natural 
components. Those factors indicated that chemical derivatization was not always 
applicable. On the other hand, NDDS have been in focus in recent years with the 
development and improvement of many drug delivery systems including microparticles 
and nanoparticles, among others216,217. Those systems intend to improve the 
therapeutic outcome with minimized adverse or toxic effects and improved patient 
compliance due to an improved drug dosage, compatibility with physiologic mediums, 
targeted delivery and favourable release profile, without alterations on the molecule 
structure216.  
The discovery that some dietary components, containing phospholipids, improve the 
absorption of low bioavailable drugs led to the development of lipidic based-
systems216,218. Those can assume diverse forms as liposomes, nanosomes, niosomes, 
ethosomes and, the more interesting for natural product delivery: phytosomes. 
Phytosome is the name of a patented technology developed by the Italian 
pharmaceutical company Indena. The name derived from the conjugation of the Greek 
words “phyto” meaning “from plant” and “some” which means “cell-like”. Other 
designations have been used for phytosomes including phyto-phospholipidic 
nanoparticles, planterosomes and herbosomes216,219. 
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1.4.1. Phospholipids: structure, properties and complexation 
The main constituents of every life form membrane are phospholipids. Those polar 
lipids were constituted by both a hydrophilic (“head”) and two hydrophobic (“tail”) 
portions which in conjugation confer substantial solubility in both aqueous and oily 
mediums. Phospholipids can be classified as glycerophospholipids (with a diacylglycerol 
backbone) and sphingomyelins (with a ceramide backbone). In the eukaryotic cell 
membrane the glycerophospholipids including phosphatidylcholine (PdC), 
phosphatidylethanolamine (PdE), phosphatidylinositol (PdI), phosphatidylserine (PdS) 
and phosphatidic acid (PdA) were the most abundant constituents220. Those molecules 
were classified and named based on the constitution of the head group and the length 
and saturation of hydrophobic side chains (Figure 12).  
 
 
 
Figure 12.  Main structure of the PdC, representative PdC groups and main natural fatty acid residues. 
Animal tissues (egg yolk and bovine or swine brain) and vegetable oils (soybean, 
cotton seed, sunflower, etc.) are the most important natural sources of phospholipids. 
Naturally obtained phospholipids were composed by a saturated fatty acid (stearic or 
palmitic acid) in the glycerol carbon 1 and an unsaturated fatty acid (oleic, linoleic, α-
linoleic or arachidonic acid) in the glycerol carbon 2 (Figure 12). The more frequently 
used phospholipids in pharmaceutical applications were those obtained from soya bean 
(Glycine max) that contains about 70% of PdC with a high content of linoleic and oleic 
acids which offers excellent compatibility to the mammalian membrane221.  
In the human physiology, phospholipids were also present as emulsifiers at intestinal 
level, together with cholesterol and bile acids are able to form micelles that improve the 
absorption of both fat and water soluble substances222. Phospholipids can also be found 
as wetting agents in the pleura and alveoli of lungs, pericardium and joints220. As 
expected from physiologic relevant molecules they are biocompatible with no signs of 
carcinogenic, immunogenic or teratogenic effects even when administered at high 
dosages in clinical trials222. 
 The conjugation phenomena of phytomedicines with phospholipids have been 
briefly studied. Research on the interaction between some flavonoids and cellular PdC 
demonstrated that most molecules possessing π electron systems are able to form 
different complexes with membrane phospholipids223. Those interactions were 
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confirmed in several papers by the use of spectroscopic, thermographic and molecular 
imaging techniques that demonstrated the formation of the phytophospholipidic 
complexes (PPC).  
Thermal analysis, by differential scanning calorimetry (DSC), is a fast and reliable 
method to revealing the distribution patter and further interactions between 
phytocomponents and phospholipids in the phytosome matrix. The comparison of 
phase diagrams of natural compound, phospholipids, their physical mixture and the 
phytosome allow the estimation of the presence of an interaction by the elimination of 
endothermic peaks, appearance of new peaks, change in peak shape, area and/or 
melting points. This fact occurs presumably due to the formation of an interaction 
between the two molecules. Such interaction could be originated from the hydrogen 
bonding established between hydroxyl groups in the natural product (i.e. phenol 
moieties) and those in the polar head of the phospholipid (phosphate and/or 
ammonium groups)224. Van der Walls forces were also suggested occur between the two 
moieties224,225. Those strong interactions between the polar components allow the free 
turning of the hydrocarbon chains in the phospholipid which enwrap the polar head of 
the phospholipid containing the natural product224–227. 
The infrared spectroscopy and namely Fourier transform infrared spectroscopy (FT-
IR) could confirm the complex formation by comparing the spectrum of the complex 
with individual components and their physical mixture. The FT-IR spectra of pure 
phospholipids is generally characterized for the presence of peaks at approximately 
3500 cm-1 (hydroxyl stretching), 2900 cm-1 (C-H stretching at fatty acid residues), 1700 
cm-1 (carbonyl stretching of the fatty acid ester), 1200 cm-1 (P=O stretching), 1100 cm-1 
(P-O-C stretching) and 970 cm-1 (N-(CH3)3 stretching)228,229. Many natural products like 
polyphenols or flavonoids have in their structures one or more hydroxyl groups whose 
O-H stretching appear in the FT-IR spectra as sharp peaks in the 3800-3200 cm-1 range. 
Also some signals measured in the about 3500-3300 cm-1 range correspond to N−H 
stretching vibrations of natural products containing amine groups229. While analysing 
the FT-IR spectra of the PPC it could generally be observed a shift and broadening of the 
signal corresponding to the natural products hydroxyl O-H or amine N-H stretching along 
with the signal corresponding to the aliphatic phosphate (P=O stretching) and choline 
quaternary ammonium (N-(CH3)3 stretching) groups of the phospholipids with no 
alterations found in the bands of the aliphatic carbon chains of the fatty acids. These 
observations suggest that some weak physical interactions between free hydroxyl or 
amine of the natural components and the polar groups of phospholipids took place 
during complex formation230.  
Additional confirmatory assays could be performed using x-ray powder diffraction 
(XRD)226,228,231 or 1H, 13C and 31P nuclear magnetic resonance (NMR)228. Slight or no 
changes are verified in the side chain signals which indicate that the long aliphatic chains 
wrap around the polar head, containing the bonded phytocomponents, generating a 
lipophilic envelope232. Also UV absorbance could be used for complex analysis formation 
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but with rendering less useful information when compared to previous techniques233–
235. 
The concomitant information retrieved from those thermographic and spectroscopic 
methods on the PPCs some key findings arise: the natural drugs and phospholipids 
establish weak (non-covalent) bindings as hydrogen or Van der Walls bonds. Those 
interactions occur mainly between the hydrogen atoms of hydroxyl or amine groups and 
the polar components of the phospholipid (phosphate and choline). The aliphatic chains 
of the phospholipid do not interact directly with the natural drug but form a lipophilic 
envelope around the natural drug-phospholipid complex (Figure 13). 
 
 
Figure 13. Illustration of the potential interactions during the formation of a phyto-phospholipidic complex. I. A 
phytochemical and PdC were combined and weak interactions occur between the polar moieties of the two molecules; 
II. A Van der Walls and hydrogen bonds were established between the phosphate group of the PdC and the phenolic 
hydroxyls of the phytochemical; III. The aliphatic side chains of the PdC involve the polar head where the phytochemical 
has been complexed. This corresponds to a lower energy form of the complex (ChemDraw 3D Pro 12.0). IV. Illustration 
of the structure of a phytophospholipid complex (adapted from Indena, SPA®). 
 
1.4.2. Phytophospholipid complex optimization and preparation 
Phytophospholipid complexes were obtained by reacting close to equimolar 
proportions of phytochemical and phospholipid for a certain amount of time in a 
suitable reacting medium being the recovery of phytosomes accomplished mostly by 
solvent evaporation or precipitation (Annex 1). Reaction variables as the proportions of 
components, reaction time, temperature or solvent as long as the use of different 
strategies for the complex retrieval can influence the particle size, its dispersity and the 
entrapment efficiency were discussed in this section. 
1.4.2.1. Optimization of drug to phospholipid proportions 
The phytosome differ from other lipidic-based nanoparticles as the proportion of 
drug to phospholipid is close to equimolar. In systems as the liposomes, in which this 
proportion is much lower and being each drug molecule surrounded by hundreds of 
phospholipid molecules, exists limited drug interaction with the surrounding medium. 
Also a lower drug loading capacity is expected from liposomes when compared to 
phytosomes. The original patents on the phytophospholipidic complexation state that 
the complex ratio could range from 0.5 to 3 molar ratio236. A substantial proportion of 
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the recent papers and patents on phytosome preparation used a 1:1 molar proportion 
between its elements, however some experimental designs were focused on exploring 
other molar proportions (reviewed in Annex 1). 
1.4.2.1.1. Solvent selection 
Original phytophospholipid complexation patents stated that the reaction should 
occur in an aprotic solvent such as acetone, dichloromethane, dioxane, ethyl acetate or 
tetrahydrofuran233,237 but the use of protic solvents as ethanol have also been developed 
and patented by other groups233,238. Recalling the phytophospholipid complexation 
theory, in phospholipids, the nitrogen atom has a strong tendency to lose electrons 
while the oxygen atom of the phenolic hydroxyl group polyphenols tends to gain 
electrons, in order to make the complexation possible. This way, aprotic solvents were 
preferred, as do not interfere with the electrons exchange of the complexation 
process239. Song et al. (2008) have studied the feasibility to prepare the silybin-
phospholipid complex using four solvents with low dielectric constant. The experience 
was failed when dichloromethane or ethyl acetate were used but it was successful using  
acetone and tetrahydrofuran (THF)239. The selected solvent should be able to dissolve 
both phospholipids and natural products for the complexation to take place. Although 
the markedly differences in the solubility of the complex components could not allow 
the use of a single solvent for their dissolution. The conjugation of two or more miscible 
solvents could then be applied. Also moderate heating or sonication could improve the 
components dissolution240. However, it is necessary that such conditions do not imply 
the stability of the phytosome components. Most of those solvents possess a high 
toxicity (ICH class 1 or 2) and so the substitution of those for more biocompatible 
solvents should be taken account in newer formulations as discussed in ICH Q3C 
technical document241. Examples of solvents used for phytosome preparation were 
present in Annex 1. 
1.4.2.1.2. Combination of factors 
The optimal conditions for the synthesis of phytosomes with desired characteristics 
were generally not found with the adjustment of a single reaction factor but as a 
combination of factors. The use of different statistic methodologies was seen for the 
optimization of the phytophospholipid complexation process.  
Several examples of quadratic or orthogonal designs were available in 
literature233,235,239,242.  The overall tendency was that a higher temperature favours the 
occurrence of complexation. The drug-to-phospholipid optimized proportion was 
dependent on the compound characteristics, but the 1:2 molar ratio or similar was the 
more frequent as result from the optimization.  
1.4.2.2. Phytophospholipid complexation methodologies  
For the preparation of PPCs the chosen proportions of phospholipids and 
phytocomponents must be dissolved in suitable medium and react at an optimized 
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temperature for the adequate time. Then, the complex must be recovered as dry 
powder or converted into a phytosomal suspension (sub-section 1.5.5). 
1.4.2.2.1. Solvent evaporation 
A chosen proportion of natural product and phospholipids were mixed in a reaction 
vessel containing a suitable solvent system and the reaction is allowed to be carried for 
2 to 6h at room temperature or with moderate heating. The solvent is then evaporated 
leading to the recovery of the dry complex. In this setting, the use of volatile solvents 
was the advantage of their ease of removal229. This is true in the case of solvents with 
boiling temperature lower than 60ºC, as higher temperatures could impair the stability 
of the complex and its components. In most frameworks, the solvent evaporation occurs 
at reduced pressure using temperatures lower than 60ºC, varying the duration of the 
process from a few hours up to 24h. If the choice of solvent recall in non-volatile 
solvents, lyophilisation or spray-drying could be valuable alternatives for the solvent 
removal. For such solvent removal methods, the addition of a carbohydrate (i.e. dextran 
or mannitol) could be necessary for their cryoprotectant effects on the complex during 
the lyophilisation process229,230. The lyophilisation has also the advantage of dispensing 
an additional drying step.  
1.4.2.2.2. Anti-solvent precipitation 
This process has similarities to the solvent evaporation method, being the phyto-
components and phospholipids combined in a reaction vessel containing a polar or 
median polar solvent, being the reaction carried for a predetermined period of time at 
the selected temperature. The reaction is generally stopped by the addition of an anti-
solvent in which the product is generally insoluble, as the aliphatic hydrocarbons (i.e. n-
hexane), being the PPC recovered after its precipitation (and eventual centrifugation) 
followed by removal of the solvent243. Examples of phytosomes prepared using this 
methodology were presented at Annex 1.  
In some protocols, the precipitation technique was not very effective for the 
producing of a complex because the complex is decomposed upon the addition of the 
anti-solvent230. Authors suggested that it could be related very weak interactions during 
the complex formation and/or to the ability of the anti-solvent to dissolve the 
phospholipids leaving the crystalline drug precipitated230. 
1.4.2.2.3. Other methods 
 The use of SCF by the supercritical anti-solvent technique was been used for the 
preparation of pharmaceutical fine powders. The same principles could be applied for 
the production of phytosomes, namely by the supercritical fluid solution enhanced 
dispersion (SEDS). This method has some advantages over traditional PPC preparation 
techniques, including the controlled particle size and site distribution but also not time 
consuming and simple244.  
Also, a “mechanical dispersion method” was published245. In such, the phospholipid 
components were dissolved into the minimum amount of an apolar compatible solvent 
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(i.e. diethyl ether) under sonication. The water dissolved phytocomponent was then 
added dropwise to the phospholipid solution under sonication for 15 minutes being the 
phytosome formed245. 
1.4.2.3. From the complex to the vesicle 
The PPC presents a disorganized, irregular and amorphous structure that present 
generally a heterogeneous dispersion. The micellar phytosome structure was only 
formed when the PPC is added to an aqueous medium leading to the reorganization of 
the phospholipidic double layer. Some methods for the pharmaceutical preparation of 
phytosomes from the phytophospholipid complex are here described.  
1.4.2.3.1. Film hydration method 
Following the formation of a thin film of PPC, using a solvent evaporation method, 
the process can be continued by the hydration of the PPC using a suitable aqueous 
medium (purified water, PBS, among others). During the contact between the aqueous 
and lipidic phases, a gradual swelling of the PPC into the aqueous phase occurs leading 
to vesiculation of PPC and formation of a phytosome suspension246,247. 
1.4.2.3.2. Nanoprecipitation 
This technique used the PPC dissolved in a compatible organic solvent which was 
extruded dropwise to distilled water with gentle stirring. The organic phase was 
gradually evaporated by the use of reduced pressure or at room conditions for up to 
24h248,249. The physical process of nanoprecipitation in the preparation of mitomycin 
phytosomes from mitomycin-PdC complexes was briefly described by Hou and its 
collaborators229. Initially both mitomycin and PdC were dissolved into an organic solvent 
and gradually dispersed into the continuous phase leading to interface turbulence and 
conversion of the system into an O/W suspension. In a second moment, a decrease in 
the interfacial tension resulted in droplet size reduction and, subsequent, spontaneous 
emulsification. Then, the organic phase gradually diffuses into the continuous phase 
with integration of excess water into the nanodroplets. The evaporation of the organic 
phase contributes to a gradual concentration of the nanodroplets and after the 
complete removal of the organic phase, phytosomes were precipitated into the aqueous 
environment (Figure 14)229. 
 
 
1) Phytophospholipid 
components dissolution 
in organic solvent 
2) Organic phase dispersion in 
the continuous phase with 
conversion into O/W suspension  
3) Decrease in 
interfacial tension with 
droplet size reduction  
4) Remaining 
evaporation of the 
organic phase 
5) Precipitation of 
the phytosome in 
the aqueous media 
Figure 14. Illustration of the mechanism of phytosome formation by nanoprecipitation technique. Adapted from Hou 
et al. 2013229. 
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1.4.3. Phytosome characterization 
Phytosomes are generally characterized according to its morphology, physical 
properties and chemical composition. 
1.4.3.1. Morphology 
The shape and morphology of phytosomes are analysed using direct visualization 
techniques as scanning electron microscopy (SEM)250 or transmission electron 
microscopy (TEM) or using topographical characterization, namely by atomic force 
spectroscopy (AFM)249. When directly visualized, PPC were amorphous, fluffy, porous 
with rough surface and an apparent interaction in the solid state228. On the other hand 
phytosomes presented a liposome-like vesicle, with fairly uniform size, dispersed in the 
aqueous environment 248.  
1.4.3.2. Size and distribution 
The particle physical size and its distribution have been analysed mainly by light 
scattering methodologies as photon correlation spectroscopy (PCS) or dynamic light 
scattering (DLS) and using computer algorithms to determine the average particle size 
and the polydispersity index (PI) being the mixture monodisperse when the PI = 0. An 
alternative methodology of size dispersion is the SPAN value. This measure reflects the 
width of the size distribution. Smaller values (< 1) are generally obtained when a narrow 
distribution exists251. 
1.4.3.3. Surface charge 
The general charge present at the surface of each phytosome has been evaluated by 
the measuring the zeta potential (ζP). The knowledge of the surface charge can help to 
predict the fate of the phytosome particles in vivo concerning the ease for aggregation 
or the attraction to charged tissues. Most phytosomes present a negative or neutral 
surface charge, depending on the degree of complexation and the availability of 
negatively charged free phosphate groups from phospholipids230.  
1.4.3.4. Encapsulation efficiency and drug loading 
The amount of phytocomponents complexed with phospholipids has been generally 
evaluated by direct analysis of the dried PPC dissolved into an aggressive media as an 
organic solvent or extreme pH. The HPLC methodologies were robust, sensible and 
reproducible state of the art technique for the quantification of drug products into an 
unknown matrix227. Also some authors used simply UV-spectroscopy for the 
quantification230.  The amount of natural drug incorporated into a PPC is highly 
dependent of the drug and matrix physic-chemical characteristics but also from some 
process variables as starting materials ratio, reaction temperature and reaction time, 
among others, influence the drug yield in PPC 233,235,239,242. 
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1.4.3.5. Phytosome stability 
Several studies established long-term stability problems when phytosomes were 
dispersed into an aqueous suspension. The main problems related to this instability 
were the particle aggregation/leakage, chemical instability (PdC hydrolysis from ester 
bonds, oxidation) and biological contamination (microorganism growth)248. Some 
strategies that could result in the improvement of the phytosome stability were 
therefore described.  
The addition of an optimized proportion of cholesterol to the vesicular phytosome 
system was also demonstrated to improve the short-term stability251. This effect could 
be explained by the interaction between cholesterol and PdC (hydrogen bond between 
the cholesterol hydroxyl and the polar head of PdC) which induces a tighter packing of 
PdC in the membrane and enhances electrostatic repulsion between phospholipid 
bilayer. It also enhances the membrane flexibility. Cholesterol also increases the 
thickness of the phospholipid bilayer251. However, the use of cholesterol is limited by its 
long-term oxidation, that may originate stability problems252. 
Lyophilization has been considered a favourable technique for industrial process in 
the pharmaceutical field to obtain fine powders. It is easy to manipulate and led to a 
more stable drug product. The lyophilized phytosome of diosmin maintain their initial 
physicochemical characteristics at different pH and with the presence of enzymes 
(simulated gastric fluid). A change in the surface charge was however verified in acidic 
medium (+24 mV) as compared to a buffered pH 7.4 (-6 mV) or to a higher pH (-27 mV). 
Such changes in the surface charge could be related to the intrinsic dual charge of PdC 
(pKa = 0.8). The phosphate negative group is neutralized in acidic pH leading to a positive 
charge predominance while the opposite occur at higher pH values as alkaline medium 
should neutralize the choline positive group, leading to the predominance of negative 
charge230. Such occurrence could impair the stability of the nanoparticles as a low ZP 
could led to particle aggregation and precipitation.   
1.4.4. Targeting of phytosomes: coating and functionalization  
There is not a standard phytosome for each application. As so, some groups have 
opted to combine the phytosome technology with other encapsulating agents as 
polymers, metallic NPs or to functionalizing the phytosome surface in order to obtain 
improved targeting of bioavailability.  
Mitomycin is a water soluble anticancer drug with clinical use limited by aqueous 
media instability, short elimination half-life and lack of selectivity253. The first 
approaches to overlay such limitations were the encapsulation into a polymeric carrier, 
dextran254 or polylactic acid (PLA)253, or the incorporation in phospholipidic medium: 
liposome255 or phytosome229. The mitomycin phytosomes were able to reduce the drug 
degradation and improve its release pattern but did not archive selectivity for the 
tumour site. The same group opted then to attach to the loaded phytosome a pH-
sensitive coating of polyethylene glycol-phosphoethanolamine-polylactic acid (PEG-PE-
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PLA) which is stable at physiological pH but originating burst release at endosomal or 
lysosomal pH. This system was also functionalized with folate (FA) which conferees 
active targeting to tumour overexpressing the folate receptor248. The originated FA-PEG-
PE-PLA-phytosome hybrid system exhibited selective tumour accumulation with 
sustained release and steady-state pharmacokinetics in BALB/c nude mice inoculated 
with H22 mouse ascitic hepatoma cell line248. Those in vivo results provide evidences for 
improved antitumor activity with reduced side effects.  
Another example is the hybrid formulation concerning the conjugation of Calendula 
officinalis phytosomes with gold nanoparticles (AuNPs). It was developed for 
incorporation into wound healing dermal formulations. Those Calendula AuNP-
phytosomes had an average particle size of 80±5 nm and showed an in vitro protective 
effect up to 81% in the cytotoxicity induced by H2O2 in Vero cells (fibroblasts from African 
green monkey kidney). Also, in the in vitro wound scratch assay256, those hybrid 
phytosomes showed an improvement in the gap closure of the cell monolayer of 58.7% 
(against 42.2% of the equivalent Calendula phytosomes)257. 
The addition of a coating is another option for improvement of the delivery of 
phytosomal formulations. Polymeric structures as chitosan was used for the 
improvement of curcumin oral absorption. The chitosan microparticles containing 
curcumin phytosomes were produced by ionotropic gelation being obtained spherical 
microspheres with an average particle size of 23.21±6.72 µm249. The pharmacokinetic 
study showed an improvement of the curcumin bioavailability in 1.67 and 1.07-fold 
when compared with the phytosomes of curcumin and chitosan microparticles of 
curcumin, respectively. Also the half-life of curcumin in the microencapsulated 
phytosomes was longer (3.16h) than those of phytosome (1.73 h) and chitosan 
microparticles (2.34 h) of curcumin upon oral administration in rat model249.  
1.4.5. Applications of the Phytosome strategy 
The PPC complexes and their phytosomal equivalents can be formulated in the form 
of suspension, emulsion, syrup, lotion, gel, cream, pill, capsule, powder, granules, etc. 
resulting in a product that is better absorbed and produces better result than the 
conventional herbal extracts.  
1.4.5.1. Clinical and nutritional uses 
The use as active ingredients in food supplements was the most frequently found 
application of this technology. Some relevant phytosomes examples of such applications 
were the silymarin flavonolignans, the curcuminoid polyphenols, the green tea flavan-
3-ol catechins and the ginkosenoids from ginko258 (Figure 15).  
Flavonolignans obtained from milk thistle (Silymarin marianum, Compositae) have 
been used for their ethnomedicinal applications in liver disease for more than 2000 
years258. The major flavonoligan present in the fruit of milk thistle was silybin (42) which 
was proven to be a liver protectant by its potent antioxidant effect and glutathione 
conservative effect. Also silybin and related compounds have showed promising results 
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as chemopreventive or anticancer agents259,260 due to its inhibition effects on the silent 
information regulator 1 (SIRT1)261 and signal transducer and activator of transcription 3 
(STAT3)262. The phytosome of silybin (SiliphosTM, Indena Spa) have showed a huge 
improvement in the pharmacokinetics of the pure compound. Silybin have a low 
solubility in water (>0.5 g/L). It suffers an extended phase II metabolism and it is rapidly 
eliminated by kidney and urine, which results in a low bioavailability and short half-
life263,264. SiliphosTM showed an significant increase in the oil and water solubility and 
bioavailability up to 10-fold in rat model265,266. This formulation was well tolerated even 
at high doses267 and found clinical applications as hepatoprotective268 and cancer 
adjuvant269. 
Curcumin polyphenols (43-45) were obtained from turmeric (Curcuma longa, 
Zingiberaceae) to which conferee the characteristic yellow coloration of the rhizome. 
Those compounds have potent free radical scavenger, anti-inflammatory and anti-
cancer properties that have failed to translate to clinical practice due to their poor 
bioavailability. Three main curcuminoids were present in standardized preparations  
 
 
 
 
42 43 R=R’=OCH3 44 R=H, R’=OCH3 45 R=R’=H 
    
 
  
46 47 R=H 48 R=OH 49 
Figure 15. Chemical structure of some natural products included in phytosomal commercially available formulations. 
 
namely curcumin (diferuloylmethane; curcumin I) (52), demethoxycurcumin (curcumin 
II) (53) and bisdemethoxycurcumin (curcumin III) (54). The phospholipid complexed 
form of standardized curcumin (MerivaTM, Indena Spa) has demonstrated an 
outstanding improvement in bioavailability. The absorption of curcumin was 18-fold 
higher and the curcuminoid mixture up to 29-fold higher in comparison to unconjugated 
curcumin270. Two other different studies on curcumin-phospholipid complex 
demonstrated an improvement of the Cmax in the range of 1.6249 to 2.4-fold227. This 
formulation has been used for its protective effects against active radicals. Promising 
results were obtained in clinical trials in weight management in metabolic syndrome271, 
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muscle recovery272,273 and pain management274,275. In addition, its application in cancer 
chemoprevention, inflammation and neurodegenerative diseases is under study258. 
Green tea catechins and polyphenols obtained from the tea tree (Camellia sinensis, 
Theaceae) have long been used for their antioxidant and anti-inflammatory properties. 
The major constituents of that complex were epigallocatechin, catechin, 
epigallocatechin-3-O-gallate (EGCg) (46), gallocatechin-3-O-gallate, epigallo-3-O-
methylgallate, and epicatechin-3-O-gallate. The main applications of the green tea 
extracts were in weight lose supplements276 but can also be included in cancer277, liver278 
or cardioprotective formulations279. A single dose trial demonstrated that GreenselectTM 
phytosome was able to induce a decrease in the plasmatic oxidative status correlated 
with the plasmatic levels of ECGg280. This formulation conducted also to an improvement 
of bioavailability of ECGg (Cmax) in about 2-fold280. The weight lose effects were 
substantially improved by the use of Greenselect® in combination with hypocaloric diet 
in comparison with the diet only group (p>0.001) in a human clinical trial (n = 100)281. 
This lipidic-based formulation was also useful for control of borderline metabolic 
syndrome as in a 24-week treatment, 68% of the subjects showed a substantial 
improvement of in weight, lipidic profile and blood pressure while only 20% were able 
to manage those parameters based on lifestyle changes282.  
Ginkgo (Ginkgo biloba, Ginkgoaceae) is one of the anciently used medicinal plants 
from Chinese traditional medicine283. Terpene lactones and flavonoid glycosides were 
present in extracts of this plant from including ginkgolide A (47), B (48) and bilobalide 
(49). Although these plant extracts have been used with efficacy for the treatment of 
cardiovascular283 and neurologic conditions283,284, the phytosome form (Ginkgoselect®) 
originate an improvement of those active components bioavailability285,286. Also potent 
anti-inflammatory287 and hepatoprotective285,286 effects were also verified for this 
phytosome formulation.  
With some of the older patents reaching the end of the protection period, it would 
be expected the appearance of similar pharmaceutical products using the patented 
formulations. 
1.4.5.2. Dermatologic uses 
The lipophilic nature of the phytosome let us expect an improvement in the topical 
absorption of the complex, but as discussed earlier, the transdermal absorption should 
be negligible, being the local effects the most relevant and also the most appropriate 
for a cosmetic purpose. Their phospholipidic nature is also adequate for the 
enhancement of some skin functions as hydration, collagen structure, enzyme balance 
and restoring the barrier functions of the skin288. Standardized extracts from Gingko 
(Gingko biloba), grape seed (Vitis vinifera), hawthorn (Crataegus spp.), green tea 
(Camellia sinensis), milk thistle (Silybum marianum) and ginseng (Panax ginseng), among 
others, have been formulated as phytosomes intended to be used as innovative 
cosmetic carriers (Annex 2).   
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1.5. Hypothesis and Objectives 
Cancer and common infectious are two the top-five world death causes, according to 
World Health Organization. In the past century key advances in the treatment of such 
diseases were archived, although, few clinically relevant discoveries have been made in 
more recent years. The spreading of multidrug resistant bacteria and cancer types along 
with the lack of new antimicrobial and chemotherapeutic agents with a favorable risk-
efficacy relationship, highlight the need for the development of new and alternative 
antimicrobial and anticancer drug classes.   
Natural products have been one of the most reliable sources of drugs over the 
medicine history. Among those, the Plectranthus genus have been used for a wide range 
of ethnomedicinal purposes and is a good raw material since they easily grow in 
temperate zones. From these genus plants, several diterpenes have been obtained and 
characterized as antimicrobial or antitumoral agents.  
The bioactivity of some natural products was however limited by intrinsic physic-
chemical characteristics, namely unfavourable oil/water solubility relationship or 
susceptibility to rapid degradation in physiologic media, which limit their use as drug 
products. New drug delivery systems have been on focus in recent years and natural 
product focused delivery systems as phytosomes promise to overcome such limitations. 
The overall background drives the establishment of some research hypothesis: 
 Would the selected Plectranthus plants (P. madagascariensis, P. neochilus and P. 
porcatus) be a source of bioactive compounds?  
 Will the extracts and isolated compounds from those plants have potent activity 
against some microbial pathogens and/or cancer cell lines? 
 There will be an advantage of using phytophospholipid complexation (phytosome) 
to improve the revealed bioactivity? 
Following the established thesis hypothesis, within this work some objectives were 
established: 
 Objective I: The study of extracts from at least three Plectranthus species (P. 
madagascariensis, P. neochilus and P. porcatus) order to isolate or identify 
compounds that will be characterized by spectroscopic methods and 
physicochemical data. Such extracts and compounds would be screened for their 
antimicrobial and cytotoxic activities;  
 Objective II: The evaluation of the in vitro cytotoxic activities of extracts and their 
isolated compounds and the establishment of some structure-activity relationships; 
 Objective III: The more potent antimicrobial components obtained from 
Plectranthus plants will be incorporated into phytosomes in order to improve their 
bioactivity and/or delivery.  
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Chapter II 
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2. Screening of Plectranthus spp. for antimicrobial, 
antioxidant and cytotoxic activities 
2.1. Introduction 
The first objective of this project was the evaluation of the potential bioactivities, 
namely antimicrobial and antiproliferative (additionally the antioxidant activity was also 
measured), of plant extracts from the genus Plectranthus. The three species used in this 
study were selected based on their ethnomedicinal uses and the availability of plant 
material.  
2.3.1. Plectranthus madagascariensis 
P. madagascariensis (Pers.) Benth is a perennial aromatic herb with procumbent 
growth resulting in a dense, well-branched shrub up to 1 m high32 (Figure 2.1). This plant 
have been cultivated in Europe for its ornamental and aromatic applications and 
traditionally used for the treatment of respiratory conditions as cough and asthma, 
cutaneous wounds and scabies27. Previously, P. madagascariensis essential oil was 
characterized as containing high yields of an abietane diterpene, 6,7-
dehydroroyleanone (II.1)289. This diterpenoid was formally studied as a non-toxic weak 
antimicrobial and potent antioxidant290. Kubínová et al. identified rosmarinic acid (II.2), 
7β,6β-dihydroxyroyleanone (II.3), 7β-acetoxy-6β-hydroxyroyleanone (II.4) and coleon 
U-quinone (II.5) as the main components of this plant methanolic extract72. The acetone 
extract of P. madagascariensis was also studied as an antimicrobial and possesses insect 
antifeedant activity which was suspected to be related to the presence of coleon U in 
such extract83. 
 
 
  
II.1 II.2 
   
   
II.3 II.4 II.5 
Figure 2.1. Illustration of the Plectranthus madagascariensis (adapted from van Jaarsveld and Thomas, 200632) and 
some of the known compounds. 
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2.3.2. Plectranthus neochilus 
P. neochilus Schltr. is an aromatic herb commonly called “boldo-rasteiro” in 
Brazil291,292 (Figure 2.2). The infusion of this plant has been used in traditional medicine 
for treating dyspepsia and hepatic insufficiency291 or for the treatment of chills, cough 
and a runny or blocked nose47. Several studies characterized their essential oil 
composition and respective biologic activities from different growth locations. Essential 
oils from plants grown in Portugal293 and Brazil294 were similar, however substantially 
different from plants grown in South Africa295. Monoterpenes hydrocarbons were the 
more prevalent volatile constituents, but sesquiterpenes as β-caryophyllene and its 
oxidized form, caryophyllene oxide, were also present in high yields295. 
Antimicrobial293,296, schistosomicidal294,297,anti-fungal and cytotoxic294 activities294,298 
were evaluated from P. neochilus essential oils. A low toxicity of P. neochilus ethanol 
extract of aerial parts was also described using the brine shrimp lethality assay146. The 
non-volatile composition of this specie remains mostly unclear but some triterpenes and 
a flavonoid were isolated from the hexane extract of the whole plant, namely a ramified 
alpha-amyrin (II.6), friedelin (II.7), a mixture of sitosterol and estigmasterol and the 
flavonoid cirsimaritin (II.8)299. Also the diterpene 1,6-di-O-acetyl-9-deoxyforskolin (II.9) 
was obtained from aerial parts of this plant101.  
 
 
  
II.6 II.7 
  
 
 
II.8 II.9 
Figure 2.2. Illustration of the Plectranthus neochilus (adapted from Duarte and Lopes, 2007291) and main known 
compounds.  
2.3.3. Plectranthus porcatus  
P. porcatus Van Jaarsv. & P.J.D. Winter has been recently discovered in Leolo 
Moutains to Sekukuniland and Limpopo Province, South Africa300. Those areas present 
a subtropical climate, with hot summers and dry, sunny winters with light frost. P. 
porcatus is perennial soboliferous multi-stemmed shrub up to 1.5 m in diameter (Figure 
2.3). Its highly aromatic nature could have encourage its collection for medicinal uses300. 
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This plant was briefly studied by our group in two occasions. From the acetone extract 
was obtained a new diterpene with cycloabietane substructure designed [13S,15S]-
6β,7α,12α,19-tetrahydroxy-13β,16-cyclo-8-abietene-11,14-dione (II.10)35. The 
microwave aqueous extract was evaluated by HPLC and small yields of polyphenols 
caffeic (II.11) and rosmarinic acid (II.2) were detected, which contribute to the 
antioxidant activity of this extract25. 
 
 
 
 
II.10 II.11 
  
 
II.2 
Figure 2.3. Illustration of the Plectranthus porcatus (adapted from van Jaarsveld and Thomas, 200632) and main known 
compounds.  
 
The initial screening was performed with different polarity extracts evaluated of their 
antimicrobial (bacteria and yeasts), antioxidant (DPPH reduction) and cytotoxic (in vitro 
cancer cell model) activities. Those extracts are also profiled using HPLC-DAD and some 
of the main compounds were identified by standard co-elution (Figure 2.4). 
 
 
Figure 2.4. General scheme of the workflow described in chapter 2. 
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In this chapter, the biologic activities screening and initial phytochemical profiling 
were presented and discussed. 
2.2. Experimental 
2.2.1. Chemicals and equipment 
All the laboratorial work of this chapter has been accomplished at CBIOS facilities 
(Universidade Lusófona de Humanidades e Tecnologias, Lisbon, Portugal). 
2.2.1.1. Chemicals 
Extraction and chromatography solvents, namely n-hexane, ethyl acetate, methanol 
and acetone were from analytic grade and purchased from Sigma-Aldrich (Steinheim, 
Germany). Reverse osmosis water was obtained from a Millipore system (Millipore, MA, 
USA) system with a resistivity of 18.2 Ω⋅cm at 25°C. Trichloroacetic acid was obtained 
from Panreac (Barcelona, Spain). HPLC reagents were from HPLC-grade (VWR Chemicals, 
Fontenay-sous-Bois, France) and were filtered through a 0.22 μm membrane (Vygon, 
Ecouen, France) before use. Dimethyl sulfoxide (DMSO) and absolute ethanol was 
supplied by Merck (Darmstadt, Germany), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 
tetrazolium chloride and ascorbic acid were supplied by Sigma-Aldrich (Steinheim, 
Germany). TLC plates (Kieselgel 60 GF254 2mm 1.05554.0001) were purchased from 
Merck (Darmstadt, Germany) and filter paper nº5 was obtained from Whatman 
(Maidstone, United Kingdom). Standards of caffeic acid, chlorogenic acid, rosmarinic 
acid, rutin and naringin were supplied by Sigma-Aldrich (Steinheim, Germany). Authentic 
standards of coleon U and 7α-acetoxy-6β-hydroxyroyleanone were obtained and fully 
characterized by Gaspar-Marques34. Mueller-Hinton broth was supplied by Sigma-
Aldrich (Steinheim, Germany) and and Sabouraud agar was supplied by Biokar 
Diagnostics (Allonne, France). Fetal bovine serum and penicillin/streptomycin for cell 
culture were supplied by Sigma-Aldrich (Steinheim, Germany) and Dulbecco’s Modified 
Eagle’s medium was supplied by Biowest (Nuaillé, France). Vancomycin, norfloxacin, 
amphotericin B and doxorubicin were supplied by Sigma-Aldrich (Steinheim, Germany). 
2.2.1.2. Equipments 
The HPLC-DAD system was composed by an Agilent Technologies 1200 Infinity Series 
with diode array module (Agilent Technologies, Santa Clara, CA, USA) using a reverse 
phase (RP-18) HPLC column LiChrospher® 100 (Merck, Darmstadt, Germany). Other 
equipments used were hotplate magnetic stirrer (MC-8, Bunsen, Madrid, Spain), 
lyophilizer (Freezone 2.5 L, Labconco, Kansas City, USA), rotary evaporator (IKA RV06-
ML 1-B, Staufen, Germany) ultrasonic bath (Bandelin SONOREX RK 510H, Berlin, 
Germany), ultraviolet 254/366 nm lamp (CAMAG, Muttenz, Swithzerland) and weighting 
scales (KERN 770, KERN & Sohn GmbH, Balingen, Germany). 
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2.2.1.3. Plant material 
Plectranthus madagascarensis Benth., P. neochilus Schltr. and P. porcatus Winter & 
Van Jaarsv were cultivated in Parque Botânico da Tapada da Ajuda (Instituto Superior 
Agrário, Lisbon, Portugal) from cuttings obtained from the Kirstenbosch National 
Botanical Garden (Cape Town, South Africa). Voucher specimens were deposited in 
Herbarium João de Carvalho e Vasconcellos (ISA) with numbers 841/2007 for P. 
madagascariensis, number 570/2008 for P. neochilus and 109/2008 for P. porcatus. The 
plant material used in this study was collected between 2007 and 2008, dried at room 
temperature and stored protected from light and humidity. 
2.2.1.4. Microbial strains 
The antimicrobial assays were performed in 7 Gram positive bacteria strains: Bacillus 
subtilis (ATCC 6633), Enterococcus faecalis (ATCC 29212), Mycobacterium smegmatis 
(ATCC 607), Staphylococcus aureus (ATCC 25923), methicillin-resistant S. aureus (MRSA) 
(CIP 106760) and Staphylococcus epidermidis (ATCC 12228); 3 Gram negative bacteria 
strains: Escherichia coli (ATCC 25922), Klebsiella pneumoniae (ATCC 9997) and 
Pseudomonas aeruginosa (ATCC 27853); and 2 yeast strains: Candida albicans (ATCC 
10231) and Saccharomyces cerevisiae (ATCC 9763). Microbial strains were originally 
obtained from American Type Culture Collection (ATCC) or form “Collection de l'Institut 
Pasteur" (CIP).  
2.2.1.5. Cell lines 
The human breast cancer MDA-MB-231 cell line (Cailleau et al., 1974301) was obtained 
from ATCC and maintained at CBIOS at Universidade Lusofóna de Humanidades e 
Tecnologias (Lisbon, Portugal) facilities.  
2.2.1.6. Software editing  
Chemical structures were drawn on ChemBioDraw Ultra 12.0.2.1076. ChemStation 
was used for HPLC-DAD controller and data exportation. Statistical analysis and graphic 
design were archived using GraphPad Prism 6.01 for Windows 10.  
2.2.2. Extract preparation 
Dried plant was grinded to small pieces and then pulverized. Plant material was 
extracted using different combinations of aqueous or organic solvents and extraction 
techniques. Each crude extract was separated from the remaining plant material by 
paper filtration (Whatman paper nº1, Sigma-Aldrich, Steinheim, Germany) and the 
organic solvents were evaporated in a rotary evaporator (IKA RV06-ML 1-B, Staufen, 
Germany) bellow 40 °C while aqueous extracts were freeze-dried as 1 mL aliquots 
(Freezone 2.5 L, Labconco, Kansas City, USA). The weight was determined for each 
extract and were stored at -20 °C until further usage. 
2.2.2.1. Decoction (DEC) 
Plant material (10 g) is boiled in 100 mL distilled water for 10 min. 
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2.2.2.2. Infusion (INF) 
Plant material (10 g) is added to 100 mL of boiling distilled water and kept in contact 
for 10 min.  
2.2.2.3. Microwave assisted extraction (MW) 
Plant material (10 g) is added to 100 mL of distilled water and subject to continuous 
irradiation (2.45 GHz) for 2 min into a conventional microwave.  
2.2.2.4. Maceration (ME) 
Plant material (10 g) is added to 200 mL of organic solvent (acetone or methanol) and 
kept stirring (MC-8, Bunsen, Madrid, Spain) for 24 h.  
2.2.2.5. Ultrasound assisted extraction (UAE) 
Plant material (10 g) is added to 200 mL of organic solvent (acetone or methanol) and 
sonicated into an ultrasonic bath (Bandelin SONOREX RK 510H, Berlin, Germany) at 35 
kHz for 2 h.  
2.2.2.6. Supercritical fluid extraction (SCFE) 
The supercritical fluid extraction was performed in an apparatus already described 
elsewhere302. The extraction was performed using 30g of ground plant for 3h at a 
temperature of 40ºC, pressure 23 MPa and scCO2 flow rate of 0.3 kg.h-1. 
2.2.2.7. Re-extraction of SCFE remaining plant material (R-SFE) 
Remaining plant material resulting from SCFE is recovered, air dried and added to 200 
mL of acetone which is kept stirring (MC-8, Bunsen, Madrid, Spain) for 24 h. 
2.2.3. Chemical characterization 
Extracts were briefly analysed for their phytochemical profile using high performance 
liquid chromatography (HPLC) and by comparison of the UV spectra and retention time 
with pure authentic standards36. 
2.2.3.1. HPLC-DAD fingerprinting 
Analysis were performed in an Agilent Technologies 1200 Infinity Series system 
equipped with a LiChrospher® 100, RP-18 (5 mm) column (Merck, Darmstadt, Germany) 
and ChemStation software. Extracts were analysed injecting 20 µL and using a gradient 
composed of solution A (methanol), solution B (acetonitrile) and solution D (0.3% w/v, 
trichloroacetic acid in water) as follows: 0 min, 15% A, 5% B and 80% D; 20 min, 80% A, 
10% B and 10% D; 25 min, 80% A, 10% B and 10% D; and 28 min, 15% A, 5% B and 80% 
D. The flow rate was set at 1 mL/min. Detection was carried out between 200 and 600 
nm with a diode array detector (DAD). Solvents were filtered and degassed using a 0.22 
μm membrane filter previously to the analysis. All analyses were performed in triplicate.  
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2.2.3.2. Pure standards overlay 
Standards in methanol at 1 mg/mL were run injecting 20 µL under the same analytic 
conditions used for extracts. The UV spectra of each pure compound was retrieved and 
compared to peaks in the extract with similar retention times. When overlay of UV 
spectra is verified, a co-elution of extract with pure compound is performed for 
confirmation.  
2.2.4. Microbiology 
The antimicrobial activity of each extract was determined in 7 Gram positive bacteria 
strains: Bacillus subtilis (ATCC 6633), Enterococcus faecalis (ATCC 29212), 
Mycobacterium smegmatis (ATCC 607), Staphylococcus aureus (ATCC 25923), 
methicillin-resistant S. aureus (MRSA) (CIP 106760) and Staphylococcus epidermidis 
(ATCC 12228); 3 Gram negative bacteria strains: Escherichia coli (ATCC 25922), Klebsiella 
pneumoniae (ATCC 9997) and Pseudomonas aeruginosa (ATCC 27853); and 2 yeast 
strains: Candida albicans (ATCC 10231) and Saccharomyces cerevisiae (ATCC 9763).  
2.2.4.1. Well diffusion assay 
For screening of antimicrobial activity, a well diffusion assay was used. Briefly 100 µL 
of microorganism suspension, concentrated at 0.5 in McFarland scale, were inoculated 
in a petri dish containing Mueller-Hinton (bacteria) or Sabouraud agar (yeasts). Wells 
were dug in the agar using a sterile Pasteur pipette. Then 50 µL of sample (at 10 mg/mL), 
negative control (DMSO) or positive control (vancomycin for Gram positive bacteria; 
norfloxacin for Gram negative bacteria; amphotericin B for yeast) were added to each 
well. After incubation at 37ºC for 24 h the growth inhibition zones around the well were 
measured and the results expressed in millimetres (mm). Assays were performed in 
triplicate. 
2.2.4.2. Minimum inhibitory concentrations 
Positive samples from the well diffusion assay screening were subjected to a 
microplate broth microdilution method303. Briefly 100 μL of liquid Mueller-Hinton 
medium was distributed in each well of a 96-well plate. To the first well of each row was 
added 100 μL of extract, positive control or negative control solutions at a 1 mg/mL 
concentration and 1:2 serial dilutions were prepared (1.95–500 μg/mL range). Lastly, 10 
μL of bacterial suspension were added to every well and plates were incubated at 37°C 
for 24h. Bacterial growth was measured with an absorbance microplate reader set to 
620 nm. Assays were performed in triplicate. 
2.2.4.3. Bioautography 
The evaluated extracts were applied on a TLC silica plate (10x4 cm) and developed 
using a mixture of n-hexane:ethyl acetate (8:2; v/v). After elution, the TLC 
chromatogram was allowed to dry completely and placed on a petri dish. Then, a 
solution of Mueller-Hilton containing tetrazolium chloride (10 % w/v) and inoculated 
with S. aureus (ATCC 25923) was used to cover the TLC chromatogram. The plate was 
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incubated overnight at 37°C and the inhibition zones compared to non-incubated TLC 
chromatogram of the same extract. The assay was performed in quadruplicate. 
2.2.5. Radical scavenging activity  
The antioxidant activity was screened by the evaluation of DPPH radical scavenging 
ability36. Ten microliters of each plant extract (10 mg/mL) were mixed with 990 μL of 
DPPH solution (0.002% in ethanol). The resultant solution was incubated for 30 min at 
room temperature and then, the absorbance was measured at 517 nm against a 
corresponding blank. The antioxidant activity was calculated as: 
𝐴𝐴% =
𝐴𝐷𝑃𝑃𝐻 − 𝐴𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝐷𝑃𝑃𝐻
 
Where AA% corresponds to the antioxidant activity in percentage, ADPPH is the 
absorption verified for the DPPH solution (blank) and Asample is the absorption verified 
for the sample (extract in DPPH solution). Each assay was carried in triplicate and 
ascorbic acid was used as positive control.  
2.2.6. Cytotoxicity evaluation 
The extracts cytotoxicity was assessed in the human breast cancer MDA-MB-231 cell 
line. Cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 
U/mL penicillin and 0.1 mg/mL streptomycin. The cultures were maintained at 37ºC, 
under a humidified atmosphere containing 5% CO2.  
Cell viability was evaluated using the crystal violet staining assay304. Briefly, a 96-well 
microplate was inoculated with approximate 6000 cells per well and incubated for 24 h. 
The samples were then added to obtain a final concentration of 15 µg/mL. After 48 h 
the medium was discarded and the cells washed with PBS, fixed with 96% ethanol and 
stained with crystal violet. The absorbance was measured at 595 nm and the sample 
cytotoxicity was expressed as the fraction of absorbance comparing with non-treated 
control cultures. At least two independent experiments were performed, and four 
replicate cultures were used in each independent experiment. Doxorubicin (5 µM) was 
used as positive control.  
2.3. Results and discussion 
2.3.1. Extract preparation 
Extracts from P. madagascariensis, P. neochilus and P. porcatus were prepared using 
combinations of different solvents and extraction methodologies to obtain the 
preferential extraction of polar (aqueous extracts), median polar (acetone and 
methanol) and less polar constituents (scCO2) in variable yields (Table 2.1). The 
methanol extracts present a higher extraction yields in all studied plants, being 
maceration extraction able to retrieve generally higher extraction yields (Table 2.1). This   
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Table 2.1. Extraction technique, solvents applied, weighted dry residue and calculated yield from studied 
Plectranthus species extracts. n/d – not determined. 
Number Plant Solvent  Technique  Dry residue (mg) Yield (mg/g) 
E1 
P. madagascariensis 
Water 
Infusion 0.23 ± 0.10 2.3 
E2 Microwave 0.11 ± 0.04 1.1 
E3 Decoction 0.22 ± 0.02 2.2 
E4 
Acetone 
Ultrasound 0.151 1.51 
E5 Maceration 0.377 3.77 
E6 
Methanol 
Ultrasound 0.656 6.56 
E7 Maceration 1.146 11.46 
E8 scCO2 SCFE 0.394 0.01 
E9 Acetone R-SCFE 0.885 0.03 
E10 
P. neochilus 
Water 
Infusion 0.26 ± 0.04 2.6 
E11 Microwave 0.15 ± 0.04 1.5 
E12 Decoction 0.22 ± 0.01 2.2 
E13 
Acetone 
Ultrasound 0.180 1.80 
E14 Maceration 0.125 1.25 
E15 
Methanol 
Ultrasound 0.702 7.02 
E16 Maceration 0.600 6.00 
E17 scCO2 SCFE 0.251 0.84 
E18 Acetone R-SCFE 0.417 1.39 
E19 
P. porcatus 
Water 
Infusion n/d n/d 
E20 Microwave n/d n/d 
E21 
Acetone 
Ultrasound 0.865 8.65 
E22 Maceration 0.872 8.72 
E23 
Methanol 
Ultrasound 1.566 15.66 
E24 Maceration 2.237 22.37 
E25 scCO2 SCFE 0.191 0.64 
E26 Acetone R-SCFE 0.868 2.89 
 
could be related to the ability of ethanoic solvents like methanol to disrupt the cellular  
wall with higher efficacy than other solvents. The higher extraction yield verified to 
maceration versus ultrasound extraction should be related to the longer extraction time 
employed. 
2.3.2. Chemical characterization 
The phytochemical composition of crude extracts was briefly analysed by HPLC-DAD, 
in order to identify some of the most prevalent chemicals present in their constitution 
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(Figure 2.5). Insights about P. madagascariensis constituents have been previously 
published about its aquaeous307, acetonic83 and methanolic72 extracts. 
This analysis confirmed the presence of some known compounds as the polyphenols 
caffeic acid (II.11), chlorogenic acid (II.12) and rosmarinic acid (II.2) and the abietane 
diterpenes 7α-acetoxy,6β-hydroxyroyleanone (II.13) and coleon U (II.14). The flavonoids 
rutin (II.15) and naringenin (II.16) were identified for the first time in these plant extracts 
and was found in both organic and aqueous extracts (Figure 2.6 and Table 2.2). The 
abietane diterpenes were more prevalent in organic extracts and should presumably be 
responsible for the higher antimicrobial and cytotoxic activities verified in those 
extracts. 
 
  
II.11 II.12 II.2 
   
II.13 II.14 
 
 
II.15 II.16 
Figure 2.5.  Chemical structure of identified phytochemicals from studied Plectranthus species extracts: Caffeic acid 
(II.11), chlorogenic acid (II.12), rosmarinic acid (II.2), 7α-acetoxy,6β-hydroxyroyleanone (II.13), coleon U (II.14) rutin 
(II.15) and naringenin (II.16). 
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Figure 2.6. HPLC-DAD fingerprinting of each of each extract at 10 mg/mL (5-20 min section; λ=270 nm). 
 
 Table 2.2. Detection of analysed compounds in each Plectranthus extract and characteristic retention times for the 
developed HPLC method (within parenthesis, expressed in minutes). 
Extract II.12 (6.54) II.11 (8.32) II.16 (10.14) II.15 (11.67) II.2 (12.43) II.13 (14.75) II.14 (15.44) 
1 + + - + + - - 
2 + + - + + - - 
3 + + - + + - - 
4 + + - + + + - 
5 + + - - + + + 
6 + + - - + - - 
7 + + - - + - - 
8 + + - - + + - 
9 + + - + + + - 
10 + + - + + - - 
11 + + - + + - - 
12 + + - + + - - 
13 + + - + + - - 
14 + + - - + - - 
15 + + - + + - - 
16 + + - - + - - 
17 + - - - - - - 
18 + + - - + - - 
19 - + + + + - - 
20 + + + + + - - 
21 - + + - - - - 
22 + + + - + - - 
23 - - - - - - - 
24 - + + - - - - 
25 + - - - - - - 
26 + + + - + - - 
 
Chlorogenic acid (II.12), Caffeic acid (II.11), Naringin (II.16), Rutin (II.15), Rosmarinic acid (II.2), 7α-acetoxy-6β-hydroxyroyleanone 
(II.13), coleon U (II.14); +: detected compound; -: not detected. 
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To our knowledge there were no data of HPLC-DAD analysis of P. neochilus. The 
extracts from P. neochilus were rich in polyphenol compounds, namely chlorogenic acid, 
caffeic acid and rosmarinic acid but the flavonoid rutin was also detected in each non-
acetonic extract. P. porcatus possess also the polyphenols chlorogenic acid, caffeic acid 
and rosmarinic acid in most of its extracts. The flavonoids naringin and rutin were 
present in aqueous extracts. Many of those compounds demonstrated both 
antimicrobial33 and antioxidant25 activities in previous studies and could be explain the 
activities verified for some of those plant extracts. 
2.3.3. Antimicrobial activity 
The initial screening of antimicrobial activity of Plectranthus species extracts was 
performed with the well diffusion assay. This simple procedure was used for the 
exclusion of inactive extracts from further antimicrobial studies. Extracts of P. 
madagascariensis and P. neochilus obtained using acetone and methanol were active in 
some Gram positive (Bacillus subtilis ATCC 6633, Mycobacterium smegmatis ATCC 607, 
Staphylococcus aureus ATCC 25923 and Staphylococcus epidermidis ATCC 12228) and 
Gram negative (Klebsiella pneumonia ATCC 9997 and Pseudomonas aeruginosa ATCC 
27853) bacteria strains (Table 2.3 and Figure 2.7). No inhibitory activity was verified for 
Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922 and the two yeasts 
(Candida albicans ATCC 10231 and S. cerevisiae ATCC 9763) by any of the extracts tested. 
The extracts with relevant activity in well assay screening were subjected to the 
determination of the MIC by a microdilution procedure in the susceptible strains. 
Extracts from P. madagascariensis prepared using ultrasound (E4) and maceration (E5) 
in acetone and P. neochilus prepared using ultrasound (E13) in acetone showed potent 
activity against both Gram positive and Gram negative bacteria (MIC values ranging 
between 250-0.48 μg/mL) (Table 2.3). 
 
 
Figure 2.7. Well diffusion assay of extract E4 and E5 against K. pneumonia ATCC 9997 (left) and S. aureus ATCC 25923 
(right). Positive control (+): vancomycin; negative control (-): DMSO.  
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 Table 2.3. Well diffusion assay diameter (mm) of microbial growth inhibition in bioactive extracts. Extracts not 
presented were inactive against all tested strains. Positive controls: vancomycin (Gram positive bacteria); rifampicin 
(mycobacteria); norfloxacin (Gram negative bacteria); nystatin (yeasts).   
Microbial Strains 
Extract number 
Control 
E4 E5 E6 E7 E13 E14 E15 E16 
Gram positive strains 
B. subtilis ATCC 6633 24 20 12 11 15 14 11 10 31 
E. faecalis ATCC 29212 5 5 5 5 5 5 5 5 27 
M. smegmatis ATCC 607 26 26 23 17 20 15 15 20 33 
S. aureus ATCC 25923 24 20 7 8 8 8 8 8 24 
S. epidermidis ATCC 12228 10 25 - 13 15 11 - 5 20 
Gram negative strains 
E. coli ATCC 25922 5 5 5 5 5 5 5 5 33 
K. pneumonia ATCC 9997 25 22 5 5 5 5 5 5 25 
P. aeruginosa ATCC 27853 5 5 5 5 11 11 5 5 35 
Yeast strains 
C. albicans ATCC 10231 5 5 5 5 5 5 5 5 17 
S. cerevisiae ATCC 9763 5 5 5 5 5 5 5 5 22 
 
 
A qualitative evaluation of the antimicrobial activity within the extract components 
was also performed by bioautography. This technique is based on the separation of the 
extract components by TLC chromatography and evaluate their individual ability to 
inhibit the growth of a specific microorganism inoculated above the chromatogram. The 
extracts E4 and E13 were selected for this assay as the most active for P. 
madagascariensis and P. neochilus respectively. Due to its lack of antimicrobial activity, 
P. porcatus extracts were not included in this study. 
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The results showed clear inhibition zones as yellow areas against a red background 
(Figure 2.8). Those areas correspond in both extracts to areas with a lower retention 
factor (Rf) which considering the solvent system selected (fairly apolar), led as to 
conclude that the compounds responsible for the anti-staphylococcal activity were, in 
both extracts, those with more polarity features.  
 
  
Figure 2.8. Representative digital images of the TLC chromatogram and bioautography of the extracts E4 and E13 from 
P. madagascariensis and P. neochilus, respectively.  
2.3.4. Antioxidant activity  
The antioxidant activity was determined based on Plectranthus extracts ability to 
scavenge the free radical DDPH. Most methanol extracts showed moderate or high 
antioxidant activity, being the most active, the extracts of P. madagascariensis (E6 - 
89.0%; E7 - 64.8%), P. neochilus (E15 - 64.9%; E16 - 62.3%) and P. porcatus (E23 - 60.8%; 
 
Table 2.4. Minimum inhibitory concentrations (μg/mL) determined for the extracts with higher activity in the 
screening. Positive controls were: vancomycin (Gram positive bacteria); rifampicin (mycobacteria); norfloxacin 
(Gram negative bacteria). 
Microbial strains 
Extract number 
Control 
E4 E5 E13 
Gram positive 
B. subtilis ATCC 6633 3.91 62.5 125 <0.48 
M. smegmatis ATCC 607 31.25 62.5 15.62 <0.48 
S. aureus ATCC 25923 3.91 250 250 <7.81 
S. aureus CIP 106760 1.95 16.25 31.25 <0.98 
S. epidermidis ATCC 12228 7.81 62.5 62.5 <7.81 
Gram negative 
K. pneumonia ATCC 9997 <0.48 3.91 0.98 31.25 
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E24 - 65.9%) (Figure 2.9). The aqueous extracts of P. neochilus also showed relevant 
antioxidant values (62.5-68.9%) in contrast to aqueous extracts of P. madagascariensis 
(10.2-20.6%) and P. porcatus (3.2-17.3%). 
The higher antioxidant values verified for methanolic extracts along with the known 
presence of polyphenols in the plants of the Plectranthus genus led us to speculate that 
those extracts possess higher amounts of such compounds in the extracts obtained 
using methanol. This is in accordance with previous studies of Plectranthus plants that 
revealed the extraction of high amounts of polyphenols by the use of methanol as 
solvent69,72,83.  
The antioxidant activity is present in almost every higher plant, due to the plant ability 
to biosynthetize a wide range of secondary metabolites able to attenuate the oxidative 
stress damage. However, the extent in which a potent antioxidant activity in vitro 
translates into a useful modulator of the oxidative status in vivo is yet to be determined, 
being dependent on the compound absorption and its physiologic half-life305.    
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Figure 2.9. Antioxidant activity verified for each extract at 100 ng/mL using DPPH reduction method. Ascorbic acid in 
the same concentration was used as positive control. 
 
 
  
 
71 
 
2.3.5. Cytotoxicity screening 
The extracts cytotoxicity to cancer cells was evaluated in the MDA-MB-231 breast 
cancer cells. This cell line was selected due to its availability, ease of manipulation and 
lack of studies of Plectranthus plants extracts in this cell line. When used at 15 μg/mL, 
all extracts showed low cytotoxicity in this cancer cell line (Figure 2.10). The most 
cytotoxic extract was the one obtained by maceration in acetone of P. madagascariensis 
(E5), with a reduction in cell viability of 20.13%, followed by the extract obtained by re-
extraction in acetone of P. neochilus plant material previously extracted by SCFE (11.44% 
decrease in cell viability). The inhibitory concentration at 50% of the curve (IC50) was 
determined for the most active extract and a value of 64.52 μg/mL was found (Figure 
2.11). This extract can thus be considered moderately cytotoxic306 and was selected for 
further studies (described in Chapter 3). 
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Figure 2.10. Cell viability of MDA-MB-231 cell exposed to 15 μg/mL of each extract for 48 h, assessed by the crystal 
violet staining assay. Positive control (C) was doxorubicin (5 μM). Results are expressed as mean ± SD from at least two 
independent experiments. 
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Figure 2.11. Concentration-response profile of P. madagascariensis acetonic maceration extract (E5) in terms of MDA-
MB-231 cells viability (48 h incubation, crystal violet staining assay). Results are expressed as mean ± SD from at least 
two independent experiments. 
2.4. Chapter conclusions 
Ethnopharmacological studies on traditionally used medicinal plants led to 
indications of the presence of bioactive compounds on those plants extracts. In this 
study the preparation and screening of plant extracts from three Plectranthus species 
led to the identification of some extracts with potent antimicrobial, antioxidant and 
cytotoxic activities. The acetonic extract from P. madagascariensis produced by 
ultrasound assisted extraction (E4) showed an antimicrobial activity comparable to 
reference antibiotics against S. aureus strains (MIC < 3.91 μg/mL), including a MRSA 
strain (MIC < 0.98 μg/mL), but also against B. subtilis, K. pneumonia and S. epidermidis. 
This extract possess in its constitution the known abietane diterpenes 7α-acetoxy,6β-
hydroxyroyleanone and coleon U which have been isolated from other Plectranthus 
species as antimicrobial compounds34. The presence of those compounds could explain 
the traditional use of this plant for the treatment of respiratory conditions related to 
infectious agents. The same plant methanolic ultrasound extract presented an 
antioxidant activity similar to the positive control ascorbic acid. As high yields of 
polyphenols are also present in this extract, the concomitant radical scavenging 
activities of both abietane diterpenes and polyphenols could explain this relevant 
antioxidant activity. The acetonic extract of P. madagascariensis, obtained by 
maceration (E5) showed the most relevant cytotoxic effects. This extract was also rich 
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in abietane diterpenes, namely 7α-acetoxy,6β-hydroxyroyleanone and coleon U. Those 
compounds have been identified as antiproliferative agents against some cancer cell 
lines40,82. Also coleon U was been characterized as a PKCδ activator which could explain, 
at least partially, its cytotoxic activity156. 
Extracts from P. neochilus and P. porcatus were also rich in polyphenols and some 
flavonoids but did not show activities as potent as those from P. madagascariensis. 
However, the interesting antimicrobial activity verified for the acetonic extracts of P. 
neochilus obtained by ultrasound could explain the traditional use for the treatment of 
infection-related symptoms as cough or chills. 
In order to better establish the compounds responsible for individual activities in the 
plant a bioassay guided fractionation of those plant extracts could help retrieve the most 
bioactive compounds in order to confirm if the identified compounds were the main 
responsible for the verified bioactivities in the crude extracts.  
Overall, this study helped to characterize the bioactivities and phytochemical 
composition of three plants traditionally used for medicinal or aromatic purposes.  
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3. Cytotoxic components from P. madagascariensis 
3.1. Introduction 
The Plectranthus genus have been a source of cytotoxic compounds as some forskolin 
derivatives, coleon U and parvifloron D (detailed in the subsection 1.3.1.). The presence 
of such compounds in Plectranthus plants, intensified our interest on the screening of 
this genus in the surge for new compounds with potential anticancer application.  
The screening of 26 extracts from three Plectranthus plants, described in chapter 2, 
supported the identification of organic extracts of P. madagascariensis as those with 
more potent bioactivities. The extract obtained by maceration acetone extraction was 
the most cytotoxic with an IC50 of 64.5 μg/mL in the MDA-MB-231 breast cancer cell line.  
In this chapter, the chemical composition of the P. madagascariensis extracts was 
detailed using HPLC-DAD and complementary spectroscopic methodologies being the 
major compounds identified and quantified. The cytotoxic effects of the pure 
compounds were evaluated in breast, lung and colon cancer cell lines and some 
structure-activity relationships were disclosed. Those results were used to establish 
potential connections between the chemical composition of the plant extracts and their 
therapeutic uses in skin cancer27. 
3.2. Experimental 
3.2.1. Chemicals and equipment 
Most of the laboratorial work described in this chapter was been done at the CBIOS 
facilities (Universidade Lusófona de Humanidades e Tecnologias). Some procedures 
were performed in collaborating institutions, namely Faculdade de Farmácia da 
Universidade de Lisboa (RMN studies), Faculdade de Farmácia da Universidade do Porto 
(cytotoxicity assays) and Institute for Biological Research “Sinisa Stankovic” at University 
of Belgrade, Serbia (cytotoxicity assays).  
3.2.1.1. Chemicals 
Extraction and chromatography solvents, namely n-hexane, ethyl acetate, methanol 
and acetone were from analytic grade and purchased from Sigma-Aldrich (Steinheim, 
Germany). Reverse osmosis water was obtained from a Millipore system (Millipore, MA, 
USA) system with a resistivity of 18.2 Ω⋅cm at 25°C. Trichloroacetic acid was obtained 
from Panreac (Barcelona, Spain). HPLC reagents were from HPLC-grade (VWR Chemicals, 
Fontenay-sous-Bois, France) and were filtered through a 0.22 μm membrane (Vygon, 
Ecouen, France) before use. Dimethyl sulfoxide (DMSO) and absolute ethanol was 
supplied by Merck (Darmstadt, Germany). TLC plates (Kieselgel 60 GF254 2mm 
1.05554.0001) were purchased from Merck (Darmstadt, Germany) and filter paper nº5 
was obtained from Whatman (Maidstone, United Kingdom). Standard of rosmarinic acid 
was supplied by Sigma-Aldrich (Steinheim, Germany). Authentic standards of coleon U, 
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7α,6β-dihydroxyroyleanone  and 7α-acetoxy-6β-hydroxyroyleanone were obtained and 
fully characterized by Gaspar-Marques34. Fetal bovine serum and 
penicillin/streptomycin for cell culture were supplied by Sigma-Aldrich (Steinheim, 
Germany) and Dulbecco’s Modified Eagle’s medium was supplied by Biowest (Nuaillé, 
France). Doxorubicin was supplied by Sigma-Aldrich (Steinheim, Germany). 
3.2.1.2. Equipments 
The HPLC-DAD system was composed by an Agilent Technologies 1200 Infinity Series 
with diode array module (Agilent Technologies, Santa Clara, CA, USA) using a reverse 
phase (RP-18) HPLC column LiChrospher® 100 (Merck, Darmstadt, Germany). Other 
equipments used were hotplate magnetic stirrer (MC-8, Bunsen, Madrid, Spain), 
lyophilizer (Freezone 2.5 L, Labconco, Kansas City, USA), rotary evaporator (IKA RV06-
ML 1-B, Staufen, Germany) ultrasonic bath (Bandelin SONOREX RK 510H, Berlin, 
Germany), ultraviolet 254/366 nm lamp (CAMAG, Muttenz, Swithzerland) and weighting 
scales (KERN 770, KERN & Sohn GmbH, Balingen, Germany). Magnetic resonance 
experiments were performed on a INOVA-400 (Varian, Palo Alto, CA, USA). 
3.2.1.3. Plant material 
Plectranthus madagascarensis Benth., P. neochilus Schltr. and P. porcatus Winter & 
Van Jaarsv were cultivated in Parque Botânico da Tapada da Ajuda (Instituto Superior 
Agrário, Lisbon, Portugal) from cuttings obtained from the Kirstenbosch National 
Botanical Garden (Cape Town, South Africa). Voucher specimens were deposited in 
Herbarium João de Carvalho e Vasconcellos (ISA) with numbers 841/2007 for P. 
madagascariensis, number 570/2008 for P. neochilus and 109/2008 for P. porcatus. The 
plant material used in this study was collected between 2007 and 2008, dried at room 
temperature and stored protected from light and humidity. 
3.2.1.4. Cell lines 
The human breast cancer MDA-MB-231 cell line (Cailleau et al., 1974301) was obtained 
from ATCC and maintained at CBIOS at Universidade Lusofóna de Humanidades e 
Tecnologias (Lisbon, Portugal) facilities. 
Human estrogen-dependent breast carcinoma (MCF-7), colorectal carcinoma 
(HCT116) and non-small cell lung carcinoma (NCI-H460) cells were obtained from ATCC 
and cultivated at Faculdade de Farmácia da Universidade do Porto. 
MRC-5 normal human embryonal bronchial epithelial cells and NCI-H460 non-small 
cell lung carcinoma cell line were maintained at Institute for Biological Research “Sinisa 
Stankovic” at University of Belgrade (Belgrade, Serbia) and obtained from American 
Type Culture Collection (ATCC), Rockville, MD. From the original NCI-H460 was obtained 
the multidrug resistant non-small cell lung carcinoma cell line with P-glycoprotein 
overexpression by continuous treatment with stepwise increasing concentrations of 
doxorubicin (5-100 nM) for a period of 3 months in a procedure optimized by Pesic et 
al. 2006308. 
  
 
77 
 
3.2.1.5. Software editing  
Chemical structures were drawn on ChemBioDraw Ultra 12.0.2.1076. ChemStation 
was used for HPLC-DAD controller and data exportation. MestreNova was used for the 
RMN analysis and editing.  Statistical analysis and graphic design were archived using 
GraphPad Prism 6.01 for Windows 10. 
3.2.2. P. madagascariensis extraction 
The P. madagascariensis extraction with acetone or methanol by UAE or ME, by SCFE 
with scCO2 and R-SCFE with acetone, was performed in accordance to previously 
described in sub-section 2.2.1.  
3.2.3. HPLC-DAD profiling and identification of their major compounds 
The extract profiling was performed using an Agilent Technologies 1200 Infinity Series 
LC System (Santa Clara, CA, USA) coupled to a diode array detector (DAD) and processed 
using the ChemStation Software. From each dried extract, a sample was prepared in 
methanol (methanolic extracts) or acetone (other extracts) at a concentration of 20 
mg/mL. A 20 μL sample was injected to a LiChrospher® 100 RP-18 5 m (4.0 x 250 mm) 
column (Merck, Darmstadt, Germany) and eluted in a gradient of methanol (A), 
acetonitrile (B) and 0.3% (w/v) trichloroacetic acid in ultrapure water (C) as follows: 0 
min, 15% A, 5% B and 80% C; 20 min, 70% A, 30% B and 0% C; 25 min, 70% A, 30% B and 
0% C; and 28 min, 15% A, 5% B and 80% C. The flow rate was established at 1 mL/min at 
room temperature. Solvents were filtered and degassed using a 0.22 μm membrane 
filter previously to the analysis. All analyses were performed in triplicate.  
The major peaks from each extract sample were identified by comparing the 
retention time and UV-vis spectra overlay with commercial standards (rosmarinic acid, 
Sigma-Aldrich, Steinheim, Germany) or authentic standards previously obtained from 
Plectranthus spp., namely 7α,6β-dihydroxyroyleanone, 7α-acetoxy-6β-
hydroxyroyleanone and coleon U (Gaspar-Marques et al. 2006)34. 
The calibration curves were constructed as a linear regression of the analyte 
concentration (mM) versus the average peak area. The limit of detection (LOD) and limit 
of quantification (LOQ) were determined to evaluate the sensitivity of the analysis 
corresponding to the concentrations of analyte that resulted in signal-to-noise ratios of 
3 (LOD) and 10 (LOQ) following the guidelines from ICH Q2(R1) on validation of analytical 
procedures309. 
The LOD and LOQ were calculated as:  
 
𝐿𝑂𝐷 =
3.3σ
𝑆
 𝐿𝑂𝑄 =
10σ
𝑆
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Where σ correspond to the standard deviation of the response and S correspond to 
the slope of the calibration curve. The slope S is estimated from the calibration curve of 
the analyte. 
3.2.4. Isolation of 7α-formyloxy-6β-hydroxyroyleanone (III.3) 
An ultrasound acetonic extract of P. madagascariensis was obtained by sonicating 
100 g of plant material into 2000 mL of acetone for 2 h. This extract was treated with 
activated charcoal and immediately applied to a silica gel (Merck 60 gel 463934, 
Germany) chromatography column (30 g). Using a gradient of hexane and ethyl acetate, 
10 fractions were obtained and grouped by their similarity in TLC (silica gel 60 F254 plate 
0.2 mm thicknesses, Merck, Germany; using as eluent system hexane:ethyl acetate, 7:3). 
Compound III.3 was purified from the fraction eluted with hexane:ethyl acetate (95:5) 
by repeated elution (eluent system: hexane/ethyl acetate, 75:25 v/v) using a preparative 
chromatography (Merck 60 F254 20x20 cm 1.05715) followed by crystallization 
(methanol). 
3.2.5. Spectroscopic structure elucidation (III.3) 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian INOVA-400 
spectrometer equipped with a 5 mm inverse detection z-gradient probe. The 1H and 13C 
NMR spectra (respectively at 400 and 100 MHz) were measured at room temperature 
(22-23 °C) using CDCl3 as solvent. The 1H and 13C NMR chemical shifts are reported with 
respect either to the residual CHCl3 signal (δ7.25 and δ77.00, respectively). One-
dimensional 1H and 13C NMR spectra were acquired under standard conditions. The 
pulse programs of the COSY, HSQC and HMBC experiments were taken from the Varian 
software library. Homonuclear two-dimensional spectra (COSY) and inverse proton-
detected heteronuclear two-dimensional spectra (HSQC) were acquired in the phase-
sensitive mode and HMBC spectra were acquired in the absolute value mode. 
3.2.6. Cytotoxicity assays  
The cytotoxicity of the extracts and pure compounds was assessed using human 
breast cancer MDA-MB-231 cell line. The cells were cultured in DMEM supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin and 0.1 mg/mL streptomycin. The cell 
viability was evaluated using the crystal violet staining assay304,310. Briefly, cells were 
inoculated on a 96-well microplate and incubated for 24 h. Cells were exposed to the 
testing solutions for 48 h, and afterwards the medium was discarded and the cells were 
washed with phosphate saline buffer, fixed with 96% ethanol and stained with crystal 
violet. The absorbance was read at 595 nm and cell viability was calculated as a fraction 
of the absorbance presented by non-treated control cultures. At least two independent 
experiments were performed, and four replicate cultures were used in each 
independent experiment. 
The cytotoxicity of pure compounds (III.1-III.5) on HCT116, MCF-7 and H460 cells lines 
was assessed after 48 h treatment using the sulphorhodamine B assay by the procedure 
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supervised by Saraiva311. Briefly, cells were cultured in RPMI-1640 with ultraglutamine 
medium from Lonza, supplemented with 10% fetal bovine serum from Gibco and 
maintained in a humidified incubator at 37 C with 5% CO2 in air. For the evaluation of 
cytotoxic effects of tested compounds, cells were plated in 96-well plates at a final 
density of 5.0 x 103 cells/well and incubated for 24 h. Then, cells were exposed to serial 
dilutions of each compound (from 1.85 to 150 μM), being the effect of the compounds 
analysed after 48h of incubation, using the sulforhodamine B (SRB) assay. Briefly, 
following fixation with 10% trichloroacetic acid from Scharlau, plates were stained with 
0.4% SRB and washed with 1% acetic acid. The bound dye was then solubilized with 10 
mM Tris Base and the absorbance was measured at 510 nm in a microplate reader 
(Biotek Instruments Inc., Synergy MX, USA).  
The cytotoxicity on NCI-H460 cells and its multidrug resistant selected strain, NCI- 
H460/R308, along with the normal cell line MCR-5 was evaluated in the concentration 
range of 2.5-50 μM by (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) 
reduction assay by the procedure described by Pesic et al., 2013308,312.  Briefly, the cells 
were incubated with compounds at 8000 cells/cm2 for NCI-H460, 16,000 cells/cm2 for 
NCI- H460/R in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 4.5 g/L 
glucose, 10,000 U/mL penicillin, 10 mg/mL streptomycin, 25 mg/mL amphotericin B 
solution at 37ºC in a humidified 5% CO2 atmosphere for 72 h. Afterwards, 100 ml of MTT 
solution (1 mg/mL) was added to each well and plates were incubated at 37ºC for 4 h. 
Formazan product was dissolved in 200 ml of DMSO and the absorbance of obtained 
dye was measured at 540 nm using an automatic microplate reader (LKB 5060–006 
Micro Plate Reader, Vienna, Austria). 
3.3. Results and discussion  
3.3.1. P. madagascariensis extraction  
The extraction yield was evaluated for all prepared extracts (mg of extract/g of dried 
plant) considering the combination of several extraction processes and solvents (Table 
3.1). The extracts with higher extractive yield were those obtained using methanol as 
solvent (E6, E7). This can be explained by the ability of ethanolic solvents to disrupt 
biologic membranes, favouring the diffusion of secondary metabolites to the bulk 
extract. Moreover, considering the relative polarity of the extraction solvents (dielectric 
constant, ε), it could be verified a trend for the more polar solvents to archive higher 
extraction yields (εmethanol > εacetone >> εscCO2). The SCFE method using scCO2 (E8) was the 
least efficient extraction technique with the lower yield. Due to this low extraction 
efficiency, a re-extraction of the remaining plant material (R-SCFE) was performed in 
order to extract the remaining non-extracted secondary metabolites. The reminiscent 
plant material of the SCFE was macerated in acetone for 3 weeks, resulting in a higher 
extraction yield when compared to SFE (Table 3.1). 
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Table 3.1. Total extraction yields of selected extracts and substance quantification in those extracts. 
Extract Solvent Technique 
Extraction yield 
(mg/g) 
Substance yield in extract (mg/g) 
III.1 III.2 III.3 III.4 III.5 
E4 Acetone UAE 1.51 29.85 4.62 1.64 1.04 15.52 
E5 Acetone ME 1.45 17.49 3.19 6.74 1.21 5.77 
E6 Methanol UAE 6.56 4.60 4.20 0.81 0.77 t 
E7 Methanol ME 11.96 26.44 1.05 0.24 t t 
E8 scCO2 SCFE 1.31 17.79 4.98 0.20 0.84 n/d 
E9 Acetone R-SCFE 2.95 50.52 0.33 0.17 n/d n/d 
 
ME – Maceration extraction; UAE – Ultrasound assisted extraction; SCFE – Supercritical fluid extraction; R-SCFE – Re-extraction of SCFE remaining 
plant material. t – traces; n/d – not detected.  
  
3.3.2. HPLC-DAD extract profiling and identification of major compounds 
Previous phytochemistry studies on the Plectranthus genus revealed the presence of 
polyphenols and diterpenes as the most frequent secondary metabolites (as reviewed 
previously in section 1.2.2). These compounds have characteristic absortion parterns in 
the UV spectra zone due to the presence of conjugated carbonyl groups (270 nm), 
aromatic rings (280 nm) and phenolic groups (330 nm). For this reason measurements 
at 270, 280 and 330 but also the reference 254 nm were selected to monitoring the high 
peak resolution of extracts profile chromatograms (Figure 3.1).  
The peak eluted at 10.47 min was presented in all extracts and exhibited a UV 
spectrum with a characteristic maximum absorption (λmax) at 330 nm and at 265 nm. 
This could be associated with a phenolic compound with aromatic rings36,307. After co-
elution with rosmarinic acid (III.1) an overlay of both UV spectra and retention time was 
verified being this peak positively identified as rosmarinic acid (Figure 3.2). This 
polyphenol has been found in numerous Plectranthus species and was previously 
identified in P. madagascariensis72,307.  
The peaks obtained at the average retention times of 17.80, 19.40 and 19.80 min 
possess the typical royleanone-type abietane UV spectra with λmax at 272 nm and a 
secondary  broad λmax between 300 and 500 nm56. This is in accordance to other 
phytochemical studies of Plectranthus species55. The co-elution of extracts with 
authentic samples of 7α,6β-dihydroxyroyleanone (III.2) and 7α-acetoxy-6β-
hydroxyroyleanone (III.4) demonstrated the overlay of the UV spectra at 17.80 and 
19.80 min (Figure 3.2). This allowed the identification of the peak at 17.80 and 19.80 
min as corresponding to compound III.2 and III.4, respectively (Figure 3.3). 
A major peak eluted at 21.08 min presented a UV spectrum with λmax at 259, 283, 331 
and 383 nm, which supported the presence of a conjugated carbonyl with an aromatic 
ring (Figure 3.2). These spectral characteristics were comparable to those verified for 
coleon U83, a diterpene often found in Plectranthus species. The co-elution of the 
extracts with authentic sample of coleon U demonstrated an overlay of the UV spectra 
(Figure 3.2). This led to the attribution of the 21.13 peak to coleon U (III.5) (Figure 3.3). 
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Figure 3.1. HPLC representative chromatogram from P. madagascariensis extracts E4-E9 (270 nm). 
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Figure 3.2. Overlay of sample extracts and a standard solution of rosmarinic acid (III.1), 6α,7β-dihydroxyroyleanone 
(III.2), 7α-acetoxy-6β-hydroxyroyleanone (III.4) and coleon U (III.5). Full line corresponds to 1 mg/mL of each standard 
and discontinued line to the corresponding component in the sample extracts. 
 
   
III.1 III.2 R=H III.5 
 III.3 R=CHO  
 III.4 R=COCH3  
 
Figure 3.3. Chemical structure of the compounds III.1-III.5 quantified from P. madagascariensis organic solvent extracts: 
rosmarinic acid (III.1); 7α,6β-dihydroxyroyleanone (III.2); 7α-formyloxy-6β-hydroxyroyleanone (III.3); 7α-acetoxy-6β-
hydroxyroyleanone (III.4); coleon U (III.5). 
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The latter compound was reported to have some intrinsic instability, being easily 
converted to the oxidized form coleon U-quinone (III.6)56,83. This degradation product 
was also detected in some P. madagascariensis extracts as a trace at the retention time 
of 19.19 min. The periodic analysis of an authentic sample of III.5 demonstrated the 
gradual increase of the peak at retention time 19.19 min with respective reduction of 
the peak at 21.08 min, which represents a gradual conversion of the compound III.5 into 
the oxidized form III.6. (Figure 3.4). 
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III.5 (Rt≈21.08 min) III.6 (Rt≈19.19 min) 
 
Figure 3.4. Proposed mechanism of coleon U (III.5) degradation on coleon U-quinone (III.6) and evidence of 
decomposition over time, followed by HPLC. Rt = retention time.  
 
Kubínová et al. was previously studied the methanolic extract of P. madagascariensis 
which resulted in the identification of rosmarinic acid, 7β,6β-dihydroxyroyleanone, 7β-
acetoxy-6β-hydroxyroyleanone and coleon U-quinone as the major components of that 
extract72. However, the full spectroscopic elucidation of those compounds was not 
accomplished by those authors.  
3.3.3. Isolation of 7α-formyloxy-6β-hydroxyroyleanone (III.3) 
The ultrasound acetone extract of P. madagascariensis yielded 480 mg (0.48% 
(w/w)).  The extract was subjected to active charcoal to eliminate the high content in 
chlorophylls plant pigments and the procedure was monitored by TLC.  
Compound III.3 was purified from the fraction eluted with hexane:ethyl acetate 
(95:5) by repeated elution in a preparative chromatography yielding 6.1 mg (1.27% 
(w/w)) of yellow needles after crystallization. The purified compound III.3 showed a 
retention time and UV-spectra in HPLC-DAD that overlay the peak detected in extracts 
at 19.40 min.  
3.3.4. Spectroscopic characterization of III.3 
The 1H NMR spectra of III.3 was very similar to that of III.437. The main differences 
were the absence of the signal at δ 2.02 (s, 3H) corresponding to the methyl protons of 
  (n m )
2 0 0 3 0 0 4 0 0 5 0 0 6 0 0
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the acetoxyl group at C7 in III.4 and the presence of a distinct doublet at δ 8.05 (J = 1.2 
Hz) which might correspond to an acidic proton from a secondary formyloxyl group31 
(Table 3.2) . This observation suggested the substitution of the 7α-acetoxyl group of III.4 
by a 7α-formyloxyl in III.3, which was confirmed by the literature31 and extensive NMR 
studies (1H and 13C NMR, COSY, HMBC and HMQC) (Table 3.2). The compound III.3 was 
identified as 7α-formyloxy-6β-hydroxyroyleanone, which was previously isolated from 
P. hadiensis80 and P. myrianthus56. This was, to our knowledge, the first isolation of this 
compound from P. madagascariensis and the first fully spectroscopic characterization 
of this compound (1H and 13C NMR). 
 
Figure 3.5. Structure of 7α-formyloxy-6β-hydroxyroyleanone (III.3). 
 
Table 3.2. NMR data of compound III.3 in CDCl3 (400 MHz).  
C 13C (ppm) 1H (m, J) (ppm) COSY (1H x 1H) HMBC (1H x 13C) 
1 38.49 1.19 (s)  2.64 (1β)  
  2.64 (d, 12.9) 1.19 (1α)  
2 19.09 1.50 (m)* 1.19 (1α)  
  1.85 (d, 4.5)   
3 42.45 1.20 (m)*   
  1.50 (m)*   
4 33.83    
5 49.80 1.38 (s)   21.71 (10) 
6α 67.25 4.37 (m) 5.80 (7Hβ)  
7β 68.42 5.80 (m) 4.37 (6Hα)  
8 136.45    
9 150.38    
10 38.79    
11 183.34    
13 124.35    
15 24.34 3.17 (qi, 14.1; 7.1) 1.21 (16Me); 1.24 (17Me) 124.35 (13) 
16 33.85 1.24 (d, 7.1) 3.17 (15H)  
17 20.01 1.21 (d, 7.1) 3.17 (15H) 124.35 (13) 
18 33.57 0.96 (s)  24.06 (19); 42.38 (3); 49.80 (5) 
19 23.97 1.25 (s)  33.57 (18); 42.38 (3); 49.80 (5) 
20 21.71 1.62 (s)  38.49 (1); 49.8 (5) 
6-OH 33.83 2.31 (t, 7.5)   
12-OH 151.13 7.20 (m, 3.1)   
CHO 159.64 8.04 (d, 1.2)   
  
 
85 
 
 
3.3.5. HPLC-DAD quantification of major compounds 
The quantification of the major compounds in P. madagascariensis extracts was 
based on the validated calibration curves for the main polyphenol rosmarinic acid (III.1) 
and the main abietane diterpenes 7α,6β-dihydroxyroyleanone (III.2), 7α-formyloxy-6β-
hydroxyroyleanone (III.3), 7α-acetoxy-6β-hydroxyroyleanone (III.4) and coleon U (III.5) 
(Table 3.3). Linear responses and high sensitivity were obtained for all compounds. 
 
Table 3.3. Linear regression analysis parameters for the proposed HPLC-DAD method 
Analyte λ (nm)a RT (min)b Crange (mM) Regression equation R2 LOD LOQ 
III.1 330 10.47 ± 0.065 0.1 – 1.5 y = 9733.1x - 378.8 0.999 0.001 0.003 
III.2 280 17.80 ± 0.022 0.02 – 0.5 y = 85490,4x - 155,2 0.998 0.001 0.002 
III.3 280 19.40 ± 0.014 0.04 – 0.26 y = 40748x - 245.93 0.999 0.001 0.004 
III.4 280 19.80 ± 0.020 0.02 – 0.27 y = 65383x – 204 0.997 0.003 0.009 
III.5 330 21.13 ± 0.004 0.02 – 0.12 y = 82084x + 818.47 0.987 n/d n/d 
a Wavelength used for the calibration curve; b Retention time of the compound as average of 12 samples ± standard deviation; n/d – not determined. 
 
Rosmarinic acid (III.1) was the secondary metabolite present in higher yields in the 
extracts A-D and F with yields ranging from 4.60 to 50.52 mg/g (Table 3.1). This finding 
is in agreement with the described abundance of this polyphenol in other Plectranthus 
species36. High yields of royleanone-type diterpenes were found in all extracts, but 
particulary in the acetonic extracts (Table 3.1). Coleon U (III.5) was the diterpene 
quantified in higher yields (5.77-15.52 mg/g), followed by 7α-formyloxy-6β-
hydroxyroyleanone (III.3) (6.74-0.17 mg/g), 7α,6β-dihydroxyroyleanone (III.2) (0.33-
4.98 mg/g) and lastly 7α-acetoxy-6β-hydroxyroyleanone (III.4) (0.11-1.21 mg/g).  
The cytotoxic effects of the P. madagascariensis  extracts have been previouly 
evaluated in the MDA-MB-231 cancer cells and those results presented in chapter 2. The 
quantification of the major compounds adds new information that could help explain 
the differences in the cytotoxicity of those extracts. The higher content in diterpenoids 
seems to be related to the higher cytotoxic effect as verified in by the extract E5 which 
had the higher combinatory yield of coleon U and royleanone-type abietane diterpenes 
of all the extracts prepared (Table 3.1). The royleanone-type compounds are known to 
have cytotoxic activities namely against breast cancer cell lines39,40. Aditionally, coleon 
U (III.5) was described in literature as a potent cytotoxic, active against breast, leukemia 
and melanoma cancer cell lines39,40,82,155. Those P. madagascariensis components would  
contribute for the cytotoxicity verified in this plant extracts. However, the extract E4, 
with the highest yields of compounds III.4 and III.5 do not correspond to the extract with 
the highest cytotoxicity. This can be explained by synergistic effects between the extract 
elements. The most cvytotoxic extract (E5) present a lower yield of rosmarinic acid 
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compared to other extracts. This compound is known to be a potent antioxidant58, and 
some studies related the cytotoxic effect of abietane diterpenes possessing quinone 
methide moieties to the induction of radicalar reactions112,113. Those factors could let us 
speculate a potential antagonistic effect between antioxidant polyphenols and quinone 
methide diterpenes. 
3.3.6. Cytotoxicity of the pure compounds (III.1-III.5)  
The cytotoxicity of compounds III.1-III.5 was tested in breast cancer (MDA-MB-231 
and MCF-7), colon cancer (HCT116), non-small cell lung cancer (NCI-H460) and normal 
lung bronchial (MCR-5) cell lines (Table 3.4). Those results showed growth inhibition 
effects in most cancer cell lines by all the abietane diterpenes. It is especially relevant 
the high selectivity of the royleanones III.2 and III.4 based on the comparison of GI50 of 
a cancer (NCI-H460) and normal lung cell line (MCR-5). Also, these two royleanones 
showed similar growth inhibition of the NCI-H460 cancer cell line and of its multidrug 
resistant variant (NCI-H460/R) which overexpress the multidrug resistance protein 1 
(MDR1) (also known as P-glycoprotein)308. This is a strong indication that compounds 
III.2 and III.4 were not substrates for such efflux pumps. 
The growth of MDA-MB-231 cancer cells was not particularly affected by the P. 
madagascariensis abietane diterpenes. This cell line is a highly metastatic triple negative 
breast cancer cell line, not displaying estrogenic receptors (ER), progesterone receptors 
(PR) or human epidermal growth factor receptor 2 (HER2), and thus, being clinically 
difficult to target313. It was known that the ER negative cells have a higher expression of 
PKC classic isoforms when compared to ER positive cell lines314,315. The upregulation of 
the classic isoform PKCα promotes the invasiveness and metastasis formation315–317 
along with increased drug resistance318 in breast cancers. On the other hand, the PKCδ 
activation supports both prosurvival319 and proapoptotic functions in breast cancer 
cells320,321. Also, some abietane diterpenes (coleon U156 and a benzyloxy derivative of 
7α-acetoxy,6β-hydroxyroyleanone322) have demonstrated to exert proapoptotic effects 
by the specific activation of the PKCδ. In this cell line, where its verified an 
overexpression of classic PKC isoforms, in detriment to new PKC isoforms, the 
preferential mechanism of apoptosis induction by coleon U (and eventually of other 
abietanes) by activation of PKCδ should be less effective, which justifies a lower growth 
inhibition of this cell line by such compounds. 
There have been demonstrated some relationship between the PKC overexpression 
and the drug resistance by MDR1. Following the treatment with the PKC activator TPA, 
a cellular increase of the MDR1 expression was verified, which was suppressed by the 
use of a PKC inhibitor (staurosporine)323. Also, the use of a PKC inhibitor, bryostatin 1, 
potentiate the cytotoxic effects of anticancer drugs transported by efflux pumps as 
vincristine, by the reduction of MDR1 expression324. Those findings could be especially 
relevant in the case of abietane diterpenes not transported by MDR1, in which the PKC 
activation and the secondary MDR1 overexpression shouldn’t increase the cell 
resistance to those compounds. 
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Table 3.4. Growth inhibitory effects of the P. madagascariensis major compounds in different cell lines. 
 Cell line / GI50 (µM) 
MDA-MB-231 MCF-7 HCT116 NCI-H460 NCI-H460/R MCR-5 SI# 
III.1 ˃ 100 nt nt ˃ 100 ˃ 100 ˃ 100 - 
III.2 ˃ 100 26.0 ± 0.6 ≥ 50 25 ± 2 25 ± 2 91 ± 13 4.3 
III.3 ˃ 100 7.9 ± 0.8 7.9 ± 1.2 14.9 ± 2.9 nt nt - 
III.4 ˃ 100  6.4 ± 0.4* - 2.7 ± 0.4 3.1 ± 0.4 8.6 ± 0.4 3.2 
III.5 46.9  5.5 ± 0.8* - 3.0 ± 0.2* nt nt - 
#Selectivity index. SI= GI50 (MCR-5)/GI50 (NCI-H460); nt – not tested; *Previously published results from our group39. 
 
3.4. Structure activity relationships 
The conjugation of the new data on abietane diterpene cytotoxicity (Table 3.4) with 
other studies on the cytotoxicity of this compound classes (Table 3.5) allowed the 
prospection of some structure-activity relationships (SAR). The compounds III.2-III.4 
present as main difference the polarity of the group 7α (Figure 3.3). In this SAR, a clear 
tendency could be verified for the increasing cytotoxicity with the higher lipophilicity of 
the 7α substituent. The same tendency was verified between horminone (Figure 3.6, 
R1=H, R2=OH and R3=OH) and its more cytotoxic 7α-acetoxy derivate (Figure 3.6, R1=H, 
R2=OAc and R3=OH)325,326.  
The bibliographic exhaustive surge of reported cytotoxicity of royleanone-type 
compounds, bearing a p-benzoquinone moiety in the C-ring (Figure 3.6), additional 
tendencies could be explored (Table 3.5). Burmistrova et al. (2013) studied the cytotoxic 
effects from a series of derivatives of the 7α-acetoxy-6β-hydroxyroyleanone (III.4)40. The 
overall compounds affect the cell proliferation with an intensity apparently cell-type 
dependent. When such compounds were displayed by their log P value, a strong 
tendency for higher cytotoxic effects was verified for log P values between 2 and 5.5.  As 
the “Lipinski rule of 5”, establish that the log P for an oral bioavailable compound should 
be under 5, the useful compounds must be considered in the 2-5 range of log P327. The 
only exception for this trend was royleanone (Figure 3.6, R1=H, R2=H and R3=OH) that 
showed only slight cytotoxic effects in some cell lines40,325,328. This could indicate that 
the presence of a lipophilic substituent was needed at position 6 and/or 7 for the 
cytotoxic effects to take place. However, the royleanone 6,7dehidro derivative has 
showed some potent cell-type-specific cytotoxic effects329–331. This way, the presence of 
an electron donating group at position 6 or 7 seems necessary for the cytotoxicity. 
 
  
 
Table 3.5. Cytotoxicity of several royleanone derivatives, expressed as GI50 (µM) in different cell lines. 
Compound features / Cell line (GI50 in µM) [reference] Breast CNS Colon Gastric Leukaemia/Lymphoma Melanoma Papil. Pancreas Renal Lung Normal 
R1 R2 R3 logP 
MCF-7 
[39,40] SF-268 HCT116 
AGS 
[328] 
HL-60 
[329,330] 
P-388 
[331] 
U937 
[40] 
Molt-3 
[40] 
MEL-1 
[40] 
UACC-62 
[39] 
MV-3 
[325] 
KB 
[331] 
PaCa-2 
[325] 
TK-10 
[39] 
H460 
MCR-5 
[328] 
OH OH OH 0.85 + - -       -    - - + 
OH OCHO OH 0.97 ++ ++ ++              
OH OCOCH3 OH 1.08 ++    +  + + + +++    ++ +++ ++ 
OCOCH3 OCOCH3 OH 1.31 +    +  + ++ +        
OCOCH3 OCOCH3 OCOCH3 1.54 ++    ++  ++ +++ ++        
H =O OH 1.57           -  -    
H βOH OH 1.74    -            + 
H OH OH 1.74    +  +++     + + +   + 
OCOCH2CH3 OCOCH3 OH 1.96 +    +  ++ ++ ++        
H OCOCH3 OH 1.97           ++  +++    
OH OCH3 OH 2.10      +++      +     
OH OCOCH3 OCOBzNO2(p) 2.30 +    ++  +++ ++ ++        
OCO(CH2)2CH3 OCOCH3 OH 2.38 ++    ++  +++ +++ +++        
H6,7 H6,7 OH 2.51    - +++/+ +++      ++    +/- 
H H OH 2.83    - -  - + -  -  -   + 
OCOCH2CH3 OCOCH3 OCOCH2CH3 2.85 +    +++  +++ + +        
OH OCOCH3 OCOBzCH3(p) 3.69 +++    +++  +++ +++ ++        
OH OCOCH3 OCOBzCl(p) 3.77 +++    +++  +++ +++ +++        
OCOBzNO2(p) OCOCH3 OH 4.31 ++    +++  +++ +++ ++      
 
 
OCOBz OCOCH3 OCOBz 5.33 +    +++  +++ ++ +++        
OCOBzCl(p) OCOCH3 OCOBzCl(p) 6.45 -    ++  ++ - -        
OH O-FA OH >7 - -        -    - -  
Otherwise stated all R2 conformation was β; logP values estimated using ChemBioDraw; –: not active (GI50>30); +: low cytotoxic (10<GI50≤30); ++: cytotoxic (5<GI50≤10); +++: highly cytotoxic (GI50≤ 
Papil. – papilloma; Bz – benzene; FA – fatty acid. 
8
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Figure 3.6. Structure and proposed SAR of 6,7,12-substituted royleanone-type abietane diterpenes based on data 
compilated at Table 3.5. 
3.7. Chapter conclusions 
This chapter study presented the preparation of several P. madagascariensis 
extracts, which have been screened for their cytotoxic activity. The main compounds in 
these extracts were identified by HPLC-DAD and the compound III.3 was isolated and 
spectroscopically characterized. The acetonic maceration extract (E5) showed high 
yields of abietane diterpenes, presenting also the highest cytotoxic effect in MDA-MB-
231 breast cancer cells (IC50 of 63.9 µg/mL). The observed cytotoxic activity may be 
justified by the presence of known cytotoxic diterpenes, namely 7α,6β-
dihydroxyroyleanone (III.2, 3.19 mg/g), 7α-formyloxy-6β-hydroxyroyleanone (III.3, 6.74 
mg/g), 7α-acetoxy-6β-hydroxyroyleanone (III.4, 1.21 mg/g) and coleon U (III.5, 5.77 
mg/g). To the best of our knowledge this is the first report of the presence of compounds 
III.2-III.5 in P. madagascariensis. The complete 13C RMN data for compound III.3 is also 
presented for the first time. 
The compounds III.1-III.5 were tested for their individual cytotoxic effects in a battery 
of cell lines and all abietane diterpenes originated the growth inhibition of some cancer 
lines. The royleanones III.2 and III.4 displayed a high selectivity toward cancer cells and 
were not target of efflux proteins overexpressed in the NCI-H460/R multidrug resistant 
cell line. An initial SAR of the cytotoxicity of 6,7 and/or 12-substituted royleanone 
abietanes was established with a clear trend for log P values between 2 and 5 
corresponding to compounds with improved cytotoxic effect. The whether those 
structural alterations correspond to an improved fitting on the target or the cytotoxic 
activity was instigated by favorable log P for the membrane crossing is still to be 
answered. 
Overall, compounds III.2-III.5 may be considered a very promising compound for 
further studies in order to fully understand the potential of the abietane diterpenoids 
as chemopreventive, chemoadjuvancts or chemotherapeutic agents. 
 
  
Electron donating group 
at position 6 and/or 7 
Log P in the 2-5 range 
Increasing cytotociticy with 
less polar 7α substituents 
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4. Antibacterial phytosomal formulations 
4.1. Introduction 
 The antibiotic resistance problem had been recently highlighted by key organizations 
including the World Health Organization119 and the World Economic Forum332 as a major 
concern for the humanity in the following years. Bacteria can acquire resistance to 
antibiotics by gene mutations, horizontal gene transfer or they could be intrinsically 
resistant to some antibiotic classes333. The most relevant predisposal factor of non-
intrinsic resistance is considered to be the worldwide misuse of antibiotics, including 
medical overprescribing practices, patient self-medication and use as veterinary 
growing stimulants334,335. Such issues could originate a life threating situation in the case 
of hospital associated infections (i.e. septicaemia, pneumonia), but can also complicate 
the treatment of apparently simple situations as a superficial wound. In recent years, 
the arise of some microorganisms with resistance to the traditional topical treatments, 
namely mupirocin336 and fusidic acid337, have shown to be a public health problem, 
namely in the management of both acute or chronic skin and soft tissue infection338.  
The skin has protection and barrier functions, that could be compromised by the 
occurrence of physical trauma or wounding. The following skin repair processes intend 
the complete reestablishment of the damaged tissue integrity. However, this processes 
could be impaired if microbial infection occurs. It is often recommended by dermatology 
guidelines to use topical antibiotic agents for the prophylaxis of wound bacterial 
infection339,340. Also, in the wound environment often occur the formation of biofilms 
which enhance the bacterial tolerance to topical antibiotics341. Such reasons highlight 
the need for new therapeutic alternatives for topical antibacterial treatment.  
The screening performed by Weckesser and collaborators (2009)342, suggested that 
natural extracts from plants as Gentiana lutea, Harpagophytum procumbens, Boswellia 
serrata, Usnea barbata, Rosmarinus officinalis and Salvia officinalis could be effective in 
controlling common skin pathogenic agents. Following such results, Elston et al.338 
suggested that such natural compounds could be alternative options for topical skin 
antimicrobial treatments. Also the concomitant use of natural products, as essential oils, 
with traditional antibiotics was suggested to be an effective strategy in reverting the 
bacterial resistance343.  
The investigation presented in chapter 2. showed that the ethnomedicinal use of P. 
madagascariensis as wound disinfectant could be justified by the presence of several 
antibacterial oxygenated abietane diterpenes and some polyphenols. One of the 
extracts (E4) obtained in that study, showed outstanding activity against some of the 
typical skin bacteria, as S. epidermidis and S. aureus, including a methicillin-resistant 
strain. Considering those results along with the need of new antimicrobial agents and 
the acceptance that natural products could be a reliable alternative to traditional 
antibiotics, it is proposed the development of an optimized antibacterial system for 
possible topical application. Based on some reports344, we state that an ideal 
antibacterial topical formulation should be (i) active against the expected skin 
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pathogens and including MDR strains to prevent the emergence of superinfections; (ii) 
non-toxic for keratinocytes at the concentration of activity; (iii) the formulation 
elements should preferentially have synergic effects and different modes of action; (iv) 
should not contain any antimicrobial that would be used parentally; and (v) should not 
occur systemic toxicity caused by the absorption of the antibacterial formulation 
through the intact skin or wound.  
The use of nanotechnology has been also suggested as an additional resource for the 
improvement of antibacterial activityp345,346. Their favourable effects occur through 
mainly three mechanisms: by incorporating different components with synergic or 
concomitant antibacterial effects347,348; by overcoming existing mechanisms of 
resistance favouring increased uptake348 and disrupting the biofilm formation347; and by 
drug targeting assuring higher concentrations of the drug to the infection site348.  
In order to test the feasibility of Plectranthus extracts encapsulation in polymeric 
matrixes, a preliminary study focused on the production of alginate beads containing an 
antioxidant and anti-S. epidermidis microwave aqueous extract of P. madagascariensis, 
which was selected from a screening of 5 Plectranthus plants (annex 10)307. In this study, 
the obtained particles were spherical, homogenous in colour and particle size and 
showed very high encapsulation efficiency of the main extract component, rosmarinic 
acid. The long-term stability studies also demonstrated the viability of this system to the 
improvement of the stability of this extract and, consequently, of its biological activities. 
These properties may be beneficial for the healing. 
This initial approach in the encapsulation of P. madagascariensis extracts, led as to 
test the phytosome technology as strategy for the improvement of antibacterial activity 
of Plectranthus components. Phytosomes were mainly known for their uses in oral 
formulations due to its improvement of bioavailability. Although, considering the 
phytosome high phospholipid content, it could exert a nourishing effect in the skin, and 
also being highly biocompatible with the skin layers could increase the penetration of 
bioactive compounds to inner layers of the skin and thus intensifying the therapeutic 
outcome349.  
Some excellent reference texts have focused on the basis of transdermal penetration 
of drugs and particulate materials350,351. The free drug percutaneous penetration 
potential trough skin was mainly characterized based on the  maximum flux (Jmax)352 
being this parameter related in many mathematic models to the log of octanol solubility 
(log So), molecular weight, octanol water partition coefficient (o/w coefficient) and 
melting point352,353.  
Micro- and nanoparticle could penetrate the stratum corneum by three main 
mechanisms: particles smaller than 5-7 nm through lipidic intercellular route; particles 
smaller than 36 nm through aqueous pores; and larger particles (up to 21 µm) through 
transfollicular route but only offering a negligible contribution (less than 0.1% of total 
skin surface) to the overall permeation354. As most phytosome possess an average 
particle size higher than 50 nm it is unlikely that a high degree of transdermal 
permeation occurs through the epidermis layers for those particles, being the main 
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mechanism of transdermal penetration the intrafollicular route. The eventual 
permeation of phytosomes would also be affected by factors as superficial charge, pKa, 
o/w partition coefficient, particle shape and deformability, composition and stability of 
the particle could influence the permeation ability of such nanoparticles354. Those 
factors also have influence in the physical stability and aggregation upon contact to skin 
medium maintaining this way the maximum potential for permeation. Another factor 
was the interactions with skin components which were influenced by the particle 
charge, the formation of dipole, hydrophobic and/or hydrogen-bond interactions351. 
Those factors stated that phytosome could not be appropriated for transdermal 
delivery, although, Das and collaborators demonstrated that their rutin phytosomes 
with an average size of 1.2 µm presented a 24h-permeation of the stratum corneum 
about 60% higher when compared to the lipophilic free drug355. Being due to the higher 
permeation or due to a still unidentified mechanism, there was an evident improvement 
of topical activity of some natural products as boswellic acid (anti-inflammatory)247 and 
curcumin (antioxidant)246 with advantage over their equivalent niosome and liposome 
formulations246,247. The functionalization of phytosomal systems seems a valid strategy 
for the improvement of the intended biologic activity. This is highlighted by the 
Calendula extract phytosomes associated to gold nanoparticles (AuNP) with antioxidant 
and wound healing effects superior to the equivalent phytosome formulation257. 
Chitosan is a semi-natural polysaccharide being the most important derivative of 
chitin (poly-β-(1→4)-N-acetyl-d-glucosamine) from which is obtained by alkaline or 
enzymatic deacetylation356. Chitosan is weak base, becoming soluble in acidic media by 
the protonation of -NH2 group on the carbon 2 of the d-glucosamine polysaccharide 
(Figure 4.1). The combination of its aqueous solubility with the natural cationic character 
finds it many applications in the production of viscous solutions, gels, films and fibres. 
Chitosan matrixes have shown interesting antimicrobial properties against a wide range 
of bacteria357,358. Such biologic activity was currently accepted to be more bacteriostatic 
rather than bactericide359 and resulting from the independent or simultaneous 
contribution of three mechanisms: 1) interaction between the positively charged 
chitosan molecules and the negatively charged bacterial membrane, involving a cross-
linkage between the chitosan protonated groups and the anions on the bacterial surface 
and changes in membrane permeability with possible cell rupture359,360; 2) inhibition of 
the mRNA and protein synthesis via the penetration of chitosan into the nuclei of the 
 
 
 
Figure 4.1. Structural representation of the chitosan polymer. Depending on the deacetylation degree, R could 
represent be H (amine) or COCH3 (amide). A more deacetylated sample is richer in H substituents.   
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microorganisms359; 3) the formation of an external barrier, chelating metals and led to 
the suppression of essential nutrients to microbial growth361. Such versatile 
antimicrobial mode of action led some groups to use those properties for the production 
of nanocomposite antibacterial films, wound coating materials362 and antibacterial 
nanoparticles363. 
Chitosan nanoparticles have been obtained mainly by the spontaneous formation of 
complexes between chitosan and polyanions as the tripolyphosphate (TPP) or dextran. 
The better established method for those nanoparticle preparation is internal gelation. 
Is such method, a chitosan solution in acetic acid is prepared and extruded dropwise 
into an aqueous solution of magnetically stirred TPP.  
The insights through which the cross-linking occurs were still badly understand with 
few mechanistic approaches made so far. Various authors suggest a simplified model in 
which the anionic groups of TPP form stable interactions with chitosan amine groups364–
366.  A recent study demonstrated that could exist simultaneously three types of primary 
ionic cross-linking interactions between TPP and chitosan oligomers designed H-links, 
M-links and T-links. However, due to the highest interaction energies and the availability 
of free spatial area for their occurrence, H-links were proposed as the most frequent 
cross-linking types367. 
The aim of this chapter is to prepare phytosomes and optimize the production 
method. The selection of both formulation and process parameters will be done 
according physic-chemical and biologic characterizations.   
4.2. Experimental 
4.2.1. Chemicals and equipment 
Most of the laboratorial work has been performed at the CBIOS facilities 
(Universidade Lusófona de Humanidades e Tecnologias). Some procedures were 
performed in collaborating institutions, namely Faculdade de Farmácia da Universidade 
de Coimbra (animal experiments), Faculdade de Ciências da Universidade de Lisboa 
(AFM, DSC, DRIFTS and SEM studies) and Institute for Biological Research “Sinisa 
Stankovic” at University of Belgrade, Serbia (cytotoxicity assays).  
4.2.1.1. Chemicals 
Phosphatidylcholine (48% purity from soybean), cholesterol, acetic acid, sodium 
laureth sulfate, carboxymethyl cellulose, sodium tripolyphosphate (technical grade 
85%) and chitosan (low molecular weight) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Extraction and reaction solvents, namely dichloromethane, 
ethanol and acetone were from analytic grade and purchased from Sigma-Aldrich 
(Steinheim, Germany). Reverse osmosis water was obtained from a Millipore system 
(Millipore, MA, USA) system with a resistivity of 18.2 Ω⋅cm at 25°C. Trichloroacetic acid 
was obtained from Panreac (Barcelona, Spain). HPLC reagents were from HPLC-grade 
(VWR Chemicals, Fontenay-sous-Bois, France) and were filtered through a 0.22 μm 
membrane (Vygon, Ecouen, France) before use. Dimethyl sulfoxide (DMSO) was 
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supplied by Merck (Darmstadt, Germany) was supplied by Sigma-Aldrich (Steinheim, 
Germany). Filter paper nº5 was obtained from Whatman (Maidstone, United Kingdom).  
An authentic standard of 7α,6β-dihydroxyroyleanone was obtained and fully 
characterized by Gaspar-Marques34. Mueller-Hinton broth was supplied from Sigma-
Aldrich (Steinheim, Germany).  Vancomycin was supplied by Sigma-Aldrich (Steinheim, 
Germany). Polydimethylsiloxane (PDMS) membranes with a thickness of 75 μm were 
kindly donated by Dow Corning Europe S.A (Seneffe, Belgium). 
4.2.1.2. Equipments 
The HPLC-DAD system was composed by an Agilent Technologies 1200 Infinity Series 
with diode array module (Agilent Technologies, Santa Clara, CA, USA) using a reverse 
phase (RP-18) HPLC column LiChrospher® 100 (Merck, Darmstadt, Germany). Other 
equipments used were hotplate magnetic stirrer (RT15 power, IKA, Staufen, Germany), 
centrifuge (Z36 HK HERMLE Labortechnik, Wasserburg, Germany), lyophilizer (Freezone 
2.5 L, Labconco, Kansas City, USA), particle size and zeta potential analyser (Delsa Nano 
C, Coulter, CA, USA), rotary evaporator (IKA RV06-ML 1-B, Staufen, Germany) ultrasonic 
bath (Bandelin SONOREX RK 510H, Berlin, Germany) and weighting scales (KERN 770, 
KERN & Sohn GmbH, Balingen, Germany). The atomic force microscopy (AFM) was 
performed in a Multimode Nanoscope IIIa (Digital Instruments, Veeco, Cambridgeshire, 
UK) and the scaning electron microscopy (SEM) was performed in a 5200LV (JEOL Ltd., 
Tokyo, Japan). Infrared spectroscopy experiments were performed in a Nicolet 6700 
(Thermo Fisher Scientific, Waltham, MA, USA) while DSC experiments were performed 
in a DSC 7 with TAC 7/3 controller (PerkinElmer, Waltham, MA, U.S.A.) with weightings 
performed in an ultra-microbalance (XP2U, Mettler-Toledo, Greifensee 8606 
Switzerland). 
4.2.1.3. Plant material 
Plectranthus madagascarensis Benth. was cultivated in Parque Botânico da Tapada 
da Ajuda (Instituto Superior Agrário, Lisbon, Portugal) from cuttings obtained from the 
Kirstenbosch National Botanical Garden (Cape Town, South Africa). A voucher specimen 
was deposited in Herbarium João de Carvalho e Vasconcellos (ISA) with the number 
841/2007. The plant material used in this study was collected between 2007 and 2008, 
dried at room temperature and stored protected from light and humidity. 
4.2.1.4. Microbial strains 
The antimicrobial assays were performed in 3 Gram positive bacteria strains:  
Staphylococcus aureus (ATCC 25923), methicillin-resistant S. aureus (MRSA) (CIP 
106760) and Staphylococcus epidermidis (ATCC 12228). Microbial strains were originally 
obtained from American Type Culture Collection (ATCC) or form “Collection de l'Institut 
Pasteur" (CIP).  
4.2.1.5. Cell lines 
HaCaT is an immortalised non-tumorigenic human keratinocyte cell line derived from 
normal human trunk skin and able to stratify (Boukamp et al., 1988)368. This line was 
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maintained at Institute for Biological Research “Sinisa Stankovic” at University of 
Belgrade (Serbia) and obtained from CLS (Cell Lines Service), Eppelheim, Germany. 
4.2.1.6. Software editing  
Chemical structures were drawn on ChemBioDraw Ultra 12.0.2.1076. ChemStation 
was used for HPLC-DAD controller and data exportation. Statistical analysis and graphic 
design were archived using GraphPad Prism 6.01 for Windows 10.  
4.2.2. Plectranthus madagascariensis extract  
The bioactive P. madagascariensis extract was prepared as previously reported in 
sub-section 2.2.2. Briefly, E4 was prepared by USAE carried using 10 g of dried and 
pulverized plant, immersed in 100 mL of acetone, into an ultrasonic bath (Bandelin 
SONOREX RK 510H, Germany) with a working frequency of 35 kHz and 400 W of power 
and sonicated for 1 hour. The bulk extract was separated from the remaining plant 
material by filtration through paper nº5 (Whatman, Maidstone, United Kingdom) and 
evaporated under reduced pressure in a rotary evaporator (IKA RV06-ML 1-B, Staufen, 
Germany) until drying. 
The extract was characterized by HPLC-DAD and main compounds identified and 
quantified using the methodology described at subsection 3.2.3.  
4.2.3. Optimization of phytosome preparation  
Different solvents (acetone, dichloromethane and ethanol), reaction time (60, 120 
and 240 min) and cholesterol concentration in the formulation (0, 2.5 and 5 molar %) 
were tested in order to obtain the smallest and more uniform phytosomes. Briefly, 
molar equivalent concentrations of PdC and extract were solubilized in 20 mL of solvent 
and kept magnetic stirring (RT15 power, IKA, Staufen, Germany) at 50ºC during the 
reaction time. To obtain the phytosomes, 40 mL of reverse osmosis water was then 
added and the organic solvent was partially eliminated in the rotary evaporator (IKA 
RV06-ML 1-B, Staufen, Germany) and the pellet was recovered by centrifugation at 
23,540 G for 10 min (Z 36 HK HERMLE Labortechnik, Germany). 
4.2.4. Preparation of loaded-phytosomes (PS) 
Based on previous section results, PdC (424 mg), extract (200 mg) and cholesterol 
(11.6 mg) were dissolved into 40 mL of acetone and the mixture was magnetic stirred at 
55ºC for 2 h (HTS 1003, LMS, Tokyo, Japan). The solution was then added to 80 mL of 
2% (w/v) acetic acid being the organic fraction evaporated under reduced pressure (IKA 
RV06-ML 1-B, Staufen, Germany) for about 2h at 50ºC until the volume became stable. 
4.2.5. Chitosan microencapsulation of PS (ChiPS) 
The prepared phytosome suspension was mixed with 400 mL of a 1% chitosan (w/v) 
solution in 2% acetic acid (v/v). The resultant solution was then added dropwise to 600 
mL of the counter-ion sodium tripolyphosphate solution (0.3% w/v) under vigorous 
magnetic stirring (500 rpm) (HTS 1003, LMS, Tokyo, Japan). The resultant suspension 
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was centrifuged at 33,320 x g for 5 minutes to recover the particles in the pellet. The 
pellet was washed several times with distilled water and freeze-dried using a 
temperature of −50°C and a vacuum of 0.020 mbar (Freezone 2.5 L, Labconco, Kansas 
City, USA). 
4.2.6. Determination of encapsulation efficiency and drug loading 
Encapsulation efficiency of the extract in the phytosomes was determined by 
evaluation of the content of the major peak in the extract (7α,6β-dihydroxyroyleanone). 
For this compound, a calibration curve was established using authentic samples. Three 
independent batches of Chi-Ps were freeze-dried using a temperature of −50°C and a 
vacuum of 0.020 mbar (Freezone 2.5 L, Labconco, Kansas City, USA) and precisely 
weighted for the quantification of the ChiPS recovery yield after production.  
The encapsulation efficiency and drug loading were determined by dissolving 10 mg 
of freeze-dried particles in 1 mL methanol overnight249. The mixture was then 
centrifuged at 23,540 x g and the supernatant filtered through a 0.46 µm filter previously 
to the analysis. The amount of 6β,7α-dihydroxyroyleanone (Roy) detected by HPLC-DAD 
was used to estimate the encapsulation efficiency (EE) (I) and drug loading (DL) (II) using 
the following equations:  
 
(𝑰) 𝐸𝐸 (%) =
𝑅𝑜𝑦𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝑅𝑜𝑦𝑡𝑜𝑡𝑎𝑙
× 100 
 
(𝑰𝑰) 𝐷𝐿 (%) =
𝑅𝑜𝑦𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝐶ℎ𝑖𝑃𝑆
× 100 
 
Were Royencapsulated corresponds to the weight of Roy detected after the disruption 
of the particles, Roytotal is the total weight of Roy used for particle production and ChiPS 
is the weight of particles. Tests were performed in triplicate being results expressed as 
the means ± S.D.  
4.2.7. Physic and morphological characterization  
Loaded phytosomes and loaded ChiPS were diluted with distilled water and analysed 
in by DLS in a Delsa Nano C (Coulter, CA, USA) to obtain the average particle size, 
polydispersity index (PI) and Zeta potential (ζP). Morphology was assessed by SEM369 
(5200LV SEM, JEOL Ltd., Tokyo, Japan) or AFM370 (Multimode Nanoscope IIIa, Digital 
Instruments, Veeco, Cambridgeshire, UK) using previously optimized methods.  
4.2.8. Physic-chemical analysis  
The differential scanning calorimetry (DSC) measurements were carried out on a 
PerkinElmer DSC 7 with TAC 7/3 instrumental controller (PerkinElmer, Waltham, MA, 
USA). The samples with 2.5-4.9 mg mass were sealed in air, inside aluminium sample 
pans. Each crucible was transferred to the apparatus and heated at a rate of 10ºC/min 
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in the range 25-250ºC. Nitrogen (Air Liquide N45, Lisbon, Portugal) at a flow rate of 0.5 
cm3/s was used as the purging gas. The temperature and heat flow scales of the 
instrument were calibrated at the same heating rates with indium (mass fraction: 
0.99999; Tfus = 429.75K, fush0 = 28.45 J/g). All weightings were performed with a 
precision of ±0.1 µg on a XP2U ultra-microbalance (Mettler-Toledo, Greifensee 8606 
Switzerland). 
 
Table 4.1. Samples evaluated for interaction between its components by DSC and DRIFTS.   
Sample DSC DRIFTS 
A Cholesterol Cholesterol 
B Extract E4 Extract E4 
C PdC PdC 
D Mixture of Cholesterol, E4 and PdC Mixture of Cholesterol, E4 and PdC 
E Loaded-phytosomes Loaded-phytosomes 
F - TPP 
G - Chitosan 
H - Mixture of TPP/Chitosan 
I - Mixture of TPP/Chitosan/PS 
J - Loaded-ChiPS 
 
The diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS) 
experiments were performed in the range 400-4000 cm−1, with a resolution of 2 cm−1 
and 528 scans on a Nicolet 6700 spectrometer with Omnic software (Thermo Fisher 
Scientific, Waltham, MA, USA), being the samples dispersed in pulverized KBr and 
analysed directly. 
4.2.9. In vitro release studies 
The release pattern of extract components from ChiPS was studied in vitro using a 
membrane-free model. Briefly, 10 mg of PM-PS-Chi were added to 100 mL of PBS pH 5.5 
and pH 7.4 and kept stirring at 300 rpm at 37ºC. One aliquot of 1 mL of the mixture was 
collected at fixed time-points, centrifuged at 23,540 x g for 5 min (and the supernatant 
stored at -20ºC until analysis. The same volume of collected medium was used to 
solubilize the pellet and added to the medium. Extract components released from the 
nanoparticles were quantified by HPLC. All results were made in triplicate and expressed 
as the mean of the repetitions with SD. 
4.2.10. In vitro skin permeation studies  
The permeation studies were performed using an adapted Franz cell model. The 
Franz cells were kept immersed in thermostated water (32ºC) and receptor chambers 
were filled with 5 mL of PBS pH 7.4 and stirred continuously with mini-magnetic stir bars. 
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Polydimethylsiloxane (PDMS) membranes with a thickness of 75 μm were used in the 
Franz cell interface (0.98 cm2) and the formulations (extract E4 and loaded ChiPS) were 
applied at donor chambers (average chamber volume of 3.9 mL). Collections were made 
at specific time intervals (2, 4, 6, 8, 10 and 24h) by withdraw 200 μL of sample followed 
by reposition of the same volume of fresh PBS pH 7.4 at each time point. Components 
released from the extract or ChiPS were quantified by HPLC. Experiments were made in 
quadruplicate and expressed as the means ± SD. 
4.2.11. Biological activities 
4.2.11.1. Antibacterial activities 
The antimicrobial activities of Roy, extract E4, phytosome and ChiPS (Table 4.2) were 
evaluated qualitatively by well diffusion assay and quantitatively by broth microdilution 
method as described in sub-section 2.2.2.  
 
Table 4.2. Samples evaluated for its antibacterial effects in well diffusion and broth microdilution assays.  
Sample 
Well diffusion assay Broth microdilution 
S. epidermidis S. aureus MRSA S. epidermidis 
A Roy Roy Roy Roy 
B E4 E4 E4 E4 
C - Loaded PS Loaded PS Loaded PS 
D Loaded ChiPS Loaded ChiPS Loaded ChiPS Loaded ChiPS 
E Unloaded Chi - - - 
Control Vancomycin Vancomycin Vancomycin Vancomycin 
 
4.2.11.2. Cytotoxicity in human keratinocyte cell line 
The cytotoxicity profile of the extracts was characterized in the human keratinocyte 
cell line, HaCaT using the MTT test by the procedure described by Pesic et al., 2013308,312.  
Briefly, the cells were incubated with compounds at 32,000 cells/cm2 in DMEM 
supplemented with 10% FBS, 4 g/L glucose, L-glutamine (2 mM) and 5000 U/ml penicilin, 
5 mg/mL streptomycin solution at 37ºC in a humidified 5% CO2 atmosphere for 72h. 
Afterwards, 100 ml of MTT solution (1 mg/mL) was added to each well and plates were 
incubated at 37ºC for 4 h. Formazan product was dissolved in 200 mL of DMSO and the 
absorbance of obtained dye was measured at 540 nm using an automatic microplate 
reader (LKB 5060–006 Micro Plate Reader, Vienna, Austria). 
4.2.11.3. Acute and Sub-chronic mice irritation study 
Male hairless Sho® SCID mice (Charles River Laboratories, Massachusetts, USA) with 
12 weeks old and 20-30 g were housed under normal conditions according to 
established animal care guidelines as follows: temperature of 20±2ºC, humidity of 60-
90% RH and a 12h light/dark cycle and provided with ad-labium access to a commercial 
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mice-diet and drinking water. This study was conducted in accordance to the 
internationally accepted principles for laboratory animal use and healthcare as found in 
Directive 2010/63/EU. The project was approved by the Portuguese Veterinary General 
Division (DGAV). 
ChiPS and extract E4 were incorporated into 5% carboxymethyl cellulose (CMC) 
hydrophilic gel, with very high viscosity, as vehicle. Eleven mice were randomly divided 
into 4 groups. Sodium laureth sulfate (SLES) solution at 5% (w/v) was used as positive 
control371.  
The animals were treated as follows: Group I (n = 4): CMC gel with 5% (w/w) ChiPS; 
Group II (n = 3): CMC gel containing 1% (w/w) extract E4; Group III (n = 2): CMC gel; 
Group IV (n = 2): SLES 5% (w/v). 
To each group 0.1 mL of the test or control formulation was applied with a gloved 
finger in an area of approximate 10 cm2 on the back of each animal, housed in individual 
cages, daily for 15 days. Each animal was monitored during the first hours after 
application in order to guarantee that the formulation remain in the target area enough 
time to be absorbed. Mice were observed daily. Reactions, defined as erythema and/or 
edema, were observed at 24, 48 and 72h after the formulation application. Photos were 
taken at time of observation and the reaction degree was evaluated according to the 
scoring system for skin reactions (Table 4.3). 
The Score of Primary Irritation (SPI) was calculated372 for test and control in each mice 
as following: 
 
𝑆𝑃𝐼 =  
∑ 𝐸𝑟𝑦𝑡ℎ𝑒𝑚𝑎 𝑎𝑛𝑑 𝑒𝑑𝑒𝑚𝑎 𝑔𝑟𝑎𝑑𝑒 𝑎𝑡 24, 48 𝑎𝑛𝑑 72ℎ
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛𝑠
 
 
The Primary Irritation Index (PII) was calculated as follows according to table 4.4: 
 
𝑃𝐼𝐼 =  
∑ 𝑆𝑃𝐼𝑡𝑒𝑠𝑡 − ∑ 𝑆𝑃𝐼𝑏𝑎𝑠𝑒
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑛𝑖𝑚𝑎𝑙𝑠
 
 
From the midback region of each mice skin samples from each animal were collected 
at day 16 of consecutive application and fixed in 10% buffered formalin for further 
toxicological assessment of the skin samples. 
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Table 4.3. Classification system for skin reaction, adapted from 372,373. 
Erythema Reaction Score 
No erythema 0 
Very slight erythema 1 
Well defined erythema 2 
Moderate to severe erythema 3 
Severe erythema (beet redness) to eschar formation 4 
Edema Reaction Score 
No edema 0 
Very slight edema 1 
Well defined edema (edges of the area well defined by define raising) 2 
Moderate edema (raising approximately 1mm) 3 
Severe edema (raised > 1 mm and extended beyond the area of exposure) 4 
Total possible score for irritation 8 
 
 
Table 4.4. Response categories of irritation, adapted from from372,373. 
Erythema Primary Irritation Index (PII) 
Negligible 0-0.4 
Slight irritation 0.5-1.9 
Moderate irritation 2-4.9 
Severe irritation 5-8 
 
4.2.12. Statistical analysis 
All results are expressed as means ± standard deviation. t-student analysis was 
applied to demonstrate statistical differences in all tested parameters. All analyses were 
performed using a software program (GraphPad Prism 5®, GraphPad Software, San 
Diego, CA) with a statistical significance level of 0.05. 
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4.3. Results and discussion 
4.3.1. Plectranthus madagascariensis antibacterial extracts 
The selected extract was analysed by the previously described HPLC-DAD method 
(subsection 3.2.2). The E4 was obtained as a yellowish gum with a yield of 0.22 % 
(wextract/wdry plant). This extract profiling in HPLC-DAD showed that polyphenols and 
diterpenes were the main components of this extract (Figure 4.2). The main compound 
yield was also quantified, namely 7α,6β-dihydroxyroyleanone (Roy) as 4.59±0.02% 
(wcompound/wextract). 
 
 
Figure 4.2. Representative chromatogram of the P. madagascariensis extract E4 (270 nm) and structure of the main 
component: 7α,6β-dihydroxyroyleanone. 
 
4.3.2. Optimization of phytosome preparation methodology 
The results from the optimization process were presented in the tables 4.5 to 4.7. 
Under the process conditions studied, the smallest and most uniform particles were 
produced using acetone, a reaction time of two hours and adding 2.5% of cholesterol.  
Original methodologies for the preparation of PPC state the use of an aprotic solvent 
in order to avoid solvent interferences in the complexation process. However, in the 
recent years, some protic ethanolic solvents as ethanol or methanol have been used for 
the preparation of PPCs (as reviewed in Annex 1). In this preliminary study, two polar 
aprotic solvents (acetone and dichloromethane) and a polar protic solvent (methanol) 
were tested. The overall smaller particles were obtained by the use of acetone (Table 
4.5). This solvent was also the solvent used in the plant extraction methodology and for 
such reason should be most efficient in re-solubilizing the extract. This improved 
solubility of the components would allow more favourable conditions for the 
complexation process to occur, leading to more compact and uniform particles. Also, 
previous studies have demonstrated superior efficiency of acetone over ethanoic 
solvents for the preparation of drug-phospholipid complexes239. Acetone is also 
considered less toxic than dichloromethane in pharmaceutical formulations (ICH class 2 
vs ICH class 3). 
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Table 4.5. Influence of solvent choice in phytosome physical properties. Results are present as the means ± S.D. of 
three independent batches. 
Solvent Acetone Dichloromethane Ethanol 
Particle size (nm) 107.2 ± 16.55 142.2 ± 23.3 175.7 ± 91.65 
Polydispersity index 0.419 ± 0.06 0.511 ± 0.12 0.359 ± 0.001 
 
Smaller and more uniform particles were obtained with an intermediate reaction 
time of 2h (Table 4.6). This is in accordance with many PPCs preparation 
examples235,239,240,246,374,375 (Annex 1). This time should be adequate for the total 
complexation of the PPC components while not enough for the occurrence of further 
aggregation with longer reaction times, as occur at time 4h. The substantially higher 
particles and heterogenic distribution obtained at 1h reaction time should be originated 
by the incomplete solubilisation of some components with the formation of precipitate 
aggregates along with the phytosomes.  
 
Table 4.6. Influence of reaction time in phytosome physical properties. Results are present as the means ± S.D. of at 
three independent batches. 
Reaction time (h) 1 2 4 
Particle size (nm) 469.85 ± 201.95 107.2 ± 16.55 182.1 ± 64.35 
Polydispersity index 0.772 ± 0.04 0.410 ± 0.06 0.458 ± 0.01 
 
The inclusion of cholesterol at molar percentages of 2.5 or 5% resulted in non-
substantial change of phytosome size. No statistically significant differences (p > 0.05, t-
student test) were found between the particle size in the formulation with a cholesterol 
molar percentage of 2.5 or the formulation with cholesterol at 5%. However, the mean 
size of the particles obtained with acetone and reaction time of two hours (Table 4.6) 
was smaller than the obtained with the inclusion of 2.5% of cholesterol (Table 4.7). 
Moreover, the use of the 2.5% cholesterol proportion resulted in a two-fold reduction 
in PI which would improve the formulation stability. In other studies, the inclusion of 
cholesterol in phytosomes has been justified as stability enchantment functions on such 
nanosystems257,376. For such reasons, the phytosomal formulation obtained with 
reaction solvent acetone, reaction time of 2h and the inclusion of 2.5% of cholesterol 
was selected as the optimized formulation.  
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Table 4.7. Influence of cholesterol addition in phytosome physical properties. Results are present as the means ± 
S.D. of three independent batches.  
Cholesterol (molar %) 0 2.5 5 
Particle size (nm) 332.2 ± 159.7 191.3 ± 75.3* 203.3 ± 55.8* 
Polydispersity index 0.247 ± 0.03 0.243 ± 0.18 0.263 ± 0.15 
*p > 0.05, t-student test   
 
4.3.3. Preparation and characterization of optimized formulations  
The optimized suspension of loaded phytosomes had a mean size of 191.3 ± 75.3 nm 
while the chitosan coated loaded phytosomes (ChiPS) presented a mean size of to 1082 
± 363 nm (Table 4.8). Both formulations demonstrated similar polydispersity indexes of 
0.243±0.18 and 0.22 ± 0.10 respectively.  
The particle size and its distribution were factors influencing the fate and stability of 
nanoparticle formulations377. The determined mean size for each formulation is 
adequate for topical application by minimizing the unintended transdermal penetration 
(intracellular pathways or via aqueous pores) that could occur in particles smaller than 
36 nm. Still, some transdermal absorption could occur through the transfollicular 
route373, but its contribution to the overall process is very low as follicles correspond to 
less than 0.1% of total skin surface354. 
 
  
The optimized suspension of loaded phytosomes presented an approximately neutral 
surface charge with ζP of +0.07±0.15 mV while the ChiPS presented a positive charged 
surface with ζP of +20.59 ± 12.02 mV (Table 4.9). 
The neutral character of the suspended uncoated phytosomes could represent the 
occurrence of a complete reaction. The phospholipids containing a choline group 
behave as Bronsted acids which possess tendency to become deprotonated. The PdC 
intrinsic pKa estimated as 0.8 confirms this character378. On the other hand, the hydroxyl 
group of many natural products, namely phenolic hydroxyls present in the major 
components of this extract, can act as electron acceptors which makes the complexation 
with PdC possible. The occurrence of complexation would have led to the charge 
Table 4.8. Size distribution of loaded phytosomes and chitosan coated phytosomes (ChiPS). Data is present as mean 
± standard deviation with n = 3. 
Formulation Particle Size (nm) Polydispersity index (Pi) 
Phytosomes 191.3±75.3 0.243±0.18 
ChiPS 1082 ± 363 0.22 ± 0.10 
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distribution within the formed complex being an overall neutral charge expected, as 
verified in the literature230. 
Chitosan is a biodegradable, biocompatible, cationic polymer which have been used 
for the production of polymeric nanoparticles for variable applications. It was expected 
that the microencapsulation step would led to a positive charge of the particles. It was 
verified with the increasing from neutral to +20.59 ± 12.02 mV. Also the coating with 
chitosan by ionotropic gelation, using TPP as the cross-linking agent, led to an 
enlargement of the particle size to 1082 ± 363 nm with a lowering of the polydispersity 
index. Similar methodologies have produced chitosan microspheres with higher 
dimension, namely the curcumin phytosomes coated by chitosan, that presented a 
mean particle size of 23.21±6.72 µm249. Particles presenting a higher size generally tend 
to present a worst stability, with more frequent formation of interparticle aggregates379.  
It was demonstrated that negatively charged particles have a more favourable 
penetration in the inner skin layers that those that were positively charged380. 
Possessing a positive charge, the ChiPS have less predisposal for transdermal 
penetration. The human skin presents a negative surface charge at neutral pH, mainly 
due to the presence of negatively charged phospholipids and carbohydrates381–384. This 
would originate an attraction between the negative charged skin surface and the 
positive charged ChiPS particles. Taken together with the bioadhesivity properties of 
chitosan based materials, this indicate that the ChiPS present a relevant affinity for the 
surface of the skin.  
 
SEM and AFM imaging showed that the phytosomes present an amorphous spherical 
shape with somewhat heterogeneous size distribution (Figure 4.3 and 4.4). The 
topographical analysis of the uncoated phytosomes showed a spherical shape of the 
nanoparticle vesicles with size ranging mostly from 30 to 200 nm. Those observations 
were in accordance with the values registered by DLS.  
The chitosan coated phytosomes by AFM imaging (Figure 4.4 A) presented a spherical 
shape by with a rough texture and higher size when compared to uncoated phytosomes. 
The spherical shape is favourable for the delivery of such particles as this would promote 
the higher surface area possible385. The SEM imaging of ChiPS (Figure 4.4 B) resulted in 
the observation of an aggregate of smaller phytosomes. This could be related to the 
sample preparation as it seems that the water loss in the drying process favours the 
aggregation of the water rich ChiPS. In AFM phase contrast visualization (Figure 4.5), it  
 
Table 4.9. Zeta potential of phytosomes, and chitosan coated phytosomes (ChiPS). Data is present as mean ± 
standard deviation with n = 3. 
Formulation Zeta potential (ζP) (mV) 
Phytosomes (loaded) +0.07±0.15 
ChiPS (loaded) +20.59 ± 12.02 
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A 
  
B 
  
Figure 4.3. SEM images of uncoated phytosomes (A) and coated phytosomes (B). A, left: magnification = 10,000x, scale 
bar = 1 μm; A, right: magnification = 20,000x, scale bar = 1 μm; B, left: magnification = 750x, scale bar = 10 μm; B, right: 
magnification = 2,000x, scale bar = 10 μm. 
 
A 
 
 
B 
  
Figure 4.4.  Topographical, phase contrast and 3D AFM images of the uncoated phytosomes (A) and of the chitosan 
coated phytosomes (B). Scale bars represents 0.5 µm.     
0.5 μm 
0.5 μm 
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Figure 4.5.  Topographical and phase contrast of a single chitosan coated phytosome nanoparticle. Scale bar represents 
100 nm.  
 
was clear the presence of a rough coating involving a softer material. The inner, softer 
material is similar to the verified for the uncoated particles, and thus this image could 
represent a phytophospholipidic core involved by the TPP cross linked chitosan coating. 
Additional AFM images were presented at annex 9. 
The formation of the complex between the PdC, cholesterol and the antibacterial 
extract E4 was confirmed by DSC (Figure 4.6) and DRIFTS (Figure 4.7 and 4.8). 
Thermograms for cholesterol (A), extract E4 (B), PdC (C), physical mixture (1.2:20:42.4 
w/w) of cholesterol, extract and PdC (D) and loaded phytosomes (E) were obtained as 
presented in Figure 4.6. The cholesterol thermogram (Figure 4.6 A) possess a single 
sharp peak with onset at 147.77ºC and maximum at 150.17ºC which should occur due 
to the pure compound melting (reported melting point of 147-149ºC). As in the case of 
the P. madagascariensis extract E4 (Figure 4.6 B), a single mild endothermic peak was 
verified starting at 34.33ºC and with maximum at 58.33ºC. The phase diagram of PdC 
(figure 4.6 C) presented two resolved peaks. The first peak at 133.83ºC was mild and 
might be related to the movement of phospholipidic polar head during the heating 
process224–227. The second peak was sharp with onset at 169.30ºC and maximum at 
180.33ºC. This highly endothermic (H = 28.25 J/g) peak should occur due to the phase 
transition from gel to liquid crystalline state during which occur the non-polar tail 
melting226,227. 
When the physical mixture of cholesterol, extract and PdC (Figure 4.6 D) is analysed, 
an apparent summation between those elements was verified. The endothermic peak 
from E4 was maintained and also peaks with similar thermal behaviour to those of PdC 
were verified but presenting a lower onset and peak value. This implies the occurrence 
of minimal interactions between those elements. However, the analysis of the 
100 nm 100 nm 
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thermogram corresponding to phytosomes (Figure 4.6 E) showed the disappearance of 
the endothermal peaks corresponding to the extract E4 or cholesterol, which occur due 
to the presumable formation of interactions between those molecules and the 
phospholipids. A broad and mild peak was present at 135ºC which could correspond to 
the PdC polar head movement due to the heating process as its onset (125.06ºC) was 
similar but lower to the verified for the first peak of PdC (126.23ºC). The disappearance 
of the sharp second peak of phospholipids (Figure 4.6 C) and the decrease of the 
transition temperature from 180.33 to 170.67ºC after the formation of phytosomes 
(Figure 4.6 E) was been suggested to be related to the establishment of strong 
interactions between the polar head of the phospholipids and natural products and the 
consequent formation of a new entity224–227. Those interactions allow the free turning 
of the hydrocarbon chains of the PdC and favours its enwrapping of the polar head 
containing the natural product224–227. 
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Figure 4.6. DSC thermogram of (A) cholesterol, (B) extract E4, (C) PdC, (D) physical mixture of cholesterol, extract and 
PdC and (E) phytosomes. The isolated values represent the peak temperature (ºC). Individualized spectra were 
presented at annex 9. 
 
The infrared spectroscopy analysis of the coated and uncoated phytosomes, its 
components and their mixtures was performed in order to confirm the complexation of 
phytosomes (Figure 4.7) and the chitosan/TPP coating (Figure 4.8). While the cholesterol 
IR spectra was concordant with literature references, for the extract E4, no standard 
reference was available. From the HPLC-DAD characterization of this extract presented 
  
109 
 
in chapter 3, it is known that compounds bearing ketone, phenol and hydroxyl groups 
were present, and thus, those signals were found between 3500 and 3200 cm-1 (medium 
broad peak, hydrogen bonded O-H stretching vibrations), 2918 and 2848 cm-1 (C-H 
stretching in aromatics); 1707 cm-1 (C=O stretching), 1585 cm-1 (C=C stretching), 1456 
cm-1 (CH3-CH2 bending), 1165 cm-1 (C-O stretching).  
The characteristics peaks of PdC were present in the DRIFTS spectra as a broad peak 
between 3500 and 3200 cm-1 (hydroxyl and/or amine stretching), 2926 and 2856 cm-1 
(C-H stretching at fatty acid residues), 1741 cm-1 (carbonyl stretching of the fatty acid 
ester), 1456 cm-1 (CH3-CH2 bending), 1228 cm-1 (P=O stretching), 1059 cm-1 (P-O-C 
stretching) and 970 cm-1 (N-(CH3)3 stretching)228,229,249.  
The analysis of phytosome IR spectra presented a shift and broadening of the signal 
corresponding to the hydroxyl O-H stretching (3500-3200 cm-1), to the aliphatic 
phosphate (P=O stretching) and to the choline quaternary ammonium (N-(CH3)3 
stretching) groups of the phospholipids. No relevant alterations were found in the bands 
of the aliphatic carbon chains of the fatty acids (2924, 2850 and 1460 cm-1). These 
observations suggest that some weak physical interactions between free hydroxyl of the 
natural components and the polar groups of phospholipids took place during complex 
formation with dispersion of the extract components into the phospholipid 
matrix228,229,249.   
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Figure 4.7. DRIFTS spectra of (a) cholesterol, (b) extract, (c) PdC, (d) physical mixture of cholesterol/extract/PdC and (e) 
phytosome. Individualized spectra available at annex 9. 
 
The evaluation of chitosan/TPP coating by DRIFTS was based on the reference peaks 
of chitosan at 2865 cm-1 corresponding to C-H stretching and those at 1646, 1569 and 
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1371 cm-1 corresponding to different vibrational modes of the N-H amide386. At the 
physical mixture of phytosomes with chitosan and TPP, the reference signals for 
chitosan appear diluted in the phospholipidic base, however, when analysing ChiPS, the 
chitosan reference signals remain identifiable at 1633, 1531 and 1371 cm-1 with some 
shift which could be due to a conformational change due to the crosslinking with TPP. 
Also, a substantial change in the signals for the phytosome were noted, with 
disappearance of the major peaks at 3014 and 1055 cm-1 along with a clear diminishing 
of the peaks at 2924, 2850, 1734 and 1460 cm-1. This should represent the occurrence 
of coating by chitosan at most of the surface of the phytosomes, which is coherent with 
the observations of AFM visualization and the zeta potential shift for a positive value.  
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Figure 4.8. DRIFTS spectra of (f) TPP, (g) chitosan, (h) physical mixture of TPP/Chi, (e) loaded phytosomes, (i) physical 
mixture of TPP/Chi/PS and (j) loaded Chi coated phytosomes. Individualized spectra available at annex 9. 
 
4.3.4. Determination of encapsulation efficiency (EE%) and drug loading (DL) 
The EE% of the P. madagascariensis extract in the nanoparticle system was estimated 
based on the major antibacterial diterpenic compound (7α,6β-dihydroxyroyleanone, 
Roy) present in the extract. In order to calculate the content of Roy in the ChiPS a 
standard curve was established with high linearity (R² = 0.9999) in the range of 0.005 to 
1 mg/mL (y = 32946x - 139.43) with adequate sensitivity (LOD: 0.002; LOQ: 0.004). The 
EE% in the ChiPS system was of 57.7±0.1%. In other studies, when phytosomes were 
combined with a polymer coating249 or conjugated with a metallic core257, similar or 
lower encapsulation efficiencies were verified.  
  
111 
 
The DL was of 0.670±0.001% for Roy. The low drug loading for the reference 
compound in the extract was expected as the extract contains only 4.6±0.02% (w/w) of 
Roy. However, if we based on the amount of extract that contains 0.67 mg of Roy, we 
estimate an extract DL of 14.56% which is similar or superior to the drug loading of 
phytocomponents in similar phytosome formulations249.  
4.3.5. In vitro release studies 
The evaluation of Roy release from the lyophilized ChiPS in PBS at different 
physiologic pH was used to establish the release profile of those nanoparticles (Figure 
4.9). The particle mass to volume proportion selected was adequate in order to assure 
the maintenance of the sink conditions. An initial burst release was verified with 
approximately 70% of the Roy being released from the ChiPS after 1h. A second phase 
of slower release was verified, reaching maximum release at 10h (100.8% at pH 7.4 and 
82.9% at pH 5.5). Those media represent the physiologic pH verified at the surface of 
the skin (5.5)387 and at blood vessels (7.4)388.  
It was known that quinone-methide compounds, as the case of Roy, possess an 
improved reactivity in acidic media, due to the protonation of the carboxyl oxygen with 
possible further esterification or nucleophilic substitution of this group389. This improved 
reactivity could explain the incomplete release curve verified at pH 5.5, in which some 
Roy degradation could occur at this more acidic pH.  
The skin pathogens S. aureus and S. epidermidis possesses a doubling time, in a 
reconstructed epidermis model, of about 55 and 230 min, respectively390. According to 
this study, after 1h, about three fourths of the total Roy have already been released 
(70.18-75.86% of total Roy), the release curve of Roy from phytosomes should be 
adequate for the control of those bacterial strains multiplication.  
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Figure 4.9. Cumulative release of Roy from Chi-PS at phosphate buffer saline adjusted to pH 5.5 or pH 7.4 (T = 37ºC). 
 
4.3.6. In vitro permeation studies 
The diffusion patterns of permeation of Roy through PDMS in a Franz cell model 
showed a lower flux value for the Roy permeation from ChiPS (0.52±0.17 µg/cm2/h) in 
comparison to this compound permeation from the non-encapsulated extract E4 
(1.90±0.08 µg/cm2/h) (Figure 4.10 and 4.11). This observation is favourable for the 
formulation as a high permeability of the antibacterial compounds was unintended. This 
result could be explained by a conjugation of factors. At first, in the extract, their 
components were solubilized in the PBS which favourers the direct contact to the 
membrane while in ChiPS the Roy was incorporated into the polymeric-phytosome 
formulation and it is required that Roy is released from this matrix for the membrane 
permeation to occur. This effect was only responsible by a partial contribution on the 
lower flux as the release studies demonstrated a rapid initial release up to 75% in the 
first hour. A second factor could be related to the saturation of PDMS membrane by 
substances adsorbed at its surface that could therefore limit the crossing of Roy. The 
main substance that could be retained is chitosan due to its cationic properties which 
could led to adsorption at the negative charged PDMS membrane391. This strengthens 
our speculation that only residual permeation of ChiPS would occur through 
transdermal pathways other than the follicular pores.  
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Figure 4.10. Permeation of Roy from the P. madagascariensis extract E4 or loaded ChiPS in Franz cell permeation model 
using PDMS membrane.  
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Figure 4.11. Permeation of Roy from the P. madagascariensis extract E4 or ChiPS in Franz cell permeation model 
using PDMS membrane.  
4.3.7. Biological activities 
4.3.7.1. Antibacterial activities 
The activity of the selected extract from P. madagascariensis (E4), the main diterpene 
(6β,7α-dihydroxyroyleanone, Roy) and the phytosomes incorporating the extract or the 
blank sample. A preliminary qualitative evaluation by well diffusion assay in S. 
epidermidis (Table 4.8) demonstrated an apparent maintenance of the anti-
staphylococcal activity with similar inhibition halo verified between the extract E4, the 
main compound Roy and the ChiPS. Also, chitosan/TPP mixture presented a slight 
inhibition which could indicate potential bacterial growth inhibition effects at higher 
concentrations.  
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Table 4.10. Inhibition diameter against S. epidermidis ATCC 12228. 
Analyte Inhibition (mm) Plate Image 
A Roy 19 
 
B P. madagascariensis E4 21 
D ChiPS 17 
E Chi/TPP mixture 8 
F PBS 5 
C- DMSO 5 
C+ Vancomycin 22 
 
Samples A-D were tested at 1 mg/mL. A and B were diluted in DMSO; C and D were diluted in PBS.  
Roy - 7α,6β-dihydroxyroyleanone; C+ = PBS – phosphate saline buffer pH 7.4; C-: DMSO - Dimethyl 
sulfoxide. 
 
 
The quantitative evaluation of the antibacterial activity of the extract E4, Roy, loaded 
phytosome and the correspondent chitosan coated loaded phytosomes was performed 
by the determination of the MIC value for two bacterial pathogens of the human skin: 
S. aureus (including a MRSA strain) and S. epidermidis. The extract E4 showed potent 
antibacterial activity with MIC values in the range of 1.95-7.81 µg/mL. The isolated 
compound Roy showed inhibitory effects lower than those of the extract (MIC 15.6-62.5 
µg/mL), which suggests the existence of synergic effects between this compound and 
other antibacterial abietane diterpenes.  
The antibacterial activity of the loaded phytosomes (MIC 3.91-15.6 µg/mL) and of the 
chitosan coated loaded phytosomes (MIC 0.98-31.3 µg/mL) was proportional or superior 
to those of the reference antibiotic vancomycin (MIC 0.98-7.81 µg/mL). Those values 
represent a clear increment in the antibacterial activity of the phytosome formulations 
over the extract, which become evident by the normalized MIC values as function of the 
Roy content in each sample (Table 4.9).  
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Table 4.11. Antibacterial activity of P. madagascariensis components including phytosomal forms. 
 Microorganism strain / MIC (µg/mL) 
Analyte  
S. aureus  
ATCC 25923 
S. aureus (MRSA) 
CIP 106760 
S. epidermidis 
ATCC 12228 
Roy 62.5 15.6 - 
E4 3.91 (0.18) 1.95 (0.09) 7.81 (0.36) 
Phytosome 3.91 (0.05) 3.91 (0.05) 15.6 (0.21) 
ChiPS 0.98 (0.02) 15.6 (0.25) 31.3 (0.50) 
Control (Vancomycin) 0.98 7.81 7.81 
Roy - 7α,6β-dihydroxyroyleanone; E4 – P. madagascariensis extract 4; ChiPS – chitosan coated phytosomes of E4. 
Values under brackets represent MIC values normalized for the Roy content: ( ) = MIC x [Roy]sample 
 
It was also verified that the ChiPS showed pronounced selectivity for S. aureus over 
S. epidermidis. This was a favourable observation due to the commensal character of S. 
epidermidis which unfrequently present a pathogenic behaviour and contrasts with S. 
aureus which is the most common skin pathogen339,392.  
 
4.3.7.2. Cytotoxicity in human keratinocyte cell line 
The evaluation of in vitro cytotoxicity in HaCaT human skin keratinocyte cell line 
showed low or none cytotoxicity. At the MIC concentration for S. aureus strains the 
ChiPS formulation showed less than 10% reduction in cell viability (Figure 4.12). Also, it 
seems that the encapsulation process originates a ChiPS formulation with lower 
cytotoxicity (IC50 = 85.87 µg/mL) over the original extract E4 from P. madagascariensis 
(IC50 = 56.77 µg/mL). Similar results have been observed for Calendula phytosomes with 
the phytosome formulation presenting lower cytotoxicity than the plant extract257. Also, 
all formulation components of ChiPS were environmental friendly, biocompatible and 
approved for skin use393–395. This means that such components should not be 
responsible for any toxicological effects. The residual toxicity verified for higher 
concentrations of ChiPS could be explained by toxicological specificities of the 
nanosystems. A recent review on nanotoxicological effects of lipid carriers pointed that 
occlusive effects possess relevant influence in the cytotoxicity profiles of nanosystems 
at higher concentrations396. Such effect was verified even in nanoparticles formulations 
composed only by biocompatible ingredients as in the betamethasone lipidic 
nanoparticles developed by Silva et al. (2015)397. The use of in vivo models could help to 
exclude such effects. 
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Figure 4.12. Growth inhibitory effects of the P. madagascariensis extract E4 and its correspondent ChiPS. 
  
4.3.7.3. Acute and sub-chronic mice irritation study 
This in vivo study was intended to discriminate the presence of any potential irritation 
effect due to the application of the extract E4 or the correspondent chitosan coated 
loaded phytosomes. The overall result showed negligible irritation or edema in each 
treatment group with PII < 0.5 (Figure 4.12 and Table 4.9). As expected, the positive 
control group had a slight irritation based on a PII score of 0.67. 
  
Table 4.12. Irritation and edema score of each mice by group.   
Mice Group 
Erythema + Edema 
SPI PII 
24h 48h 72h 
1 
A  
(CMS gel + ChiPS) 
0 + 0 0 + 0 0 + 0 0 
0.25 
2 0 + 0 0 + 0 0 + 0 0 
3 0 + 0 1 + 0 2 + 0 1 
4 0 + 0 0 + 0 0 + 0 0 
5 
B  
(CMS gel + E4) 
0 + 0 0 + 0 0 + 0 0 
0 6 0 + 0 0 + 0 0 + 0 0 
7 0 + 0 0 + 0 0 + 0 0 
8 C  
(CMS gel) 
0 + 0 0 + 0 0 + 0 0 
0 
9 0 + 0 0 + 0 0 + 0 0 
10 D  
(SLES 5%) 
0 + 0 0 + 0 4 + 0 1.33 
0.67 
11 0 + 0 0 + 0 0 + 0 0 
 
4.4. Chapter conclusions 
The present study was focused on the development of an antibacterial formulation 
based on the phytosome of a potent antibacterial extract from P. madagascariensis (E4). 
This plant had been used in traditional African medicine for the treatment of cutaneous 
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wounds. As the extract possesses high yields of abietane diterpenes as 6β,7α-
dihydroxyroyleanone (Roy) those should be responsible for its antibacterial activity.  
The use of phytosome strategy have been successful for both per oz as topical 
delivery of natural compounds. Also, chitosan has been on focus because of the 
combination of the properties of a water soluble, cationic, bioadhesive, biodegradable 
polymer of natural origin with some intrinsic antibacterial activity. The combination of 
the phytosome strategy with the encapsulation by chitosan surged as a strategy for the 
improvement of the antibacterial activity of the extract E4. 
The phytosomes were produced by the conjugation of PdC, cholesterol and the 
extract into acetone by the effect of stirring and heat, and recovered by solvent 
evaporation with dispersion in acetic acid solution and complexation confirmed by DLS 
and DRIFTS. Those nanovesicles were spherical, amorphous, with an average size of 
191.3±75.3 nm (DLS), a low size dispersion and neutral charge. The positive charge is 
important for the skin adherence of the formulation. The spherical shape was 
maintained but phase contrast in AFM showed the presence of a substance (presumably 
chitosan) involving the phospholipidic particles. This was confirmed by the IR  
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i)   
   
24h 48h 72h 
   
ii)   
   
24h 48h 72h 
   
iii)   
   
24h 48h 72h 
   
Figure 4.13. Photography of three animals at 24, 48 and 72h of sample application: i) Only a slight erythema was 
observed after 48h of application in this subject, but a well-defined erythema was visible after 72h; ii) No visible 
alterations from 24-72h; iii) No erythema or edema visible up to 72h when an eschar was formed at the zone of 
application. 
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spectroscopy of the ChiPS in which, the signals for the phytosome were clearly  
diminished or even disappeared but the chitosan signals were still present, which might 
represent the presence of a coating of chitosan covering the phospholipidic core. Those 
nanoparticles showed a sustained release profile with a reduction of the membrane flux 
in comparison to the non-encapsulated extract. This could be important for the 
retention of the active compounds at the skin surface were they should exert its 
antibacterial effects, with minor transdermal systemic absorption.  
The antibacterial effects were enhanced by this strategy, being the anti-
staphylococcal activity superior even to the reference antibiotic, vancomycin, and active 
against MRSA. Also, negligible in vitro keratinocyte cytotoxicity and in vivo mice skin 
irritation were verified, which implies the security of this formulation topical application.  
This promising formulation could be used as an innovative ideal skin antibacterial as 
it is active against skin pathogens, including MDR strains; non-toxic for keratinocytes at 
MIC; different antibacterial mechanisms of its elements (chitosan and extract 
diterpenes), including synergic effects between some of them (extract diterpenes). 
Future work directions should focus on the long term stability of those particles along 
with its activity against other skin pathogens, including other resistant strains, and 
biofilm forming bacteria.   
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Chapter V 
 
  
  
  
121 
 
5. Conclusions 
In this study, three plants of the Plectranthus genus (P. madagascariensis, P. 
neochilus and P. porcatus) were selected, based on their ethnopharmacological uses 
(respiratory conditions as cough and asthma, cutaneous wounds and scabies for P. 
madagascariensis; dyspepsia, hepatic insufficiency, chills, cough and a runny or blocked 
nose for P. neochilus; and aromatic purposes for P. porcatus). From those plants, 26 
extracts (E1-E26) were obtained by the combination of extraction techniques (infusion, 
decoction, microwave, ultrasound, maceration and supercritical fluid extraction) with 
different polarity solvents (water, acetone, methanol and scCO2). All the prepared 
extracts were briefly profiled by HPLC-DAD and the majority of the components were 
identified as polyphenols (caffeic acid (IV.1), chlorogenic acid (IV.2) and rosmarinic acid 
(IV.3)), diterpenes (7α-acetoxy,6β-hydroxyroyleanone (IV.4) and coleon U (IV.5)) and 
flavones (rutin (IV.6) and naringenin (IV.7)). 
 
 
  
IV.1 IV.2 IV.3 
   
IV.4 IV.5 
 
 
IV.6 IV.7 
 
The extracts were screened for their antimicrobial (Gram positive, Gram negative 
bacteria and yeasts), antioxidant (DPPH method) and cytotoxic (MDA-MB-231 cancer 
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cell line) activities. Extracts from P. madagascariensis (acetone maceration E5 and 
acetone ultrasound E4) and P. neochilus (acetone ultrasound E13) showed antimicrobial 
effects against Gram positive bacteria strains, namely, Bacillus subtilis, Staphylococcus 
aureus and S. epidermidis and a Gram negative bacteria strain, Klebsiella pneumonia 
(MIC values 1.95-250 μg/mL). No activity was verified against the tested yeast strains. 
The acetonic extract from P. madagascariensis prepared by ultrasound assisted 
extraction (E4) showed the more potent antimicrobial activity, comparable to reference 
antibiotics, against S. aureus strains (MIC < 3.91 μg/mL), including a MRSA strain (MIC < 
0.98 μg/mL). 
Considering the antioxidant activity, the methanolic extracts from the three plants 
showed the more potent radical scavenging activities at 100 ng/mL (60.8-89.0%). The 
remaing extracts tested showed moderated or low antioxidant properties (2.45-
46.55%). The methanolic ultrasound extract of P. madagascariensis (E6) demonstrated 
the higher radical scavenging activity at 100 ng/mL (89.0%), which was comparable to 
the positive control, ascorbic acid (93.4%). Those antioxidant effects could be attributed 
to the presence of polyphenols (IV.1 to IV.3) with known radical scavenging abilities.  
Considering the cytotoxic effects, all extracts tested showed low cytotoxic activity at 
15 ug/mL (≥79.88% of cell viability) in the MDA-MB-231 breast cancer cell line. The 
maceration extract from P. madagascariensis (E5) showed moderate cytotoxic effects in 
the same cell line with IC50 of 64.52 µg/mL and was selected for further cytotoxicity 
studies.  
The antibacterial and cytotoxic effects shown in the acetone extracts of P. 
madagascariensis (E4 and E5) could explain the traditional uses in the treatment of 
respiratory and skin conditions related to infectious agents. The identified abietane 
diterpenes 7α-acetoxy,6β-hydroxyroyleanone (IV.4) and coleon U (IV.5) are described 
as antibacterial and cytotoxic compounds. The shown extract bioactivities could be 
explained by the presence of such compounds and thus validate their traditional uses. 
The more bioactive extracts from P. madagascariensis (organic solvent based extracts 
E4-E9) were characterized by HPLC-DAD with the identification and quantification of the 
major compounds. The remaining extracts were not included in the HPLC-DAD 
characterization due to their lack of bioactivity. Four compounds were generaly 
identified in the extracts using authentic standards overlay:  rosmarinic acid (IV.3), 
7α,6β-dihydroxyroyleanone (IV.8), 7α-acetoxy-6β-hydroxyroyleanone (IV.4) and coleon 
U (IV.5). A diterpenic compound, 7α-formyloxy-6β-hydroxyroyleanone (IV.9), was also 
isolated from the ultrasound acetonic extract of P. madagascariensis (E4) and 
characterized by 1H and 13C NMR. This compound was isolated for the first time from P. 
madagascariensis.  
The cytotoxic effects of the pure compounds (IV.3-IV.5 and IV.8-IV.9) were evaluated 
in a battery of cell lines including breast cancer (MDA-MB-231 and MCF-7), colon cancer 
(HCT116), non-small cell lung cancer (NCI-H460) and a normal lung bronchial (MCR-5) 
cell lines. All abietane diterpenes (IV.4-IV.5 and IV.8-IV.9) originated growth inhibition 
of those cancer lines, with differences in potency and selectivity. The royleanones IV.4 
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and IV.8 displayed a high selectivity toward cancer cells (selectivity index of 4.3 and 3.2, 
respectively). Moreover, royleanones IV.4 and IV.8 were also evaluated in the NCI-
H460/R cell line, which possess a multidrug resistant phenotype. The compounds 
showed similar cytotoxic effects in the multidrug resistant cell line (NCI-H460/R) and in 
the correspondent non-multidrug resistant cell line (NCI-H460). As the cytotoxic effects 
of those compounds were not reduced by the multidrug resistant phenotype, this 
showed that such compounds were not the target of efflux pumps. Thus, these 
diterpenes (IV.4 and IV.8) were also active in the tested multidrug resistant cell lines.   
 
   
IV.4 IV.8 R=H IV.5 
 IV.4 R=CHO  
 IV.9 R=COCH3  
 
 
The structure-activity relationship of the royleanone abietanes, with modifications at 
the positions 6, 7 and 12, was established based on literature and experimental data. In 
this study, compounds possessing log P values between 2 and 5 correspond to 
compounds with improved cytotoxic effect. This observation revealed the relevance of 
the lipophilic properties for the cytotoxic effects. Also, the presence of an electron 
donating group in the position 6 and/or 7, seems to be important for high cytotoxic 
effects. 
Compounds IV.4-IV.5 and IV.8-IV.9 may be considered promising compounds for 
further studies in order to fully understand the potential of the abietane diterpenoids 
as chemopreventive, chemoadjuvancts or chemotherapeutic agents. 
To improve the bioactivity of the acetone ultrasound extract E4, a phytosomal 
formulation was prepared and characterized. This extract was selected due to its 
antibacterial potency and simple preparation. The phytophospholipidic complexation 
process was optimized to obtain the smallest and more uniform particles and followed 
by subsequent chitosan coating by ionotropic gelation using TPP as counter-ion. The 
obtained ChiPS were amorphous, uniform in shape, with an average size of 1082 ± 363 
nm and zeta potential of +20.59 ± 12.02 mV. The phase contrast AFM imaging suggest 
the presence of a chitosan coating. This coating was also confirmed by the IR 
spectroscopy of the ChiPS. The signals for the phytosome were clearly diminished or 
even disappeared while the chitosan signals were still present, which should indicate 
the presence of chitosan coating over the phytosomal core. Those ChiPS showed a 
sustained release profile with a lower skin-like permeation fluxes in comparison to the 
non-encapsulated extract. This fact could be important for the retention of the active 
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compounds at the skin surface were they exert its antibacterial effects, with minor 
transdermal systemic absorption. The phytosomal formulation showed an up to 4-fold 
factor improvement of antibacterial effects against skin pathogens (S. aureus and S. 
epidermidis) with MIC values in the range of 0.98 to 31.3 µg/mL. Those values were 
comparable as those form potent antibiotics as vancomycin (MIC values in the range 
0.98-7.81 µg/mL). Also, non relevant in vitro keratinocyte cytotoxicity and negligible in 
vivo mice skin irritation were verified, demonstrating the safety of this formulation for 
topical application.  
The findings of this work allow the establishment of the formulated hypothesis to the 
category of thesis and state that:  
 
 Plectranthus spp. plants, and specifically P. madagascariensis, P. neochilus and P. 
porcatus, are a source of bioactive compounds as indicated by their 
ethnomedicinal uses; 
 
 The extracts and the isolated compounds from P. madagascariensis showed 
potent antibacterial and antiproliferative activities; 
 
 The use of phytosome, and its further chitosan coating, correspond to an effective 
method for the potency improvement of the antibacterial extracts from P. 
madagascariensis. 
  
  
125 
 
Bibliography 
 
  
  
126 
 
Bibliography 
1. Ji, H.-F., Li, X.-J. & Zhang, H.-Y. Natural products and drug discovery. Can 
thousands of years of ancient medical knowledge lead us to new and powerful 
drug combinations in the fight against cancer and dementia? EMBO Rep. 10, 194–
200 (2009). 
2. Newman, D. J., Cragg, G. M. & Snader, K. M. The influence of natural products 
upon drug discovery. Nat. Prod. Rep. 17, 215–234 (2000). 
3. David, B., Wolfender, J.-L. & Dias, D. A. The pharmaceutical industry and natural 
products: historical status and new trends. Phytochem. Rev. 14, 299–315 (2014). 
4. Newman, D. J., Cragg, G. M., Snader, K. M. & Gm, N. D. and C. Natural Products as 
Sources of New Drugs over the Period 1981−2002. J. Nat. Prod. 66, 1022–1037 
(2003). 
5. Newman, D. J. & Cragg, G. M. Natural Products as Sources of New Drugs over the 
30 Years from 1981 to 2010. J. Nat. Prod. 75, 311–335 (2012). 
6. Feher, M. & Schmidt, J. M. Property distributions: Differences between drugs, 
natural products, and molecules from combinatorial chemistry. J. Chem. Inf. 
Comput. Sci. 43, 218–227 (2003). 
7. Drewry, D. H. & Macarron, R. Enhancements of screening collections to address 
areas of unmet medical need: an industry perspective. Curr. Opin. Chem. Biol. 14, 
289–298 (2010). 
8. Banerjee, P., Erehman, J., Wilhelm, T., Preissner, R. & Dunkel, M. Super Natural II 
– a database of natural products. 43, 935–939 (2015). 
9. Cragg, G. Natural products in drug discovery and development. J. Nat. Prod. 60, 
52–60 (1997). 
10. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 
last 25 years. J. Nat. Prod. 70, 461–477 (2007). 
11. Harvey, A. L. Natural products in drug discovery. Drug Discov. Today 13, 894–901 
(2008). 
12. Harvey, A. L., Edrada-Ebel, R. & Quinn, R. J. The re-emergence of natural products 
for drug discovery in the genomics era. Nat. Rev. Drug Discov. 14, 111–129 (2015). 
13. Miller, T. W. et al. Avermectins, New Family of Potent Anthelnintic Agents: 
Isolation and Chromatographic Properties. Antimicrob. Agents Chemother. 15, 
638–371 (1979). 
14. Ōmura, S. Microbial metabolites: 45 years of wandering, wondering and 
discovering. Tetrahedron 67, 6420–6459 (2011). 
15. You-you, T. et al. Studies on the Constituents of Artemisia annua Part II*. Planta 
Med. 44, 143–145 (1982). 
  
127 
 
16. Dondorp, A. M. et al. Artesunate versus quinine in the treatment of severe 
falciparum malaria in African children (AQUAMAT): an open-label, randomised 
trial. Lancet 376, 1647–1657 (2010). 
17. Mishra, B. B. & Tiwari, V. K. Natural products: An evolving role in future drug 
discovery. Eur. J. Med. Chem. 46, 4769–4807 (2011). 
18. Samuelsson, G., Bohlin, L. & Swedish Academy of Pharmaceutical Sciences. Drugs 
of natural origin : a treatise of pharmacognosy. (Apotekarsocieteten, 2009). 
19. Hartmann, T. From waste products to ecochemicals: fifty years research of plant 
secondary metabolism. Phytochemistry 68, 2831–2846 (2007). 
20. Clark, A. M. Natural Products as a Resource for New Drugs. Pharm. Res. 13, 1133–
1141 (1996). 
21. Brusotti, G., Cesari, I., Dentamaro, A., Caccialanza, G. & Massolini, G. Isolation and 
characterization of bioactive compounds from plant resources: The role of 
analysis in the ethnopharmacological approach. J. Pharm. Biomed. Anal. 87, 218–
228 (2014). 
22. Rao, K. V. Taxol and Related Taxanes. I. Taxanes of Taxus brevifolia Bark. Pharm. 
Res. 10, 521–524 (1993). 
23. Camel, V. in Encyclopedia of Analytical Chemistry 1–26 (John Wiley & Sons, Ltd, 
2014). at <http://doi.wiley.com/10.1002/9780470027318.a9902> 
24. Azwanida, N. N. A Review on the Extraction Methods Use in Medicinal Plants, 
Principle, Strength and Limitation. Med. Aromat. Plants 04, 3–8 (2015). 
25. Rijo, P. et al. Optimization of medicinal plant extraction methods and their 
encapsulation through extrusion technology. Measurement 58, 249–255 (2014). 
26. Harley, R. M. et al. in Flowering Plants · Dicotyledons 167–275 (Springer Berlin 
Heidelberg, 2004). at <http://link.springer.com/10.1007/978-3-642-18617-
2_11> 
27. Lukhoba, C. W., Simmonds, M. S. J. & Paton, A. J. Plectranthus: A review of 
ethnobotanical uses. J. Ethnopharmacol. 103, 1–24 (2006). 
28. Rice, L. J., Brits, G. J., Potgieter, C. J. & Van Staden, J. Plectranthus: a plant for the 
future? South African J. Bot. 77, 947–959 (2011). 
29. Paton, A. J. et al. Phylogeny and evolution of basils and allies (Ocimeae, Labiatae) 
based on three plastid DNA regions. Mol. Phylogenet. Evol. 31, 277–299 (2004). 
30. Potgieter, C. J., Edwards, T. J. & Van Staden, J. Pollination of Plectranthus spp. 
(Lamiaceae) with sigmoid flowers in southern Africa. South African J. Bot. 75, 646–
659 (2009). 
31. Brits, G. J., Selchau, J. & van Deuren, G. Indigenous Plectranthus (Lamiaceae) From 
South Africa As New Flowering Pot Plants. Acta Hortic. 165–170 (2001). 
doi:10.17660/ActaHortic.2001.552.18 
  
128 
 
32. Ernst Jacobus van Jaarsveld; Vicki Thomas. The Southern African ‘Plectranthus’ : 
and the art of turning shade to glade. (Simon’s Town : Fernwood Press, 2006). 
33. Rijo, P., Faustino, C. & Simões, M. F. in Microbial pathogens and strategies for 
combating them: science, technology and education 922–931 (2013). 
34. Gaspar-Marques, C., Rijo, P., Simões, M. F., Duarte, M. a. & Rodriguez, B. 
Abietanes from Plectranthus grandidentatus and P. hereroensis against 
methicillin- and vancomycin-resistant bacteria. Phytomedicine 13, 267–271 
(2006). 
35. Simões, M. F. et al. Two new diterpenoids from Plectranthus species. Phytochem. 
Lett. 3, 221–225 (2010). 
36. Falé, P. L. et al. Rosmarinic acid, scutellarein 4′-methyl ether 7-O-glucuronide and 
(16S)-coleon E are the main compounds responsible for the 
antiacetylcholinesterase and antioxidant activity in herbal tea of Plectranthus 
barbatus (‘falso boldo’). Food Chem. 114, 798–805 (2009). 
37. Rijo, P. Phytochemical study and biological activities of diterpenes and derivatives 
from Plectranthus species. (University of Lisbon, 2011). at 
<http://repositorio.ul.pt/handle/10451/2833> 
38. Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M. & Moilanen, E. Anti-
inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and 
daidzein inhibit STAT-1 and NF-κB activations, whereas flavone, isorhamnetin, 
naringenin, and pelargonidin inhibit only NF-κB activation along with their 
inhibitory effect on i. Mediators Inflamm. 2007, (2007). 
39. Marques, C. G. et al. Effect of abietane diterpenes from Plectranthus 
grandidentatus on the growth of human cancer cell lines. Planta Med. 68, 839–
840 (2002). 
40. Burmistrova, O. et al. Antiproliferative activity of abietane diterpenoids against 
human tumor cells. J. Nat. Prod. 76, 1413–1423 (2013). 
41. Burmistrova, O. et al. The abietane diterpenoid parvifloron D from Plectranthus 
ecklonii is a potent apoptotic inducer in human leukemia cells. Phytomedicine 22, 
1009–1016 (2015). 
42. Shubha, J. R. & Bhatt, P. Plectranthus amboinicus leaves stimulate growth of 
probiotic L. plantarum: Evidence for ethnobotanical use in diarrhea. J. 
Ethnopharmacol. 166, 220–227 (2015). 
43. Castillo-Juárez, I. et al. Anti-Helicobacter pylori activity of plants used in Mexican 
traditional medicine for gastrointestinal disorders. J. Ethnopharmacol. 122, 402–
405 (2009). 
44. Kuo, Y.-S., Chien, H.-F. & Lu, W. Plectranthus amboinicus and Centella asiatica 
Cream for the Treatment of Diabetic Foot Ulcers. Evidence-Based Complement. 
Altern. Med. 2012, 1–9 (2012). 
45. Runyoro, D. K. B., Ngassapa, O. D., Matee, M. I. N., Joseph, C. C. & Moshi, M. J. 
  
129 
 
Medicinal plants used by Tanzanian traditional healers in the management of 
Candida infections. J. Ethnopharmacol. 106, 158–165 (2006). 
46. van Vuuren, S. F. Antimicrobial activity of South African medicinal plants. J. 
Ethnopharmacol. 119, 462–472 (2008). 
47. York, T., De Wet, H. & Van Vuuren, S. F. Plants used for treating respiratory 
infections in rural Maputaland, KwaZulu-Natal, South Africa. J. Ethnopharmacol. 
135, 696–710 (2011). 
48. Alasbahi, R. & Melzig, M. Plectranthus barbatus : A Review of Phytochemistry, 
Ethnobotanical Uses and Pharmacology – Part 1. Planta Med. 76, 653–661 (2010). 
49. Alasbahi, R. & Melzig, M. Plectranthus barbatus : A Review of Phytochemistry, 
Ethnobotanical Uses and Pharmacology – Part 2. Planta Med. 76, 653–661 (2010). 
50. Alasbahi, R. H. & Melzig, M. F. Forskolin and derivatives as tools for studying the 
role of cAMP. Pharmazie 67, 5–13 (2012). 
51. Bhatt, P. Antioxidant and Antibacterial Activities in the Leaf Extracts of Indian 
Borage (Plectranthus amboinicus). Food Nutr. Sci. 03, 146–152 (2012). 
52. Chiu, Y. J. et al. Analgesic and antiinflammatory activities of the aqueous extract 
from Plectranthus amboinicus (Lour.) Spreng. both in vitro and in vivo. Evidence-
based Complement. Altern. Med. 2012, (2012). 
53. Arumugam, G., Swamy, M. & Sinniah, U. Plectranthus amboinicus (Lour.) Spreng: 
Botanical, Phytochemical, Pharmacological and Nutritional Significance. 
Molecules 21, 369 (2016). 
54. Grayer, R. J. et al. The chemotaxonomic significance of two bioactive caffeic acid 
esters, nepetoidins A and B, in the Lamiaceae. Phytochemistry 64, 519–528 
(2003). 
55. Abdel-Mogib, M., Albar, H. A. & Batterjee, S. M. Chemistry of the Genus 
Plectranthus. Molecules 7, 271–301 (2002). 
56. Miyase, T., Riiedi, P. & Conrad Hans, E. Leaf-gland Pigments: Coleons U, V, W, 14-
O-Formyl-coleon-V, and two Royleanones from Pleetranthus myrianthus BRIQ.; 
cis- and trans-A/B-6,7-Dioxoroyleanon. Helv. Chim. Acta 13, 4–6 (1977). 
57. Isman, M. B. Plant essential oils for pest and disease management. Crop Prot. 19, 
603–608 (2000). 
58. Amoah, S. K. S., Sandjo, L. P., Kratz, J. M. & Biavatti, M. W. Rosmarinic Acid – 
Pharmaceutical and Clinical Aspects. Planta Med. 388–406 (2016). doi:10.1055/s-
0035-1568274 
59. Henschl, V. M., Ruedi, P. & Eugster, H. Horminone, taxoquinone and other 
royleanones, obtained from two Abysshian Plectrunthur species (Labiatae). Helv. 
Chim. Acta 58, (1975). 
60. Matloubi-Moghadam, F., Rüedi, P. & Eugster, C. H. Drüsefarbstoffe aus Labiaten: 
Identifizierung von 17 Abietanoiden aus Plectranthus sanguineus B RITTEN. Helv. 
  
130 
 
Chim. Acta 70, 975–983 (1987). 
61. Alder, A. C., Rüdi, P. & Eugster, H. Drüsenfarbstoffe aus Labiaten: Die polaren 
Diterpenoide aus Plectranthus argentatus S. T. BLAKE. Helv. Chim. Acta 67, 1523–
1530 (1984). 
62. Künzle, J. M., Rüedii, P. & Eugster, C. H. Isolierung und Strukturaufklärung von 36 
Diterpenoiden aus Trichomen von Plectranthus edulis (VATKE) T.T. AYE. Helv. 
Chim. Acta 70, 1911–1929 (1987). 
63. Yoshizaki, F., Rüedi, P. & Eugster, C. H. Diterpenoide Drüsenfarbstoffe aus 
Labiaten : 11 Coleone und Royleanone aus Coleus carnosus HASSK . Helv. Chim. 
Acta 62, 2754–2762 (1979). 
64. Gaspar-Marques, C., Simões, M. F., Valdeira, M. L. & Rodríguez, B. Terpenoids and 
phenolics from Plectranthus strigosus, bioactivity screening. Nat. Prod. Res. 22, 
167–177 (2008). 
65. Rijo, P. et al. Antimycobacterial metabolites from Plectranthus: royleanone 
derivatives against Mycobacterium tuberculosis strains. Chem. Biodivers. 7, 922–
932 (2010). 
66. Rijo, P., Rodriguez, B., Duarte, A. & Fatima Simoes, M. Antimicrobial Properties of 
Plectranthus ornatus Extracts, 11-acetoxyhalima-5, 13-dien-15-oic Acid 
Metabolite and its Derivatives. Nat. Prod. J. 1, 57–64 (2011). 
67. Abdel-Mogib, M., Albar, H. A. & Batterjee, S. M. Chemistry of the Genus 
Plectranthus. Molecules 7, 271–301 (2002). 
68. Bhatt, P., Joseph, G. S., Negi, P. S. & Varadaraj, M. C. Chemical composition and 
nutraceutical potential of Indian borage (Plectranthus amboinicus) stem extract. 
J. Chem. 2013, 1–7 (2013). 
69. Kubínová, R. et al. Polyphenols and diterpenoids from Plectranthus forsteri 
‘Marginatus’. Biochem. Syst. Ecol. 49, 39–42 (2013). 
70. Kumaran, A. & Karunakaran, R. J. Activity-guided isolation and identification of 
free radical-scavenging components from an aqueous extract of Coleus 
aromaticus. Food Chem. 100, 356–361 (2007). 
71. Chen, Y. S. et al. Chemical constituents of Plectranthus amboinicus and the 
synthetic analogs possessing anti-inflammatory activity. Bioorganic Med. Chem. 
22, 1766–1772 (2014). 
72. Kubínová, R. et al. Antimicrobial and enzyme inhibitory activities of the 
constituents of Plectranthus madagascariensis (Pers.) Benth. J. Enzyme Inhib. 
Med. Chem. 6366, 1–4 (2014). 
73. Asada, Y. et al. Labdane-type diterpenoids from hairy root cultures of Coleus 
forskohlii, possible intermediates in the biosynthesis of forskolin. Phytochemistry 
79, 141–146 (2012). 
74. Horvath, T., Linden, A., Yoshizaki, F., Eugster, C. H. & Rüedi, P. Abietanes and a 
  
131 
 
novel 20-norabietanoid from Plectranthus cyaneus (Lamiaceae). Helv. Chim. Acta 
87, 2346–2353 (2004). 
75. Kulkarni, R. R., Csir, K. S., Csir, P. & Csir, J. Chemical investigation of Plectranthus 
mollis. J. Med. Aromat. Plant Sci. 34, 125–131 (2012). 
76. Orabi, K. Y. et al. New eudesmane sesquiterpenes from Plectranthus cylindraceus. 
J. Nat. Prod. 63, 1665–1668 (2000). 
77. Marques, C. G. et al. Effect of abietane diterpenes from Plectranthus 
grandidentatus on the growth of human cancer cell lines. Planta Med. 68, 839–
840 (2002). 
78. Teixeira, A. P. et al. Abietane diterpenoids from Plectranthus grandidentatus. 
Phytochemistry 44, 325–327 (1997). 
79. Syamasundar, K. V., Vinodh, G., Srinivas, K. V. N. S. & Srinivasulu, B. A new 
abietane diterpenoid from Plectranthus bishopianus BENTH. Helv. Chim. Acta 95, 
643–646 (2012). 
80. Van Zyl, R. L., Khan, F., Edwards, T. J. & Drewes, S. E. Antiplasmodial activities of 
some abietane diterpenes from the leaves of five Plectranthus species. S. Afr. J. 
Sci. 104, 62–64 (2008). 
81. Gaspar-Marques, C., Simões, M. F. & Rodríguez, B. A trihomoabietane diterpenoid 
from Plectranthus grandidentatus and an unusual addition of acetone to the 
ortho-quinone system of cryptotanshinone. J. Nat. Prod. 68, 1408–1411 (2005). 
82. Mei, S.-X. et al. Abietane Diterpenoids from Coleus xanthanthus. J. Nat. Prod. 65, 
633–637 (2002). 
83. Wellsow, J. et al. Insect-antifeedant and antibacterial activity of diterpenoids 
from species of Plectranthus. Phytochemistry 67, 1818–1825 (2006). 
84. Napagoda, M. et al. Inhibition of 5-lipoxygenase as anti-inflammatory mode of 
action of Plectranthus zeylanicus Benth and chemical characterization of 
ingredients by a mass spectrometric approach. J. Ethnopharmacol. 151, 800–809 
(2014). 
85. de Araujo Rodrigues, P. et al. Gastroprotective effect of barbatusin and 3-beta-
hydroxy-3-deoxibarbatusin, quinonoid diterpenes isolated from Plectranthus 
grandis, in ethanol-induced gastric lesions in mice. J. Ethnopharmacol. 127, 725–
730 (2010). 
86. Rijo, P., Gaspar-Marques, C., Simões, M. F., Jimeno, M. L. & Rodriguez, B. Further 
diterpenoids from Plectranthus ornatus and P. grandidentatus. Biochem. Syst. 
Ecol. 35, 215–221 (2007). 
87. Mothana, R. A. et al. In vitro antiprotozoal activity of abietane diterpenoids 
isolated from Plectranthus barbatus andr. Int. J. Mol. Sci. 15, 8360–8371 (2014). 
88. Narukawa, Y., Shimizu, N., Shimotohno, K. & Takeda, T. Two new diterpenoids 
from Plectranthus nummularius Briq. Chem. Pharm. Bull. (Tokyo). 49, 1182–1184 
  
132 
 
(2001). 
89. Gaspar-Marques, C., Simões, M. F. & Rodríguez, B. Further Labdane and Kaurane 
Diterpenoids and Other Constituents from Plectranthus fruticosus. J. Nat. Prod. 
67, 614–621 (2004). 
90. Gaspar-marques, C. & Fa, M. Labdane and Kaurane Diterpenoids from 
Plectranthus fruticosus. J. Nat. Prod. 491–496 (2003). 
91. Waldia, S. et al. Antibacterial and cytotoxic activities of diterpenoids isolated from 
Indian Plectranthus coesta. Rec. Nat. Prod. 7, 355–358 (2013). 
92. Xu, L. L. & Kong, L. Y. Labdane diterpenoids from Coleus forskohlii (Willd.) Briq. J. 
Integr. Plant Biol. 48, 478–481 (2006). 
93. Shan, Y. et al. Diterpenes from Coleus forskohlii (WILLD.) BRIQ. (Labiatae). Chem. 
Pharm. Bull. (Tokyo). 56, 52–56 (2008). 
94. Stavri, M., Paton, A., Skelton, B. W. & Gibbons, S. Antibacterial Diterpenes from 
Plectranthus ernstii. J. Nat. Prod. 72, 1191–1194 (2009). 
95. Zhang, W.-W., Luo, J.-G., Wang, J.-S., Lu, Y.-Y. & Kong, L.-Y. LC–DAD–ESI-MS-MS 
for Characterization and Quantitative Analysis of Diterpenoids from Coleus 
forskohlii. Chromatographia 70, 1635–1643 (2009). 
96. Rijo, P. et al. Neoclerodane and labdane diterpenoids from Plectranthus ornatus. 
J. Nat. Prod. 65, 1387–1390 (2002). 
97. Yang, Q.-R., Wu, H.-Z., Wang, X.-M., Zou, G.-A. & Liu, Y.-W. Three new 
diterpenoids from Coleus forskohlii Briq. J. Asian Nat. Prod. Res. 8, 355–360 
(2006). 
98. H. shen, Y. & L. Xu, Y. Two new diterpenoids from coleus forskohlii. J. Asian Nat. 
Prod. Res. 7, 811–815 (2005). 
99. Rijo, P., Simões, M. F. & Rodríguez, B. Structural and spectral assignment of three 
forskolin-like diterpenoids isolated from Plectranthus ornatus. Magn. Reson. 
Chem. 43, 595–598 (2005). 
100. Oliveira, P. M. et al. Diterpenoids from the aerial parts of Plectranthus ornatus. J. 
Nat. Prod. 68, 588–591 (2005). 
101. Faria, D. A. et al. Isolamento do diterpeno 1 , 6-di- O -acetil-9-deoxiforscolina das 
partes aéreas de Plectranthus neochilus. in A Química Somando Forças: Ensino e 
Pesquisa com Empreendedorismo e Inovação 43, 5000 (2014). 
102. Shan, Y., Wang, X., Zhou, X., Kong, L. & Niwa, M. Two Minor Diterpene Glycosides 
and an Eudesman Sesquiterpene from Coleus forskohlii. Chem. Pharm. Bull. 
(Tokyo). 55, 376–381 (2007). 
103. Crawford, A. D. et al. Zebrafish bioassay-guided natural product discovery: 
Isolation of angiogenesis inhibitors from East African medicinal plants. PLoS One 
6, 1–9 (2011). 
  
133 
 
104. Sashidhara, K. V. et al. Cell growth inhibitory action of an unusual labdane 
diterpene, 13-epi-sclareol in breast and uterine cancers in vitro. Phyther. Res. 21, 
1105–1108 (2007). 
105. Geng, S., Sun, B., Lu, R. & Wang, J. Coleusin Factor, a Novel Anticancer 
Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic 
Protein-2-Dependent Differentiation. Mol. Cancer Ther. 13, 1431–1441 (2014). 
106. Li, Z. & Wang, J. A forskolin derivative, FSK88, induces apoptosis in human gastric 
cancer BGC823 cells through caspase activation involving regulation of Bcl-2 
family gene expression, dissipation of mitochondrial membrane potential and 
cytochrome c release. Cell Biol. Int. 30, 940–946 (2006). 
107. Nugraheni, M., Santoso, U., Suparmo & Wuryastuti, H. Potential of Coleus 
tuberosus as an antioxidant and cancer chemoprevention agent. Int. Food Res. J. 
18, 1471–1480 (2011). 
108. Mooi, L. Y., Wahab, N. A., Lajis, N. H. & Ali, A. M. Chemopreventive properties of 
phytosterols and maslinic acid extracted from Coleus tuberosus in inhibiting the 
expression of EBV early-antigen in Raji cells. Chem. Biodivers. 7, 1267–1275 
(2010). 
109. Maree, J. E. et al. Bioactive acetophenones from Plectranthus venteri. Phytochem. 
Lett. 10, cxli–cxliv (2014). 
110. Santos, R. T. dos et al. Anti-trypanosomal activity of 1,2,3,4,6-penta-O-galloyl-
&amp;#946; -D-glucose isolated from Plectranthus barbatus Andrews 
(Lamiaceae). Quim. Nova 35, 2229–2332 (2012). 
111. Stites, T. E., Mitchell, A. E. & Rucker, R. B. Physiological Importance of 
Quinoenzymes and the O-Quinone Family of Cofactors. J. Nutr.  130 , 719–727 
(2000). 
112. Cowan, M. M. Plant products as antimicrobial agents. Clin. Microbiol. Rev. 12, 
564–582 (1999). 
113. Ladeiras, D. et al. Reactivity of Diterpenoid Quinones: Royleanones. Curr. Pharm. 
Des. 22, 1682–1714 (2016). 
114. de Melo, B. A. G., Motta, F. L. & Santana, M. H. A. Humic acids: Structural 
properties and multiple functionalities for novel technological developments. 
Mater. Sci. Eng. C (2015). at 
<http://linkinghub.elsevier.com/retrieve/pii/S0928493115306123> 
115. Sousa, J. C. F. de et al. in Microbiologia (eds. Ferreira, W. F. C. & Sousa, J. C. F. de) 
239–269 (LIDEL, 1998). 
116. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol. 
Mol. Biol. Rev. 74, 417–33 (2010). 
117. Wright, G. D. Q&A: Antibiotic resistance: where does it come from and what can 
we do about it? BMC Biol. 8, 123 (2010). 
  
134 
 
118. Zloh, M., Kaatz, G. W. & Gibbons, S. Inhibitors of multidrug resistance (MDR) have 
affinity for MDR substrates. Bioorg. Med. Chem. Lett. 14, 881–5 (2004). 
119. Organization, W. H. Antimicrobial resistance. Bulletin of the World Health 
Organization 61, (2014). 
120. Gm, N. D. and C. Natural Products as Sources of New Drugs over the 30 Years. J. 
Nat. Prod. 75, 311–335 (2012). 
121. Gibbons, S. Anti-staphylococcal plant natural products. Nat. Prod. Rep. 21, 263–
277 (2004). 
122. Nyila, M. A., Leonard, C. M., Hussein, A. A. & Lall, N. Bioactivities of Plectranthus 
ecklonii constituents. Nat. Prod. Commun. 4, 1177–1180 (2009). 
123. Simões, M. F., Rijo, P., Duarte, A., Matias, D. & Rodríguez, B. An easy and 
stereoselective rearrangement of an abietane diterpenoid into a bioactive 
microstegiol derivative. Phytochem. Lett. 3, 234–237 (2010). 
124. Matloubi-moghadam, F., Riiedi, P. & Eugster, C. H. 88. Driisenfarbstoffe aus 
Labiaten: Identifizierung von 17 Abietanoiden aus. 70, (1987). 
125. Rijo, P., Duarte, A., Francisco, A. P., Semedo-Lemsaddek, T. & Simóes, M. F. In 
vitro antimicrobial activity of royleanone derivatives against gram-positive 
bacterial pathogens. Phyther. Res. 28, 76–81 (2014). 
126. Urzúa, A., Rezende, M. C., Mascayano, C. & Vásquez, L. A Structure-Activity Study 
of Antibacterial Diterpenoids. Molecules 13, 882–891 (2008). 
127. Radulović, N., Denić, M. & Stojanović-Radić, Z. Antimicrobial phenolic abietane 
diterpene from Lycopus europaeus L. (Lamiaceae). Bioorg. Med. Chem. Lett. 20, 
4988–4991 (2010). 
128. Mendoza, L., Wilkens, M. & Urz??a, A. Antimicrobial study of the resinous 
exudates and of diterpenoids and flavonoids isolated from some Chilean 
Pseudognaphalium (Asteraceae). J. Ethnopharmacol. 58, 85–88 (1997). 
129. Nicolás, I. & Castro, M. Theoretical study of the complexes of horminone with 
Mg2+ and Ca2+ ions and their relation with the bacteriostatic activity. J. Phys. 
Chem. A 110, 4564–4573 (2006). 
130. Nicolás, I. et al. Theoretical study of the structure and antimicrobial activity of 
horminone. Int. J. Quantum Chem. 93, 411–421 (2003). 
131. Pereira, F. et al. Antibacterial effect of 7α-acetoxy-6β- hidroxyroyleanone from 
Plectranthus grandidentatus. International Conference on Antimicrobial Research 
(2014). 
132. Smith, E. C. J. et al. The phenolic diterpene totarol inhibits multidrug efflux pump 
activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 4480–4483 
(2007). 
133. Smith, E., Williamson, E., Zloh, M. & Gibbons, S. Isopimaric acid from Pinus nigra 
shows activity against multidrug-resistant and EMRSA strains of Staphylococcus 
  
135 
 
aureus. Phyther. Res. 19, 538–542 (2005). 
134. Ruddon, R. W. Cancer Biology. (Oxford University Press, 2007). 
135. Bray, F., Jemal, A., Grey, N., Ferlay, J. & Forman, D. Global cancer transitions 
according to the Human Development Index (2008–2030): a population-based 
study. Lancet Oncol. 13, 790–801 (2012). 
136. Roser, M. Our World In Data. Life Expectancy (2016). at 
<https://ourworldindata.org/life-expectancy/> 
137. Hanahan, D. & Weinberg, R. A. The Hallmarks of Cancer. Cell 100, 57–70 (2000). 
138. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 
646–674 (2011). 
139. Cragg, G. M., Grothaus, P. G. & Newman, D. J. Impact of Natural Products on 
Developing New Anti-Cancer Agents†. Chem. Rev. 109, 3012–3043 (2009). 
140. Rasikari, H. Phytochemistry and arthropod bioactivity of Australian Lamiaceae. 
(2007). 
141. Saeed, M. E. M., Abdelgadir, H., Sugimoto, Y., Khalid, H. E. & Efferth, T. 
Cytotoxicity of 35 medicinal plants from Sudan towards sensitive and multidrug-
resistant cancer cells. J. Ethnopharmacol. 174, 644–658 (2015). 
142. Minker, C. et al. In vivo and in vitro evaluation of anti-inflammatory activity and 
cytotoxicity of extracts of seven Plectranthus species. Planta Med. 73, P_074 
(2007). 
143. Hasibuan, P. A. Z. Antioxidant and Cytotoxic Activities of Plectranthus amboinicus 
(Lour.) Spreng. Extracts. Int. J. Pharm. Teach. Pract. 4, 755–758 (2013). 
144. Ramalakshmi, P., Subramanian, N., Saravanan, R., Mohanakrishnan, H. & Muthu, 
M. Anticancer effect of Coleus amboinicus (Karpooravalli) on human lung cancer 
cell line (A549). Int. J. Dev. Res. 4, 2442–2449 (2014). 
145. Gurgel, A. P. A. D. et al. In vivo study of the anti-inflammatory and antitumor 
activities of leaves from Plectranthus amboinicus (Lour.) Spreng (Lamiaceae). J. 
Ethnopharmacol. 125, 361–363 (2009). 
146. Arcanjo, D. D. R. et al. Bioactivity evaluation against Artemia salina Leach of 
medicinal plants used in Brazilian Northeastern folk medicine . Brazilian Journal 
of Biology  72 , 505–509 (2012). 
147. Gabriel, A. B. et al. Cytotoxic effect of Plectranthus neochilus extracts in head and 
neck carcinoma cell lines. African J. Pharm. Pharmacol. 10, 157–163 (2016). 
148. Agarwal, K. C. & Parks, R. E. Forskolin: A potential antimetastatic agent. Int. J. 
Cancer 32, 801–804 (1983). 
149. Sheppard, J. R. et al. Experimental metastasis correlates with cyclic AMP 
accumulation in B16 melanoma clones. Nature 5959, 544–547 (1984). 
150. McEwan, D. G. et al. Chemoresistant KM12C colon cancer cells are addicted to 
  
136 
 
low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via 
effects on phosphoinositide 3-kinase. Cancer Res. 67, 5248–5257 (2007). 
151. Jian, Y. & Jingze, W. CF mediated G1 arrest is associated with induction of 
p27(Kip1) and inhibition of cyclin D1 expression in human hepatoma HepG2 cells. 
Hepatol Res 35, 88–95 (2006). 
152. Geng, S., Sun, B., Liu, S. & Wang, J. Up-regulation of connexin 43 and gap 
junctional intercellular communication by Coleusin Factor is associated with 
growth inhibition in rat osteosarcoma UMR106 cells. Cell Biol. Int. 31, 1420–1427 
(2007). 
153. Sun, B. et al. Coleusin factor exerts cytotoxic activity by inducing G0/G1 cell cycle 
arrest and apoptosis in human gastric cancer BGC-823 cells. Cancer Lett. 301, 95–
105 (2011). 
154. Sashidhara, K. V. et al. Cell growth inhibitory action of an unusual labdane 
diterpene, 13-epi-sclareol in breast and uterine cancersin vitro. Phyther. Res. 21, 
1105–1108 (2007). 
155. Xing, X. et al. Inhibition of tumor cell proliferation by Coleon C. J. Chemother. 20, 
238–245 (2008). 
156. Coutinho, I. et al. Selective activation of protein kinase C-delta and -epsilon by 
6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U). Biochem. 
Pharmacol. 78, 449–459 (2009). 
157. Kupchan, S. M., Karim, A. & Marcks, C. Tumor inhibitors. XXXIV. Taxodione and 
taxodone, two novel diterpenoid quinone methide tumor inhibitors from 
Taxodium distichum. J. Am. Chem. Soc. 90, 5923–5924 (1968). 
158. Borrás-Linares, I. et al. A bioguided identification of the active compounds that 
contribute to the antiproliferative/cytotoxic effects of rosemary extract on colon 
cancer cells. Food Chem. Toxicol. 80, 215–22 (2015). 
159. Tayarani-Najaran, Z. et al. Cytotoxic and apoptogenic properties of three isolated 
diterpenoids from Salvia chorassanica through bioassay-guided fractionation. 
Food Chem. Toxicol. 57, 346–351 (2013). 
160. Topcu, G. et al. Studies on di- and triterpenoids from Salvia staminea with 
cytotoxic activity. Planta Med. 69, 464–467 (2003). 
161. Guerrero, I. C. et al. Abietane Diterpenoids from Salvia pachyphylla and S. 
clevelandii with Cytotoxic Activity against Human Cancer Cell Lines. J. Nat. Prod. 
69, 1803–1805 (2006). 
162. Reyes-Zurita, F. J., Rufino-Palomares, E. E., Lupiáñez, J. A. & Cascante, M. Maslinic 
acid, a natural triterpene from Olea europaea L., induces apoptosis in HT29 
human colon-cancer cells via the mitochondrial apoptotic pathway. Cancer Lett. 
273, 44–54 (2009). 
163. Reyes-Zurita, F. J. et al. Maslinic Acid, a Natural Triterpene, Induces a Death 
Receptor-Mediated Apoptotic Mechanism in Caco-2 p53-Deficient Colon 
  
137 
 
Adenocarcinoma Cells. PLoS One 11, e0146178 (2016). 
164. Alyssa, X. & Alexandra, C. N. Protein kinase C pharmacology: refining the toolbox. 
Biochem. J. 452, 195–209 (2013). 
165. Newton, A. C. Protein kinase C: poised to signal. Am. J. Physiol. Metab. 298, E395–
E402 (2010). 
166. Sharkey, N. A., Leach, K. L. & Blumberg, P. M. Competitive inhibition by 
diacylglycerol of specific phorbol ester binding. Proc. Natl. Acad. Sci. 81, 607–610 
(1984). 
167. Blackburn, R. V et al. Differential induction of cell death in human glioma cell lines 
by sodium nitroprusside. Cancer 82, 1137–1145 (1998). 
168. Mandil, R. et al. Protein kinase Cα and protein kinase Cδ play opposite roles in the 
proliferation and apoptosis of glioma cells. Cancer Res. 61, 4612–4619 (2001). 
169. Tanaka, Y., Gavrielides, M. V., Mitsuuchi, Y., Fujii, T. & Kazanietz, M. G. Protein 
kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of 
p38 MAPK and inhibition of the Akt survival pathway. J. Biol. Chem. 278, 33753–
33762 (2003). 
170. Mischak, H. et al. Overexpression of protein kinase C-delta and-epsilon in NIH 3T3 
cells induces opposite effects on growth, morphology, anchorage dependence, 
and tumorigenicity. J. Biol. Chem. 268, 6090–6096 (1993). 
171. Basu, A. & Pal, D. Two faces of protein kinase Cδ: the contrasting roles of PKCδ in 
cell survival and cell death. Sci. World J. 10, 2272–2284 (2010). 
172. Pan, Q. et al. Protein kinase Cε is a predictive biomarker of aggressive breast 
cancer and a validated target for RNA interference anticancer therapy. Cancer 
Res. 65, 8366–8371 (2005). 
173. Aziz, M. H. et al. Protein kinase Cε interacts with signal transducers and activators 
of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its 
constitutive activation in prostate cancer. Cancer Res. 67, 8828–8838 (2007). 
174. Bae, K.-M. et al. Protein Kinase Cε Is Overexpressed in Primary Human Non–Small 
Cell Lung Cancers and Functionally Required for Proliferation of Non–Small Cell 
Lung Cancer Cells in a p21/Cip1-Dependent Manner. Cancer Res. 67, 6053–6063 
(2007). 
175. McJilton, M. A. et al. Protein kinase C&epsiv; interacts with Bax and promotes 
survival of human prostate cancer cells. Oncogene 22, 7958–7968 (2003). 
176. Benavides, F. et al. Transgenic overexpression of PKCε in the mouse prostate 
induces preneoplastic lesions. Cell cycle 10, 268–277 (2011). 
177. Garg, R. et al. Protein kinase C and cancer: what we know and what we do not. 
Oncogene 33, 5225–5237 (2014). 
178. Galvez, A. S. et al. Protein kinase Cζ represses the interleukin-6 promoter and 
impairs tumorigenesis in vivo. Mol. Cell. Biol. 29, 104–115 (2009). 
  
138 
 
179. Kim, J. Y. et al. c-Myc phosphorylation by PKCζ represses prostate tumorigenesis. 
Proc. Natl. Acad. Sci. 110, 6418–6423 (2013). 
180. Filomenko, R. et al. Atypical protein kinase C ζ as a target for chemosensitization 
of tumor cells. Cancer Res. 62, 1815–1821 (2002). 
181. Xin, M., Gao, F., May, W. S., Flagg, T. & Deng, X. Protein kinase Cζ abrogates the 
proapoptotic function of Bax through phosphorylation. J. Biol. Chem. 282, 21268–
21277 (2007). 
182. Martin, P. et al. Role of ζPKC in B‐cell signaling and function. EMBO J. 21, 4049–
4057 (2002). 
183. Diaz-Meco, M. T. et al. zeta PKC induces phosphorylation and inactivation of I 
kappa B-alpha in vitro. EMBO J. 13, 2842 (1994). 
184. White, A. I. & Jenkins, G. L. Salvia carnosa (dougl.). I—A phytochemical study. J. 
Am. Pharm. Assoc. 31, 33–37 (1942). 
185. Frankel, E. N., Huang, S.-W., Aeschbach, R. & Prior, E. Antioxidant Activity of a 
Rosemary Extract and Its Constituents, Carnosic Acid, Carnosol, and Rosmarinic 
Acid, in Bulk Oil and Oil-in-Water Emulsion. J. Agric. Food Chem. 44, 131–135 
(1996). 
186. Johnson, J. J. Carnosol: A promising anti-cancer and anti-inflammatory agent. 
Cancer Lett. 305, 1–7 (2011). 
187. Subbaramaiah, K., Cole, P. a. & Dannenberg, A. J. Retinoids and carnosol suppress 
cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -
independent mechanisms. Cancer Res. 62, 2522–2530 (2002). 
188. Vergara, D. et al. Antitumor activity of the dietary diterpene carnosol against a 
panel of human cancer cell lines. Food Funct. 5, 1261–1269 (2014). 
189. Matias, D. et al. Abietane diterpenes from Plectranthus madagascariensis: A 
cytotoxicity screening. Planta Med 80, P1L152 (2014). 
190. Cerqueira, F. et al. Effect of abietane diterpenes from Plectranthus 
grandidentatus on T- and B-lymphocyte proliferation. Bioorganic Med. Chem. 12, 
217–223 (2004). 
191. Zhang, Y. et al. Degradation Study of Carnosic Acid, Carnosol, Rosmarinic Acid, 
and Rosemary Extract (Rosmarinus officinalis L.) Assessed Using HPLC. J. Agric. 
Food Chem. 60, 9305–9314 (2012). 
192. Davidson, S. K., Allen, S. W., Lim, G. E., Anderson, C. M. & Haygood, M. G. Evidence 
for the Biosynthesis of Bryostatins by the Bacterial Symbiont ‘Candidatus 
Endobugula sertula’ of the Bryozoan Bugula neritina. Appl. Environ. Microbiol. 67, 
4531–4537 (2001). 
193. Pettit, G. R. et al. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104, 
6846–6848 (1982). 
194. Jones, R. J. et al. Bryostatin 1, a unique biologic response modifier: anti-leukemic. 
  
139 
 
Blood 75, 1319–1323 (1990). 
195. Hornung, R. L., Pearson, J. W., Beckwith, M. & Longo, D. L. Preclinical evaluation 
of bryostatin as an anticancer agent against several murine tumor cell lines: in 
vitro versus in vivo activity. Cancer Res. 52, 101–107 (1992). 
196. Schuchter, L. M. et al. Successful treatment of murine melanoma with bryostatin 
1. Cancer Res. 51, 682–687 (1991). 
197. Ajani, J. et al. A multi-center phase II study of sequential paclitaxel and bryostatin-
1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal 
junction adenocarcinoma. Invest. New Drugs 24, 353–357 (2006). 
198. El-Rayes, B. F. et al. Phase I Study of Bryostatin 1 and Gemcitabine. Clin. Cancer 
Res. 12, 7059–7062 (2006). 
199. Kollár, P., Rajchard, J., Balounová, Z. & Pazourek, J. Marine natural products: 
Bryostatins in preclinical and clinical studies. Pharm. Biol. 52, 237–242 (2013). 
200. Wender, P. a et al. Modeling of the bryostatins to the phorbol ester 
pharmacophore on protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 85, 7197–7201 
(1988). 
201. Wender, P. a et al. The design, computer modeling, solution structure, and 
biological evaluation of synthetic analogs of bryostatin 1. Proc. Natl. Acad. Sci. U. 
S. A. 95, 6624–6629 (1998). 
202. Keck, G. E. et al. The bryostatin 1 A-ring acetate is not the critical determinant for 
antagonism of phorbol ester-induced biological responses. Org. Lett. 11, 2277–
2280 (2009). 
203. Andrews, I. P. et al. Synthesis of seco -B-Ring Bryostatin Analogue WN-1 via C–C 
Bond-Forming Hydrogenation: Critical Contribution of the B-Ring in Determining 
Bryostatin-like and Phorbol 12-Myristate 13-Acetate-like Properties. J. Am. Chem. 
Soc. 136, 13209–13216 (2014). 
204. Gotta, H., Adolf, W., Opferkuch, H. J. & Hecker, E. on the Active Principles of the 
Euphorbiaceae .9. Ingenane Type Diterpene Esters From 5 Euphorbia Species. 
Zeitschrift Fur Naturforsch. Sect. B-a J. Chem. Sci. 39, 683–694 (1984). 
205. Zayed, S. M. A. D., Farghaly, M., Taha, H., Gotta, H. & Hecker, E. Dietary cancer 
risk conditional cancerogens in produce  of livestock fed on species of spurge 
(Euphorbiaceae). J. Cancer Res. Clin. Oncol. 124, 131–140 (1998). 
206. Drury, S. Plants and Wart Cures in England from the Seventeenth to the 
Nineteenth Century: Some Examples. Folklore 102, 97–100 (1991). 
207. Adolf, W., Chanai, S. & Hecker, E. 3-O-angeloylingenol, the toxic and skin irritant 
factor from latex of Euphorbia antiquorum L. (Euphorbiaceae) and from a derived 
Thai purgative and anthelimintic (vermifuge) drug. J Sci Soc Thail. 9, 81–88 (1983). 
208. Rizk, A. M., Hammouda, F. M., El-Missiry, M. M., Radwan, H. M. & Evans, F. J. 
Biologically active diterpene esters from Euphorbia peplus. Phytochemistry 24, 
  
140 
 
1605–1606 (1985). 
209. Hohmann, J., Evanics, F., Berta, L. & Bartók, T. Diterpenoids from Euphorbia 
peplus. Planta Med. 66, 291–294 (2000). 
210. Gillespie, S. K., Zhang, X. D. & Hersey, P. Ingenol 3-angelate induces dual modes 
of cell death and differentially regulates tumor necrosis factor–related apoptosis-
inducing ligand–induced apoptosis in melanoma cells. Mol. Cancer Ther.  3 , 1651–
1658 (2004). 
211. Ogbourne, S. M. et al. Antitumor Activity of 3-Ingenyl Angelate: Plasma 
Membrane and Mitochondrial Disruption and Necrotic Cell Death . Cancer Res.  
64 , 2833–2839 (2004). 
212. Benhadji, K. A. et al. Antiproliferative activity of PEP005, a novel ingenol angelate 
that modulates PKC functions, alone and in combination with cytotoxic agents in 
human colon cancer cells. Br. J. Cancer 99, 1808–1815 (2008). 
213. Kedei, N. Characterization of the Interaction of Ingenol 3-Angelate with Protein 
Kinase C. Cancer Res. 64, 3243–3255 (2004). 
214. Rosen, R. H., Gupta, A. K. & Tyring, S. K. Dual mechanism of action of ingenol 
mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis 
followed by lesion-specific immune response. J. Am. Acad. Dermatol. 66, 486–493 
(2012). 
215. Lee, W. Y. et al. Novel antileukemic compound ingenol 3-angelate inhibits T cell 
apoptosis by activating protein kinase C?? J. Biol. Chem. 285, 23889–23898 
(2010). 
216. Ajazuddin & Saraf, S. Applications of novel drug delivery system for herbal 
formulations. Fitoterapia 81, 680–689 (2010). 
217. Parveen, S., Misra, R. & Sahoo, S. K. Nanoparticles: A boon to drug delivery, 
therapeutics, diagnostics and imaging. Nanomedicine Nanotechnology, Biol. Med. 
8, 147–166 (2012). 
218. Palin, K. J. Effect of oils on drug absorption. (University of Nottingham, 1981). at 
<http://eprints.nottingham.ac.uk/11824/1/258642.pdf> 
219. Bhingardeve, D., Patil, S., Patil, R. & Patil, S. Phytosome- Valuable Phyto-
Phospholipid Carriers . 5, 7842 (2014). 
220. van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are 
and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112–124 (2008). 
221. Scholfield, C. R. Composition of soybean lecithin. J. Am. Oil Chem. Soc. 58, 889–
892 (1981). 
222. Phosphatidylcholine. Altern. Med. Rev. 7, 150–154 (2002). 
223. Saraf, S., Khan, J., Alexander, A., Ajazuddin & Saraf, S. Recent advances and future 
prospects of phyto-phospholipid complexation technique for improving 
pharmacokinetic profile of plant actives. J. Control. Release 168, 50–60 (2013). 
  
141 
 
224. Habbu, P. et al. Preparation and evaluation of Bacopa–phospholipid complex for 
antiamnesic activity in rodents. Drug Invent. Today 5, 13–21 (2013). 
225. Zhang, J. et al. Preparation, characterization, and in vivo evaluation of a self-
nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid 
complex. Int. J. Nanomedicine 6, 3405–3414 (2011). 
226. Semalty, A., Semalty, M., Singh, D. & Rawat, M. S. M. Preparation and 
characterization of phospholipid complexes of naringenin for effective drug 
delivery. J. Incl. Phenom. Macrocycl. Chem. 67, 253–260 (2010). 
227. Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P. & Mukherjee, P. K. Curcumin-
phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic 
study in rats. Int. J. Pharm. 330, 155–163 (2007). 
228. Singh, D., Rawat, M. S. M., Semalty, A. & Semalty, M. Emodin–phospholipid 
complex. J. Therm. Anal. Calorim. 108, 289–298 (2012). 
229. Hou, Z. et al. Phytosomes loaded with mitomycin C-soybean phosphatidylcholine 
complex developed for drug delivery. Mol. Pharm. 10, 90–101 (2013). 
230. Freag, M. S., Elnaggar, Y. S. R. & Abdallah, O. Y. Lyophilized phytosomal 
nanocarriers as platforms for enhanced diosmin delivery: Optimization and ex 
vivo permeation. Int. J. Nanomedicine 8, 2385–2397 (2013). 
231. Semalty, A., Semalty, M., Singh, D. & Rawat, M. S. M. Phyto-phospholipid complex 
of catechin in value added herbal drug delivery. J. Incl. Phenom. Macrocycl. Chem. 
73, 377–386 (2012). 
232. Choubey, A. Phytosome - A novel approach for herbal drug delivery. Int. J. Pharm. 
Sci. Res. 2, 807–815 (2011). 
233. Khan, J., Alexander, A., Ajazuddin, Saraf, S. & Saraf, S. Luteolin-phospholipid 
complex: preparation, characterization and biological evaluation. J. Pharm. 
Pharmacol. 66, 1451–1462 (2014). 
234. Xu, K. et al. Physicochemical properties and antioxidant activities of luteolin-
phospholipid complex. Molecules 14, 3486–93 (2009). 
235. Qin, X. et al. Preparation, characterization and in vivo evaluation of bergenin-
phospholipid complex. Acta Pharmacol. Sin. 31, 127–136 (2010). 
236. Bombardelli, E. & Sabadie, M. Phospholipid complexes of extracts of vitis vinifera, 
their preparation process and pharmaceutical and cosmetic compositions 
containing them. (1990). at <http://www.google.com/patents/US4963527> 
237. Bombardelli, E. & Morazzoni, P. Phospholipid complexes of proanthocyanidin a2 
as antiatherosclerotic agents. (2000). at 
<http://www.google.com/patents/WO2000037062A2> 
238. Franceschi, F. & Giori, A. Phospholipid complexes of olive fruits or leaves extracts 
having improved bioavailability. (2007). at 
<https://www.google.pt/patents/WO2007118631A1> 
  
142 
 
239. Song, Y., Zhuang, J., Guo, J., Xiao, Y. & Ping, Q. Preparation and properties of a 
silybin-phospholipid complex. Pharmazie 63, 35–42 (2008). 
240. Ma, H., Chen, H., Sun, L., Tong, L. & Zhang, T. Improving permeability and oral 
absorption of mangiferin by phospholipid complexation. Fitoterapia 93, 54–61 
(2014). 
241. ICH Expert Working Group. in ICH Harmonised Tripartite Guideline (2011). at 
<http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qual
ity/Q3C/Step4/Q3C_R5_Step4.pdf> 
242. Yue, P.-F., Yuan, H.-L., Li, X.-Y., Yang, M. & Zhu, W.-F. Process optimization, 
characterization and evaluation in vivo of oxymatrine-phospholipid complex. Int. 
J. Pharm. 387, 139–46 (2010). 
243. Maiti, K., Mukherjee, K., Murugan, V., Saha, B. P. & Mukherjee, P. K. Enhancing 
bioavailability and hepatoprotective activity of andrographolide from 
Andrographis paniculata, a well-known medicinal food, through its herbosome. J. 
Sci. Food Agric. 90, 43–51 (2010). 
244. Li, Y., Yang, D. J., Chen, S. L., Chen, S. B. & Chan, A. S. C. Comparative 
physicochemical characterization of phospholipids complex of puerarin 
formulated by conventional and supercritical methods. Pharm. Res. 25, 563–577 
(2008). 
245. Sikarwar, M. S., Sharma, S., Jain, A. K. & Parial, S. D. Preparation, Characterization 
and Evaluation of Marsupsin–Phospholipid Complex. AAPS PharmSciTech 9, 129–
137 (2008). 
246. Gupta, N. K. & Dixit, V. K. Development and evaluation of vesicular system for 
curcumin delivery. Arch. Dermatol. Res. 303, 89–101 (2011). 
247. Sharma, A., Gupta, N. K. & Dixit, V. K. Complexation with phosphatidyl choline as 
a strategy for absorption enhancement of boswellic acid. Drug Deliv. 17, 587–595 
(2010). 
248. Li, Y. et al. Mitomycin C-soybean phosphatidylcholine complex-loaded self-
assembled PEG-Lipid-PLA hybrid nanoparticles for targeted drug delivery and 
dual-controlled drug release. Mol. Pharm. 11, 2915–2927 (2014). 
249. Zhang, J., Tang, Q., Xu, X. & Li, N. Development and evaluation of a novel 
phytosome-loaded chitosan microsphere system for curcumin delivery. Int. J. 
Pharm. 448, 168–174 (2013). 
250. Yanyu, X., Yunmei, S., Zhipeng, C. & Qineng, P. The preparation of silybin-
phospholipid complex and the study on its pharmacokinetics in rats. Int. J. Pharm. 
307, 77–82 (2006). 
251. Rasaie, S., Ghanbarzadeh, S., Mohammadi, M. & Hamishehkar, H. Nano 
Phytosomes of Quercetin : A Promising Formulation for Fortification of Food 
Products with Antioxidants. Pharm. Sci. 20, 96–101 (2014). 
252. Rasaie, S., Ghanbarzadeh, S., Mohammadi, M. & Hamishehkar, H. Nano 
  
143 
 
Phytosomes of Quercetin: A Promising Formulation for Fortification of Food 
Products with Antioxidants. Pharm. Sci. 20, 96 (2014). 
253. Hou, Z. et al. New Method to Prepare Mitomycin C Loaded PLA-Nanoparticles 
with High Drug Entrapment Efficiency. Nanoscale Res. Lett. 4, 732–737 (2009). 
254. Cheung, R. Y., Ying, Y., Rauth, A. M., Marcon, N. & Yu Wu, X. Biodegradable 
dextran-based microspheres for delivery of anticancer drug mitomycin C. 
Biomaterials 26, 5375–85 (2005). 
255. Gabizon, A. et al. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in 
pegylated liposomes: studies with human gastro-entero-pancreatic ectopic 
tumor models. J. Control. Release 160, 245–53 (2012). 
256. Liang, C.-C., Park, A. Y. & Guan, J.-L. In vitro scratch assay: a convenient and 
inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329–333 
(2007). 
257. Demir, B. et al. Gold nanoparticle loaded phytosomal systems: synthesis, 
characterization and in vitro investigations. RSC Adv. 4, 34687–34695 (2014). 
258. Kidd, P. M. Bioavailability and activity of phytosome complexes from botanical 
polyphenols: The silymarin, curcumin, green tea, and grape seed extracts. Altern. 
Med. Rev. 14, 226–246 (2009). 
259. Agarwal, C. et al. Anti-Cancer Efficacy of Silybin Derivatives - A Structure-Activity 
Relationship. PLoS One 8, 1–11 (2013). 
260. Singh, R. P., Gu, M. & Agarwal, R. Silibinin inhibits colorectal cancer growth by 
inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 68, 2043–2050 
(2008). 
261. Liang, Z. et al. Inhibition of SIRT1 Signaling Sensitizes the Antitumor Activity of 
Silybin against Human Lung Adenocarcinoma Cells In Vitro and In Vivo. Mol. 
Cancer Ther. 13, 1860–1872 (2014). 
262. Bosch-Barrera, J. & Menendez, J. A. Silibinin and STAT3: A natural way of targeting 
transcription factors for cancer therapy. Cancer Treat. Rev. 41, 540–546 (2014). 
263. Wu, J. W., Lin, L. C. & Tsai, T. H. Drug-drug interactions of silymarin on the 
perspective of pharmacokinetics. J. Ethnopharmacol. 121, 185–193 (2009). 
264. Wen, Z. et al. Pharmacokinetics and metabolic profile of free, conjugated, and 
total silymarin flavonolignans in human plasma after oral administration of milk 
thistle extract. Drug Metab. Dispos. 36, 65–72 (2008). 
265. Barzaghi, N., Crema, F., Gatti, G., Pifferi, G. & Perucca, E. Pharmacokinetic studies 
on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. 
Eur J Drug Metab Pharmacokinet 15, 333–338 (1990). 
266. Morazzoni, P., Montalbetti, A., Malandrino, S. & Pifferi, G. Comparative 
pharmacokinetics of silipide and silymarin in rats. Eur. J. Drug Metab. 
Pharmacokinet. 18, 289–297 (1993). 
  
144 
 
267. Flaig, T. W. et al. A phase I and pharmacokinetic study of silybin-phytosome in 
prostate cancer patients. Invest. New Drugs 25, 139–146 (2007). 
268. Kidd, P. & Head, K. A review of the bioavailability and clinical efficacy of milk 
thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos®). Altern. 
Med. Rev. 10, 193 (2005). 
269. Agarwal, R., Agarwal, C., Ichikawa, H., Singh, R. P. & Aggarwal, B. B. Anticancer 
potential of silymarin: From bench to bed side. Anticancer Research 26, (2006). 
270. Cuomo, J. et al. Comparative absorption of a standardized curcuminoid mixture 
and its lecithin formulation. J. Nat. Prod. 74, 664–669 (2011). 
271. Bressan, A., Ranaldi, D., Rapacioli, G., Giacomelli, L. & Bertuccioli, A. Potential role 
of bioavailable curcumin in weight loss and omental adipose tissue decrease : 
preliminary data of a randomized , controlled trial in overweight people with 
metabolic syndrome . Preliminary study. 4195–4202 (2015). 
272. Pajardi, G., Bortot, P., Ponti, V. & Novelli, C. Clinical usefulness of oral 
supplementation with alpha-lipoic acid, curcumin phytosome, and B-group 
vitamins in patients with carpal tunnel syndrome undergoing surgical treatment. 
Evidence-based Complement. Altern. Med. 2014, (2014). 
273. Drobnic, F. et al. Reduction of delayed onset muscle soreness by a novel curcumin 
delivery system (Meriva®): a randomised, placebo-controlled trial. J. Int. Soc. 
Sports Nutr. 11, 31 (2014). 
274. Di Pierro, F. et al. Comparative evaluation of the pain-relieving properties of a 
lecithinized formulation of curcumin (Meriva®), nimesulide, and acetaminophen. 
J. Pain Res. 6, 201–205 (2013). 
275. Belcaro, G. et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine 
complex, during extended administration in osteoarthritis patients. Altern. Med. 
Rev. 15, 337–344 (2010). 
276. Janssens, P. L. H. R., Hursel, R. & Westerterp-Plantenga, M. S. Nutraceuticals for 
body-weight management: The role of green tea catechins. Physiol. Behav. 1–5 
(2016). doi:10.1016/j.physbeh.2016.01.044 
277. Huang, Y.-Q. et al. Green tea and liver cancer risk: A meta-analysis of prospective 
cohort studies in Asian populations. Nutrition 32, 3–8 (2016). 
278. Yin, X. et al. The effect of green tea intake on risk of liver disease : a meta analysis. 
Int. J. Clin. Exp. Med. 8, 8339–8346 (2015). 
279. Islam, M. A. Cardiovascular Effects of Green Tea Catechins: Progress and Promise. 
Recent Patents on Cardiovascular Drug Discovery 7, 88–99 (2012). 
280. Pietta, P. et al. Relationship between rate and extent of catechin absorption and 
plasma antioxidant status. IUBMB Life 46, 895–903 (1998). 
281. Pierro, F. Di, Menghi, A. B., Lucarelli, M. & Calandrelli, A. GreenSelect® Phytosome 
as an Adjunct to a Low Calorie Diet for Treatment of Obesity: A Clinical Trial. 
  
145 
 
L’integratore Nutr. 14, 154–160 (2009). 
282. Belcaro, G. et al. Greenselect phytosome for borderline metabolic syndrome. 
Evidence-based Complement. Altern. Med. 2013, (2013). 
283. Mahadevan, S. & Park, Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: 
Chemistry, efficacy, safety, and uses. J. Food Sci. 73, (2008). 
284. Birks, J. & Grimley Evans, J. Ginkgo biloba for cognitive impairment and dementia. 
Cochrane database Syst. Rev. CD003120 (2009). at 
<http://www.ncbi.nlm.nih.gov/pubmed/19160216> 
285. Naik, S. R. & Panda, V. S. Antioxidant and hepatoprotective effects of Ginkgo 
biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. Liver 
Int. 27, 393–399 (2007). 
286. Naik, S. R. & Panda, V. S. Hepatoprotective effect of Ginkgoselect Phytosome(R) 
in rifampicin induced liver injurym in rats: Evidence of antioxidant activity. 
Fitoterapia 79, 439–445 (2008). 
287. Tisato, V. et al. Inhibitory effect of natural anti-inflammatory compounds on 
cytokines released by chronic venous disease patient-derived endothelial cells. 
Mediators Inflamm. 2013, (2013). 
288. Chanchal, D. & Swarnlata, S. Novel approaches in herbal cosmetics. J. Cosmet. 
Dermatol. 7, 89–95 (2008). 
289. Ascensao, L. et al. Plectranthus madagascariensis: morphology of the glandular 
trichomes, essential oil composition, and its biological activity. Int. J. Plant Sci. 31–
38 (1998). 
290. Gazim, Z. C. et al. New natural Diterpene-Type abietane from tetradenia riparia 
essential oil with Cytotoxic and Antioxidant activities. Molecules 19, 514–524 
(2014). 
291. Duarte, M. D. R. & Lopes, J. F. Stem and leaf anatomy of Plectranthus neochilus 
Schltr., Lamiaceae. Brazilian J. Pharmacogn. 17, 549–556 (2007). 
292. Duarte, M. do R. & Lopes, J. F. Stem and leaf anatomy of Plectranthus neochilus 
Schltr., Lamiaceae . Revista Brasileira de Farmacognosia  17 , 549–556 (2007). 
293. Mota, L. et al. Volatile-Oils Composition, and Bioactivity of the Essential Oils of 
Plectranthus barbatus, P. neochilus, and P. ornatus Grown in Portugal. Chem. 
Biodivers. 11, 719–732 (2014). 
294. Caixeta, S. C. et al. Chemical composition and in vitro schistosomicidal activity of 
the essential oil of Plectranthus neochilus grown in Southeast Brazil. Chem. 
Biodivers. 8, 2149–2157 (2011). 
295. Lawal, O. a, Hutchings,  a H. & Oyedeji, O. Chemical Composition of the Leaf Oil 
of Plectranthus neochilus Schltr. J. Essent. Oil Res. 22, 546–547 (2010). 
296. Crevelin, E. J. et al. Antimicrobial Activity of the Essential Oil of Plectranthus 
neochilus against Cariogenic Bacteria. Evidence-Based Complement. Altern. Med. 
  
146 
 
2015, (2015). 
297. Baldin, E. L. L. et al. Plant-derived essential oils affecting settlement and 
oviposition of Bemisia tabaci (Genn.) biotype B on tomato. J. Pest Sci. (2004). 86, 
301–308 (2013). 
298. Tempone, A. G. et al. Brazilian flora extracts as source of novel antileishmanial 
and antifungal compounds . Memórias do Instituto Oswaldo Cruz  103 , 443–449 
(2008). 
299. José, A. & Viana, S. Estudo químico e de atividade biológica de Plectranthus 
neochilus Schltr. (Universidade Federal dos Vales do Jequitinhonha e Mucuri). 
300. Winter, P.J.D. and Van Jaarsveld, E. J. Plectranthus porcatus, a new species 
endemic to the Sekhukhuneland Centre of Plant Endemism, Limpopo Province, 
South Africa. Bothalia 35, 169–173 (2004). 
301. Cailleau, R. et al. Breast Tumor Cell Lines From Pleural Effusions. J. Natl. Cancer 
Inst. 53, 661–674 (1974). 
302. Pereira, P., Bernardo-Gil, M. G., Cebola, M. J., Mauricio, E. & Romano, A. 
Supercritical fluid extracts with antioxidant and antimicrobial activities from 
myrtle (Myrtus communis L.) leaves. Response surface optimization. J. Supercrit. 
Fluids 83, 57–64 (2013). 
303. Andrews, J. M. & Andrews, J. M. Determination of minimum inhibitory 
concentrations. J. Antimicrob. Chemother. 48 Suppl 1, 5–16 (2001). 
304. Fernandes, A. S. et al. Oxidative injury in V79 Chinese hamster cells: protective 
role of the superoxide dismutase mimetic MnTM-4-PyP. Cell Biol. Toxicol. 26, 91–
101 (2010). 
305. Kasote, D. M., Katyare, S. S., Hegde, M. V & Bae, H. Significance of antioxidant 
potential of plants and its relevance to therapeutic applications. Int. J. Biol. Sci. 
11, 982–91 (2015). 
306. Geran, R. Protocols for screening chemical agents and natural products against 
animal tumors and other biological systems. Cancer Chemother Rep 3, 51–61 
(1972). 
307. Rijo, P. et al. Antimicrobial plant extracts encapsulated into polymeric beads for 
potential application on the skin. Polymers (Basel). 6, 479–490 (2014). 
308. Pesic, M. et al. Induced Resistance in the Human Non Small Cell Lung Carcinoma 
(NCI-H460) Cell Line In Vitro by Anticancer Drugs. J. Chemother. (2013). 
309. ICH Expert Working Group. ICH HARMONISED TRIPARTITE GUIDELINE 
VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) 
Guideline on Validation of Analytical Procedures: Methodology developed to 
complement the Parent Guideline. (2005). 
310. Guerreiro, P. S. et al. Differential effects of methoxyamine on doxorubicin 
cytotoxicity and genotoxicity in MDA-MB-231 human breast cancer cells. Mutat. 
  
147 
 
Res. 757, 140–7 (2013). 
311. Leão, M. et al. Enhanced cytotoxicity of prenylated chalcone against tumour cells 
via disruption of the p53-MDM2 interaction. Life Sci. 142, 60–5 (2015). 
312. Fischedick, J. T. et al. Cytotoxic activity of sesquiterpene lactones from Inula 
britannica on human cancer cell lines. Phytochem. Lett. 6, 246–252 (2013). 
313. Cleator, S., Heller, W. & Coombes, R. C. Triple-negative breast cancer: therapeutic 
options. Lancet Oncol. 8, 235–244 (2007). 
314. Borner, C., Wyss, R., Regazzi, R., Eppenberger, U. & Fabbro, D. Immunological 
quantitation of phospholipid/CA2+-dependent protein kinase of human 
mammary carcinoma cells: Inverse relationship to estrogen receptors. Int. J. 
Cancer 40, 344–348 (1987). 
315. Morse-Gaudio, M., Connolly, J. M. & Rose, D. P. Protein kinase C and its isoforms 
in human breast cancer cells: relationship to the invasive phenotype. Int. J. Oncol. 
12, 1349–1403 (1998). 
316. Connolly, J. & Rose, D. Expression of the invasive phenotype by MCF-7 human 
breast cancer cells transfected to overexpress protein kinase C-alpha or the erbB2 
proto-oncogene. Int. J. Oncol. 10, 71–76 (1997). 
317. Tan, M., Li, P., Sun, M., Yin, G. & Yu, D. Upregulation and activation of PKC alpha 
by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by 
combined treatment with PKC alpha and Src inhibitors. Oncogene 25, 3286–95 
(2006). 
318. Li, Z. et al. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and 
tamoxifen resistance in human breast cancer cells. Oncol. Rep. 27, 1879–1886 
(2012). 
319. Lønne, G. K., Masoumi, K. C., Lennartsson, J. & Larsson, C. Protein kinase Cdelta 
supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 
pathway. J. Biol. Chem. 284, 33456–65 (2009). 
320. Yokoyama, G. et al. PKCδ and MAPK mediate G 1 arrest induced by PMA in SKBR-
3 breast cancer cells. Biochem. Biophys. Res. Commun. 327, 720–726 (2005). 
321. Vucenik, I., Ramakrishna, G., Tantivejkul, K., Anderson, L. M. & Ramljak, D. Inositol 
hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a 
PKCδ-dependent increase in p27Kip1 and decrease in retinoblastoma protein 
(pRb) phosphorylation. Breast Cancer Res. Treat. 91, 35–45 (2005). 
322. Bessa, C. et al. MC-11 Roy-Bz : the first small molecule selective activator of 
protein Kinase C d. in Livro de Resumos do Congresso de Química Orgânica e 
Química Terapêutica (ed. Sociedade Portuguesa de Química) 71 (2015). 
323. Chaudhary, P. M. & Roninson, I. B. Activation of MDR1 (P-glycoprotein) gene 
expression in human cells by protein kinase C agonists. Oncol. Res. 4, 281–90 
(1992). 
  
148 
 
324. Al-Katib, A. et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine 
cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res. 4, 1305–
1314 (1998). 
325. Fronza, M. et al. In vitro cytotoxic activity of abietane diterpenes from Peltodon 
longipes as well as Salvia miltiorrhiza and Salvia sahendica. Bioorg. Med. Chem. 
19, 4876–81 (2011). 
326. Fronza, M. et al. Abietane diterpenes induce cytotoxic effects in human 
pancreatic cancer cell line MIA PaCa-2 through different modes of action. 
Phytochemistry 78, 107–19 (2012). 
327. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997). 
328. Areche, C., Schmeda-Hirschmann, G., Theoduloz, C. & Rodríguez, J. a. 
Gastroprotective effect and cytotoxicity of abietane diterpenes from the Chilean 
Lamiaceae Sphacele chamaedryoides (Balbis) Briq. J. Pharm. Pharmacol. 61, 
1689–1697 (2009). 
329. Kusumoto, N., Aburai, N., Ashitani, T., Takahashi, K. & Kimura, K. Pharmacological 
Prospects of Oxygenated Abietane-Type Diterpenoids from Taxodium distichum 
Cones. Adv. Biol. Chem. 4, 109–115 (2014). 
330. Li, S., Wang, P., Deng, G., Yuan, W. & Su, Z. Cytotoxic compounds from invasive 
giant salvinia (Salvinia molesta) against human tumor cells. Bioorg. Med. Chem. 
Lett. 23, 6682–6687 (2013). 
331. Jonathan, L. T., Che, C.-T., Pezzuto, J. M., Fong, H. H. S. & Farnsworth, N. R. 7-O-
Methylhorminone and Other Cytotoxic Diterpene Quinones from Lepechinia 
bullata. J. Nat. Prod. 52, 571–575 (1989). 
332. Borsa, L., Frank, P., Borsa, B. L. & Doran, H. PwC Response to the WEF Global Risks 
2013 Report Case Study: ‘Dangers of Hubris in Human Health’. Resil. A J. Strateg. 
risk (2013). 
333. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. 
Molecular mechanisms of antibiotic resistance. Chem. Commun. (Camb). 47, 
4055–4061 (2011). 
334. Cully, M. The politics of antibiotics. Nature 509, S16–S17 (2014). 
335. Laxminarayan, R. et al. Antibiotic resistance-the need for global solutions. Lancet 
Infect. Dis. 13, 1057–1098 (2013). 
336. Hetem, D. J. & Bonten, M. J. M. Clinical relevance of mupirocin resistance in 
Staphylococcus aureus. J. Hosp. Infect. 85, 249–256 (2013). 
337. Williamson, D. A. et al. High usage of topical fusidic acid and rapid clonal 
expansion of fusidic acid-resistant Staphylococcus aureus: A cautionary tale. Clin. 
Infect. Dis. 59, 1451–1454 (2014). 
  
149 
 
338. Elston, D. M. Topical Antibiotics in Dermatology: Emerging Patterns of Resistance. 
Dermatol. Clin. 27, 25–31 (2009). 
339. Tognetti, L. et al. Bacterial skin and soft tissue infections: Review of the 
epidemiology, microbiology, aetiopathogenesis and treatment: A collaboration 
between dermatologists and infectivologists. J. Eur. Acad. Dermatology Venereol. 
26, 931–941 (2012). 
340. Stevens, D. L. et al. Practice guidelines for the diagnosis and management of skin 
and soft tissue infections: 2014 update by the infectious diseases society of 
America. Clin. Infect. Dis. 59, (2014). 
341. De la Fuente-Nunez, C., Reffuveille, F., Fernandez, L. & Hancock, R. E. W. Bacterial 
biofilm development as a multicellular adaptation: Antibiotic resistance and new 
therapeutic strategies. Curr. Opin. Microbiol. 16, 580–589 (2013). 
342. Weckesser, S. et al. Screening of plant extracts for antimicrobial activity against 
bacteria and yeasts with dermatological relevance. Phytomedicine 14, 508–516 
(2007). 
343. Langeveld, W. T., Veldhuizen, E. J. A. & Burt, S. A. Synergy between essential oil 
components and antibiotics: a review. Crit. Rev. Microbiol. 40, 76–94 (2014). 
344. Holder, I. A. & Boyce, S. T. Formulation of ‘idealized’ topical antimicrobial 
mixtures for use with cultured skin grafts. J. Antimicrob. Chemother. 38, 457–463 
(1996). 
345. Pelgrift, R. Y. & Friedman, A. J. Nanotechnology as a therapeutic tool to combat 
microbial resistance. Adv. Drug Deliv. Rev. 65, 1803–1815 (2013). 
346. Huh, A. J. & Kwon, Y. J. ‘Nanoantibiotics’: A new paradigm for treating infectious 
diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 
156, 128–145 (2011). 
347. Mu, H. et al. Potent Antibacterial Nanoparticles against Biofilm and Intracellular 
Bacteria. Sci. Rep. 6, 18877 (2016). 
348. Huang, C. M. et al. Eradication of drug resistant Staphylococcus aureus by 
liposomal oleic acids. Biomaterials 32, 214–221 (2011). 
349. Bombardelli, E. Phytosome: new cosmetic delivery system. Boll. Chim. Farm. 130, 
431–438 (1991). 
350. M.S. Roberts, S.E. Cross, M. A. P. in Dermatological and Transdermal Formulations 
(ed. Walters, K. A.) 89–195 (Marcel Dekker, Inc., 2002). 
351. Prow, T. W. et al. Nanoparticles and microparticles for skin drug delivery. Adv. 
Drug Deliv. Rev. 63, 470–491 (2011). 
352. Mitragotri, S. et al. Mathematical models of skin permeability: An overview. Int. 
J. Pharm. 418, 115–129 (2011). 
353. Magnusson, B. M., Anissimov, Y. G., Cross, S. E. & Roberts, M. S. Molecular size as 
the main determinant of solute maximum flux across the skin. J. Invest. Dermatol. 
  
150 
 
122, 993–999 (2004). 
354. Baroli, B. Penetration of nanoparticles and nanomaterials in the skin: fiction or 
reality? J. Pharm. Sci. 99, 21–50 (2010). 
355. Das, M. K. & Kalita, B. Design and Evaluation of Phyto-Phospholipid Complexes 
(Phytosomes) of Rutin for Transdermal Application. J. Appl. Pharm. Sci. (2014). 
doi:10.7324/JAPS.2014.40110 
356. Rinaudo, M. Chitin and chitosan: Properties and applications. Prog. Polym. Sci. 31, 
603–632 (2006). 
357. Fernandes, J. C. et al. Antimicrobial effects of chitosans and chitooligosaccharides, 
upon Staphylococcus aureus and Escherichia coli, in food model systems. Food 
Microbiol. 25, 922–928 (2008). 
358. Benhabiles, M. S. et al. Antibacterial activity of chitin, chitosan and its oligomers 
prepared from shrimp shell waste. Food Hydrocoll. 29, 48–56 (2012). 
359. Raafat, D., von Bargen, K., Haas, A. & Sahl, H.-G. Insights into the mode of action 
of chitosan as an antibacterial compound. Appl. Environ. Microbiol. 74, 3764–73 
(2008). 
360. Tsai, G.-J. & Su, W.-H. Antibacterial Activity of Shrimp Chitosan against Escherichia 
coli. J. Food Prot. 5, 239–243 (1999). 
361. Raafat, D., von Bargen, K., Haas, A. & Sahl, H.-G. Insights into the mode of action 
of chitosan as an antibacterial compound. Appl. Environ. Microbiol. 74, 3764–73 
(2008). 
362. Kang, Y. O. et al. Chitosan-coated poly(vinyl alcohol) nanofibers for wound 
dressings. J. Biomed. Mater. Res. B. Appl. Biomater. 92, 568–76 (2010). 
363. Qi, L., Xu, Z., Jiang, X., Hu, C. & Zou, X. Preparation and antibacterial activity of 
chitosan nanoparticles. Carbohydr. Res. 339, 2693–700 (2004). 
364. Sun, P., Li, P., Li, Y.-M., Wei, Q. & Tian, L.-H. A pH-sensitive chitosan-
tripolyphosphate hydrogel beads for controlled glipizide delivery. J. Biomed. 
Mater. Res. Part B Appl. Biomater. 97B, 175–183 (2011). 
365. Vyas, A., Saraf, S. & Saraf, S. Encapsulation of cyclodextrin complexed simvastatin 
in chitosan nanocarriers: A novel technique for oral delivery. J. Incl. Phenom. 
Macrocycl. Chem. 66, 251–259 (2010). 
366. Zhang, H., Oh, M., Allen, C. & Kumacheva, E. Monodisperse Chitosan 
Nanoparticles for Mucosal Drug Delivery. Biomacromolecules 5, 2461–2468 
(2004). 
367. Koukaras, E. N., Papadimitriou, S. A., Bikiaris, D. N. & Froudakis, G. E. Insight on 
the Formation of Chitosan Nanoparticles through Ionotropic Gelation with 
Tripolyphosphate. Mol. Pharm. 9, 2856–2862 (2012). 
368. Boukamp, P. Normal keratinization in a spontaneously immortalized aneuploid 
human keratinocyte cell line. J. Cell Biol. 106, 761–771 (1988). 
  
151 
 
369. Pereira, F. et al. Production and characterization of nanoparticles containing 
methanol extracts of Portuguese Lavenders. Meas. J. Int. Meas. Confed. 74, 170–
177 (2015). 
370. Marquês, J. T. et al. Formation and Properties of Membrane-Ordered Domains by 
Phytoceramide: Role of Sphingoid Base Hydroxylation. Langmuir 31, 9410–21 
(2015). 
371. 7: Final Report on the Safety Assessment of Sodium Lauryl Sulfate and Ammonium 
Lauryl Sulfate. Int. J. Toxicol. 2, 127–181 (1983). 
372. Administration, U. S. F. and D. & States, A. of F. and D. O. of the U. Appraisal of 
the safety of chemicals in foods, drugs, and cosmetics. (1959). 
373. Uchechi, O., Ogbonna, J. D. N. & Attama, A. a. Nanoparticles for Dermal and 
Transdermal Drug Delivery. Appl. Nanotechnol. Drug Deliv. 193–235 (2014). 
doi:10.5772/58672 
374. Kusumawati, I. & Yusuf, H. Phospholipid Complex As a Carrier of Kaempferia 
Galanga Rhizome Extract To Improve Its Analgesic Activity. Int. J. Pharm. Pharm. 
Sci. 3, 1–3 (2011). 
375. Pathan, R. A. & Bhandari, U. Preparation & characterization of embelin-
phospholipid complex as effective drug delivery tool. J. Incl. Phenom. Macrocycl. 
Chem. 69, 139–147 (2011). 
376. Grit, M. & Crommelin, D. J. A. Chemical stability of liposomes: implications for 
their physical stability. Chem. Phys. Lipids 64, 3–18 (1993). 
377. He, C., Hu, Y., Yin, L., Tang, C. & Yin, C. Effects of particle size and surface charge 
on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 
31, 3657–66 (2010). 
378. Moncelli, M. R., Becucci, L. & Guidelli, R. The intrinsic pKa values for 
phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine in 
monolayers deposited on mercury electrodes. Biophys. J. 66, 1969–80 (1994). 
379. Basu, S. et al. Biomolecule induced nanoparticle aggregation: Effect of particle 
size on interparticle coupling. J. Colloid Interface Sci. 313, 724–734 (2007). 
380. Ogiso, T., Yamaguchi, T., Iwaki, M., Tanino, T. & Miyake, Y. Effect of positively and 
negatively charged liposomes on skin permeation of drugs. J. Drug Target. 9, 49–
59 (2001). 
381. Bouwstra, J. A., Honeywell-Nguyen, P. L., Gooris, G. S. & Ponec, M. Structure of 
the skin barrier and its modulation by vesicular formulations. Progress in Lipid 
Research 42, (2003). 
382. Yilmaz, E. & Borchert, H. H. Design of a phytosphingosine-containing, positively-
charged nanoemulsion as a colloidal carrier system for dermal application of 
ceramides. Eur. J. Pharm. Biopharm. 60, 91–98 (2005). 
383. Honary, S. & Zahir, F. Effect of Zeta Potential on the Properties of Nano - Drug 
  
152 
 
Delivery Systems - A Review (Part 2). Trop. J. Pharm. al Res. 12, 265 – 273 (2013). 
384. Hoeller, S., Sperger, A. & Valenta, C. Lecithin based nanoemulsions: A 
comparative study of the influence of non-ionic surfactants and the cationic 
phytosphingosine on physicochemical behaviour and skin permeation. Int. J. 
Pharm. 370, 181–186 (2009). 
385. Kawashima, Y., Yamamoto, H., Takeuchi, H. & Kuno, Y. Mucoadhesive DL-
Lactide/Glycolide Copolymer Nanospheres Coated with Chitosan to Improve Oral 
Delivery of Elcatonin. Pharm. Dev. Technol. 5, 77–85 (2000). 
386. Kumirska, J., Kaczy, Z. & Bychowska, A. Application of Spectroscopic Methods for 
Structural Analysis of Chitin and Chitosan. 1567–1636 (2010). 
doi:10.3390/md8051567 
387. Schmid-Wendtner, M.-H. & Korting, H. C. The pH of the Skin Surface and Its Impact 
on the Barrier Function. Skin Pharmacol. Physiol. 19, 296–302 (2006). 
388. Standring, S. Gray’s anatomy : the anatomical basis of clinical practice. 
389. Toteva, M. M. & Richard, J. P. in Advances in Physical Organic Chemistry 39–91 
(2011). doi:10.1016/B978-0-12-386047-7.00002-3 
390. Lerebour, G., Cupferman, S. & Bellon-Fontaine, M. N. Adhesion of Staphylococcus 
aureus and Staphylococcus epidermidis to the Episkin reconstructed epidermis 
model and to an inert 304 stainless steel substrate. J. Appl. Microbiol. 97, 7–16 
(2004). 
391. Shirai, T., Takai, M. & Ishihara, K. Simple and functional modification of PDMS 
surface for microchannel electropheresis. in 14th International Conference on 
Miniaturized Systems for Chemistry and Life Sciences 1946–1948 (2010). 
392. Chen, Y. E. & Tsao, H. The skin microbiome: Current perspectives and future 
challenges. J. Am. Acad. Dermatol. 69, 143–155 (2013). 
393. Ingredient : PHOSPHATIDYLCHOLINE. CosIng - European Commission (2016). at 
<http://ec.europa.eu/growth/tools-
databases/cosing/index.cfm?fuseaction=search.details_v2&id=79710> 
394. Ingredient : CHOLESTEROL. CosIng - European Commission (2016). at 
<http://ec.europa.eu/growth/tools-
databases/cosing/index.cfm?fuseaction=search.details_v2&id=74991> 
395. Ingredient: CHITOSAN. CosIng - European Commission (2016). at 
<http://ec.europa.eu/growth/tools-
databases/cosing/index.cfm?fuseaction=search.details_v2&id=75065> 
396. Doktorovova, S., Souto, E. B. & Silva, A. M. Nanotoxicology applied to solid lipid 
nanoparticles and nanostructured lipid carriers â€“ A systematic review of in vitro 
data. Eur. J. Pharm. Biopharm. 87, 1–18 (2014). 
397. Silva, C. O. et al. Polymeric nanoparticles modified with fatty acids encapsulating 
betamethasone for anti-inflammatory treatment. Int. J. Pharm. 493, 271–284 
  
153 
 
(2015). 
398. Bhattacharyya, S., Majhi, S., Saha, B. P. & Mukherjee, P. K. Chlorogenic acid-
phospholipid complex improve protection against UVA induced oxidative stress. 
J. Photochem. Photobiol. B Biol. 130, 293–298 (2014). 
399. Singh, D., Rawat, M. S. M., Semalty, A. & Semalty, M. Chrysophanol-phospholipid 
complex: A drug delivery strategy in herbal novel drug delivery system (HNDDS). 
J. Therm. Anal. Calorim. 111, 2069–2077 (2013). 
400. Maiti, K., Mukherjee, K., Murugan, V., Saha, B. P. & Mukherjee, P. K. Exploring the 
effect of Hesperetin-HSPC complex--a novel drug delivery system on the in vitro 
release, therapeutic efficacy and pharmacokinetics. AAPS PharmSciTech 10, 943–
950 (2009). 
401. Khan, J., Saraf, S. & Saraf, S. Preparation and evaluation of luteolin–phospholipid 
complex as an effective drug delivery tool against GalN/LPS induced liver damage. 
Pharm. Dev. Technol. 00, 1–12 (2015). 
402. Bhattacharyya, S., Ahmmed, S. M., Saha, B. P. & Mukherjee, P. K. Soya 
phospholipid complex of mangiferin enhances its hepatoprotectivity by 
improving its bioavailability and pharmacokinetics. J. Sci. Food Agric. 94, 1380–
1388 (2014). 
403. Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P. & Mukherjee, P. K. Enhanced 
therapeutic potential of naringenin-phospholipid complex in rats. J. Pharm. 
Pharmacol. 58, 1227–1233 (2006). 
404. Xu, X.-R. et al. Quercetin phospholipid complex significantly protects against 
oxidative injury in ARPE-19 cells associated with activation of Nrf2 pathway. Eur. 
J. Pharmacol. 770, 1–8 (2016). 
405. Mazumder, A., Dwivedi, A., du Preez, J. L. & du Plessis, J. In vitro wound healing 
and cytotoxic effects of sinigrin–phytosome complex. Int. J. Pharm. 498, 283–293 
(2016). 
  
  
154 
 
Annexes 
 
  
 
 
Table A in Annex 1. Phytosome preparation methodologies and used natural components published in the period 2006-2016. A
n
n
e
x 1
 
 
Phytocomponent Phospholipid Proportion Solvent Time Temperature Method Characterization Ref. 
Bacopa monnieri 
Soya lecithin 
(30% PdC) 
n/d DCM 3h 60ºC Anti-solvent (hexane) SEM, DSC and FT-IR 224 
Bergenin PdC 80% 9:10 Ethanol 2h 60ºC 
Solvent evaporation 
(vacuum) 
SEM, TEM, XRD and 
FT-IR 
235 
Boswellic acid Soy PdC 100% 1:1 DCM 2h Room Solvent evaporation FT-IR 247 
Calendula officinalis Egg PdC 99% 3:1:1† Chloroform 0* Room 
Solvent evaporation and 
thin film hydration 
DLS and AFM 257 
Catechin Soy PdC 80% 1:1 DCM 3h Δ Anti-solvent (n-hexane) 
SEM, DSC, XRD and 
NMR 
231 
Chlorogenic acid HSPC 2:1 DCM 0* Room Anti-solvent (hexane) 
DTA, FT-IR, DLS and 
SEM 
398 
Chrysophanol Soy PdC 80% 1:1 DCM 5h 45-50ºC Anti-solvent (hexane) 
FT-IR, XRD, DSC and 
SEM 
399 
Curcumin HSPC 1:1 DCM 2h 60ºC Anti-solvent  DSC and OM 227 
Curcumin Soy PdC 100% 1:1 DCM 2h Room Solvent evaporation DSC and FT-IR 246 
Curcumin 
Soy 
phospholipids 
2:1 (w/w) Ethanol 2h 50ºC 
Anti-solvent (acetic acid 
2%) 
DLS, AFM, SEM, TEM, 
DSC and FTIR 
249 
Diosmin Soy PdC 100% 1:2 DMSO:TBA  3h room 
Solvent evaporation 
(Lyo) 
TEM, DSC and FT-IR, 230 
          
          
1
5
5
 
 
  
 
Phytocomponent Phospholipid Proportion Solvent Time Temperature Method Characterization Ref. 
A
n
n
e
x 1
 (co
n
tin
u
atio
n
)  
Embelin HSPC 90% 1:3 Ethanol 2h 60ºC 
Solvent evaporation 
(SD)  
FT-IR, RMN, DSC and 
XRD 
375 
Emodin Soy PdC 80% 1:1 DCM 5h 45-50ºC Anti-solvent (hexane) 
FT-IR, XRD, DSC, SEM 
and NMR 
228 
Hesperetin HSPC 1:1 DCM 2h 60ºC Anti-solvent (hexane) OM 400 
Kaempferia 
galangal 
Phospholipids 1:1 Ethanol 2h 60ºC Solvent evaporation DTA and SEM 374 
Luteolin Soy lecithin 2.5:1 (w/w) THF 5h Room 
Solvent evaporation 
(vacuum) 
UV, FT-IR, XRD and 
DSC 
234 
Luteolin HSPC 90% 2.3:1 Ethanol 2h 45ºC 
Solvent evaporation 
(vacuum, freeze drying) 
UV, FT-IR, DSC, XRD 
and PCS 
401 
Mangiferin Egg PdC 80% 1:1 
Ethanol 
(80%) 
2h 60ºC Solvent evaporation DSC, IR and SEM 240 
Mangiferin HSPC 2:1 DCM 2h 60ºC Anti-solvent  
DTA, FT-IR, DLS and 
SEM 
402 
Marsupsin 
Soy 
phospholipids 
2:1 (w/w) Diethyl ether 0.25h Room Mechanical dispersion TEM, FR-IR and NMR 245 
Mitomycin C Soy PdC 90% 1:3 THF 4h 40 °C 
Solvent evaporation; 
nanoprecipitation 
SEM, TEM, AFM, DSC, 
FTIR and XRD 
229 
Morin 
Soy 
phospholipids 
1:1.5 THF 2h 40°C Solvent evaporation TEM, FT-IR and XRD 225 
Naringenin Soy PdC 80% 1:1 DCM 3h Room Anti-solvent (hexane) 
FTIR, DSC, NMR, XRD 
and SEM 
226 
Naringenin HSPC 1:1 DCM 0* Room Anti-solvent (hexane) n/d 403  
1
5
6 
 
  
 
Phytocomponent Phospholipid Proportion Solvent Time Temperature Method Characterization Ref. 
A
n
n
e
x 1
 (co
n
tin
u
atio
n
) 
Oxymatrine PdC 60% 3:1 THF 3h 60◦C 
Solvent evaporation 
(vacuum) 
XRD and DSC 242 
Puerarin 
Soy 
phospholipids 
1:1.2 scCO2 n/a n/a SEDS 
SEM, DSC, FT-IR and 
XDR 
244 
Quercetin Soy lecithin 1:1 Ethanol 1h Room 
Solvent evaporation 
(vacuum) 
DSC, FT-IR and XRD 404 
Rutin Egg lecithin 1:1 Methanol 3h Δ Solvent evaporation 
DSC, FT-IR, XDR, SEM 
and TEM 
355 
Sinigrin HSPC 1:1 DCM 0* Room Anti-solvent (hexane) 
DLS, TEM, FT-IR and 
DSC 
405 
Silybin PdC 80% 1:1 THF 2h Room 
Solvent evaporation 
(vacuum or SD) 
ATR, NMR, XDR, DSC, 
SEM and TEM 
239 
Silybin PdC 80% n/d Ethanol 0* Room 
Solvent evaporation 
(vacuum) 
SEM, TEM and DSC 250 
*until dissolves; †PdC : cholesterol : calendula (w/w); Δ – reflux; n/d – not disclosed. n/a – not applicable; AFM – atomic force microscopy; ATR - attenuated Total Reflection; DCM – dichloromethane; 
DLS – dynamic light scattering; DMSO – dimethylsufoxide; DTA – Differential thermal analysis; FT-IR – Fourier transform infrared spectroscopy; HSPC – hydrogenated soya PdC; Lyo – lyophilisation; 
NMR – nuclear magnetic resonance; OM – optical microscopy; PCS – photon correlation spectroscopy; SD – spray drying; SEM - Scanning electron microscopy; TBA - T-butyl alcohol; TEM - 
Transmission electron microscopy; THF – tetrahydrofuran. 
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Annex 2 
 
Table 1 (Annex 2). Examples of commercially available phytosomal products with use as functional cosmetic 
ingredients. 
Designation Content Suggested uses† 
Centella asiatica 
Selected Triterpenes® 
Triterpenes including asiaticoside, 
asiatic acid and madecassic acid (30-
35%) obtained from Centella asiatica 
leaf 
Anti-wrinkles and 
Stretchmarks improver 
Ginkoselect® Ginkgoflavonglucosides (≥7%), 
ginkgoterpenes (≥2%), bilobalide (≥ 
0.8%) and ginkgolides (≥0.8%) obtained 
from Ginkgo biloba leaf. 
Antioxidant and Vasokinetic 
Greenselect® Polyphenols (25-30%) obtained from 
the young leaf of Camellia sinensis. 
Antioxidant activity and 
whitening agent 
Hawthorn® Polyphenolic substances including 
Vitexin-2″-O-rhamnoside (≥3%) 
obtained from Crataegus spp. flowering 
top. 
Antioxidant 
Leucoselect® Proanthocyanidins (25-30%) obtained 
from Vitis vinifera seed.  
Antioxidant and capillarotropic 
PA2® 
Proanthocyanidin A2 (31-37%) obtained 
from Aesculus hippocastanum bark 
UV protectant, trophodermic, 
firming and oval reshaping 
agent 
Rexatrol® Resveratrol (≥30%) obtained from 
Polygonum cuspidatum rhizome.  
Antioxidant, Anti-ageing, Sirt1 
modulator 
Sericoside® 
Sericoside (≥25%) obtained from 
Terminalia sericea root bark 
Antioxidant, UV protectant, 
Anti-wrinkles, Soothing and 
Redensifier 
Siliphos® Silybin (about 30%) obtained from 
Silybum marianum fruit.  
Anti-wrinkles and Retinoic 
acid-like activity 
Silymarin® Silybin like substances (15-20%) 
obtained from Silybum marianum fruit 
Antioxidant and UV protectant 
 
†Suggested uses claimed by Indena® SPA as described at www.indena.com/phytosome. 
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Annex 3 
Original chromatograms from Plectranthus spp. extracts obtained according to methodology described at sub-section 
2.2.5. 
 
E1 
 
E2 
 
E3 
 
E4 
 
E5 
 
  
160 
 
E6 
 
E7 
 
E8 
 
E9 
 
E10 
 
E11 
 
  
161 
 
E12 
 
E13 
 
E14 
 
E15 
 
E16 
 
E17 
 
  
162 
 
E18 
 
E19 
 
E20 
 
E21 
 
E22 
 
E23 
 
  
163 
 
E24 
 
E25 
 
E26 
 
 
 
 
  
  
164 
 
Annex 4  
1H-NMR spectrum of 7α-formyloxy-6β-hydroxyroyleanone (III.3) (300 MHz, CDCl3). 
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Annex 5 
13C-NMR spectrum of 7α-formyloxy-6β-hydroxyroyleanone (III.3) (75 MHz, CDCl3). 
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Annex 6 
COSY-NMR spectrum of 7α-formyloxy-6β-hydroxyroyleanone (III.3) (300 MHz, CDCl3). 
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Annex 7 
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Annex 8 
Original DSC thermograms of the ChiPS components.  
 
Graph A. DSC phase diagram of cholesterol. Onset = 147.77ºC; Peak = 150.17ºC. 
 
 
Graph B. DSC phase diagram of P. madagascariensis extract E4. Onset = 34.33ºC; Peak = 58.33ºC. 
 
 
Graph C. DSC phase diagram of PdC from soybean (48%, Sigma-Aldrich, Germany). Two endothermic peaks were 
visible. Onset 1 = 126.23ºC; Peak 1 = 133.83ºC; Onset 2 = 169.30ºC; Peak 2 = 180.33ºC. 
 
 
Graph D. DSC phase diagram of the physical mixture of cholesterol, extract and PdC. Three peaks were visible.  
Onset 1 = 50.69ºC; Peak 1 = 58.33ºC; Onset 2 = 113.05ºC; Peak 2 = 123.83ºC; Onset 3 = 157.83ºC; Peak 3 = 170.17ºC. 
  
 
172 
 
 
Graph E. DSC phase diagram of phytosome. Two endothermic peaks were visible. Onset 1 = 125.06ºC; Peak 1 = 
135.00ºC; Onset 2 = 159.37ºC; Peak 2 = 170.67ºC. 
 
 
Graph F. DSC phase diagram of low molecular weight chitosan (Sigma-Aldrich, Germany). A single broad endothermic 
peak was visible. Onset = 55.35ºC; Peak = 98.00ºC. 
 
 
Graph F. DSC phase diagram of TPP. 
 
 
Graph F. DSC phase diagram of lyophilized ChiPS.   
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Graph A. DRIFTS of cholesterol (99%, Sigma-Aldrich). 
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Graph B. DRIFTS of extract E4. 
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Graph C. DRIFTS of PdC (Sigma-Aldrich, 48% purity, from soybean). 
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Graph D. DRIFTS of the physical mixture of extract E4, PdC and cholesterol. 
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Graph E. DRIFTS of phytosomes. 
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Graph F. DRIFTS of TPP. 
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Graph G. DRIFTS of low molecular weight chitosan. 
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Graph H. DRIFTS of the physical mixture of TPP and chitosan. 
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Graph H. DRIFTS of the physical mixture of TPP, chitosan and phytosomes. 
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Graph I. DRIFTS of the ChiPS. 
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